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ABSTRACT 
Background: Nasopharyngeal colonisation is a pre-requisite for developing bacterial 
respiratory and invasive disease. Immunisation of children with the pneumococcal conjugate 
vaccine (PCV) impacts upon colonising pneumococcal serotypes, which in turn could also 
affect the biome of the nasopharynx in relation to colonisation by other bacteria. Due to 
limitations in standard culture methods, the association between PCV-immunisation and 
bacterial carriage density is still unclear, including among HIV-infected children. In this 
study we aimed to evaluate the effect of infant vaccination with the 7-valent PCV (PCV7) on 
vaccine-serogroup colonisation in order to determine whether the increase in non-vaccine 
serotype (NVT) colonisation was due to unmasking of previously low density colonising 
serotypes or increase in acquisition of NVT. Also, we evaluated the association between 
PCV7 immunisation and HIV-infection on the prevalence density of nasopharyngeal 
colonisation by other common potentially pathogenic bacteria. 
 
Methods: A multiplex real-time qPCR assay was set up to detect 44 common pneumococcal 
serotypes and 5 bacterial pathogens including Streptococcus pneumoniae, Haemophilus 
influenzae, Moraxella catarrhalis, Staphylococcus aureus and Streptococcus pyogenes. All 
assays were optimised according to MIQE guidelines and their ability to detect multiple 
pneumococcal serotype/group and bacteria in archived nasopharyngeal swabs were evaluated. 
The multiplex qPCR assays were then used to evaluate vaccine-serotype, non-vaccine 
serotype and bacterial nasopharyngeal colonisation in achieved swabs of PCV7-vaccinated 
(at 6, 10 and 14 weeks of age) and PCV-unvaccinated African children at 9 and 15-16 months 
of age, prior to routine vaccination of children with PCV through the public immunisation 
program. In order to address the limitations of the qPCR assays, a nanofluidic real-time PCR 
assay was developed to simultaneously detect 53 pneumococcal serotypes, 6 serotypes of H. 
influenzae and 11 bacterial pathogens. Further, all assays were optimised and evaluated 
according to the MIQE guidelines and findings from Fluidigm and traditional qPCR assays 
were compared. Lastly, Fluidigm was used to evaluate the association of HIV-infection on 
the prevalence and density of nasopharyngeal colonisation at 9 and 16 months of age by 
common, potentially pathogenic bacteria including PCV7 pneumococcal serotypes, non-
PCV7 serotypes, Haemophilus influenzae, non-typable Haemophilus influenzae, 
Staphylococcus aureus, Moraxella catarrhalis, Streptococcus pyogenes, Neisseria 
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meningitidis, Neisseria lactamica, Bordetella pertussis, Bordetella parapertusis, Bordetella 
bronchiseptica and Bordetella holmesii in achieved nasophartngeal swabs collected from 
PCV7-vacciniated HIV-infected and HIV-uninfected children.  
 
Results: Molecular qPCR was more sensitive than culture in detecting multiple concurrent 
colonising pneumococcal serotypes as well as other common nasopharyngeal colonisers, with 
the majority of additional isolates detected by qPCR having a low carriage density (<10
4
 
CFU/ml). Further, qPCR identified a lower prevalence of PCV7-serotype colonisation among 
PCV7-vaccinated compared to PCV-unvaccinated children at 9 and 16 months of age 
[adjusted Odds Ratio (aOR): 0.37; 95% CI; 0.19-0.7 and 0.41; 95% CI; 0.26-0.63, 
respectively]; and an increase in NVT-serotype [aOR: 1.88; 95% CI; 1.02-3.48 and 2.2; 95% 
CI; 1.18-4.1] colonisation respectively. The increase in NVT carriage among PCV7-
vaccinees was driven by serotype 19A, which increased by 53.4% (p=0.021) and 70.7% 
(p<0.001) at 9 and 16 months of age respectively. Further, 19A had a higher density of 
colonisation in PCV7-vaccinated groups compared to PCV-unvaccinated groups and was 
more likely to be identified as a primary than non-primary isolate in PCV7-vaccinated 
children alone. PCV immunisation was also associated with an increased prevalence of H. 
influenzae at 9 months (55.8% vs. 66.3%, p<0.001) and 16 months (72% vs. 62%, p=0.017) 
of age, while a temporary increase in the carriage prevalence of S. aureus was found in 
PCV7-vaccinated (18.9%) compared to PCV-unvaccinated children (11.1%, aOR 2.1; 95% 
CI 1.0-1.4; p=0.049) at 9 months of age only. The density of pneumococcus (4.68 vs. 4.28 
CFU/ml; p=0.007), H. influenzae (3.86 vs. 4.34 CFU/ml; p=0.008), M. catarrhalis (2.98 vs. 
3.52 CFU/ml; p<0.001) and S. aureus (3.06 vs. 4.02 CFU/ml; p=0.02) were also higher 
among PCV7-vaccinated compared to PCV-unvaccinated children at 9 months age, although 
this difference diminished with increasing age. 
 
There was excellent concordance between the qPCR and Fluidigm for carriage prevalence 
and density of the majority of assays, with Fluidigm identifying an additional 7 
pneumococcal serotypes and 11 bacterial species above those detected by qPCR. Further, 
discordant results between the two PCR methods were strongly associated with a low 
carriage density (<10
2 
CFU/ml). Using molecular Fluidigm, a lower carriage prevalence of 
overall pneumococci (58.6% vs. 69.9%; p=0.02), non-vaccine serotypes (27.8% vs. 40%; 
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p=0.047) and H. influenzae (64.2% vs. 42.3%; p=0.01) was identified in HIV-infected 
children compared to HIV-uninfected children who were immunised with PCV7 at 9 months 
of age. No difference in the carriage prevalence of overall pneumococci was however found 
at 16 months of age (p=0.20), although the carriage prevalence of non-vaccine serotypes 
(50.9% vs. 60.4%; p=0.049) and H. influenzae (56% vs. 73.4%; p=0.02) was lower in HIV-
infected children at 16 months of age. In addition, the density of overall pneumococcus was 
found to be higher in HIV-infected children (4.81 vs. 4.44 CFU/ml; p=0.014), despite the 
lower carriage prevalence at 9 months of age, which was driven by a higher density of 
vaccine serotypes/serogroups (4.21 vs. 3.72 CFU/ml; p=0.04). By 16 months of age, there 
was no difference in density of pneumococcal colonisation between the HIV-infected and 
HIV-uninfected children (p=0.89). No difference in the density of H. influenzae was found 
between HIV-infected and HIV-uninfected infants at 9 months of age (p=0.08); however, by 
16 months of age, HIV-uninfected children had a higher density of overall H. influenzae 
colonisation (4.95 vs. 4.32 CFU/ml; p<0.001), which was largely due to the higher carriage 
density of NThinf in HIV-uninfected children (5.0 vs. 4.23 CFU/ml; p<0.001).  
 
Conclusion: Molecular qPCR assays were shown to be a promising alternative to WHO 
recommended culture in that multiple pneumococcal serotypes and other bacterial pathogens 
could be simultaneously detected as well as the bacterial load of each colonising bacteria 
quantified. The mechanism behind the vaccine effect was shown to be a combination of both 
serotype replacement and unmasking; however, the reduction in PCV7-serotype colonisation 
impacted on colonisation prevalence and density of other bacterial species of the nasopharynx 
and the clinical relevance of this needs further exploration in relation to mucosal and invasive 
disease outcomes, as well as for higher valence vaccines. While the higher carriage density of 
overall pneumococcus in HIV-infected children, despite the lower carriage prevalence might 
explain the higher invasive disease burden in HIV-infected compared to HIV-uninfected 
children even in the era of antiretroviral therapy treatment and PCV immunisation, future 
studies are required to provide clarity. Nevertheless, the findings from this thesis highlight 
the importance of continued surveillance of the circulation of pneumococcal serotypes as well 
as other bacterial pathogens especially in a population with a high burden of HIV-1 infection.  
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CHAPTER 1: INTRODUCTION 
 
1.1. STREPTOCOCCUS PNEUMONIAE 
Streptococcus pneumoniae is an aetiological agent for both mucosal and invasive disease, and 
was responsible for approximately 411 000 deaths in children <5 years worldwide in 2013 
1
, 
with children living in Sub-Saharan Africa being 14 times more likely to die, than children 
living in high income countries (HIC) according to the WHO. 
 
1.1.1. Microbiology of S. pneumoniae 
S. pneumoniae (pneumococcus) is a lancet-shaped gram-positive coccus that grows in pairs or 
short chains 
2
. It was first isolated in 1881 by George Sternberg and Louis Pasteur and 
belongs to the mitis group within the genus streptococcus 
3
. Further, S. pneumoniae is alpha-
hemolytic, bile soluble and optochin-sensitive 
2
. Cells are 0.5-1.25µM in diameter and are 
non-motile 
4
. S. pneumoniae does not catalase or ferment glucose to lactic acid, and its 
optimum growth conditions include 5% CO2 with an external catalase added to neutralise 
hydrogen peroxide produced 
5
.  
 
1.1.2. Structure of S. pneumoniae 
The surface of S. pneumoniae is made up of three main components, namely; the capsule 
polysaccharide, the plasma cell membrane and the cell wall (Figure 1.1). The cell wall 
consists of peptidoglycan, teichoic acid (TA) and Lipoteiochoic acid (LTA) 
6
. The 
peptidoglycan backbone of the cell wall aids in anchoring the capsular polysaccharide and the 
cell wall polysaccharide 
7
. In addition, there are a number of proteins and enzymes such as 
Pneumolysin (Ply), Autolysin (LytA), choline binding protein A (cbpA) and Pneumococcal 
surface antigen A (psaA) that are displayed on the surface of the pneumococcus. These 
proteins and enzymes contribute to the pathogenesis of the bacteria as they are either involved 
in direct interactions with the host or conceal the bacterium from host defence mechanisms 
8
.  
 
The polysaccharide capsule is the outermost layer of the cell surface which encapsulates the 
pneumococcus 
9
. It protects that bacteria from phagocytosis, inhibits complement activation 
and is involved in competition with other bacteria to colonise the pharynx 
10-12
. The anti-
phagocytic capsule forms the basis for pneumococcal classification, with 98 capsule serotypes 
2 
 
identified to date. Pneumococcal serotypes differ in their serological response, chemical 
structure and other related genetic mutations 
13-15
, with serotypes 1, 4, 5, 7F, 8, 12F, 14, 18C, 
19A, 19F and 23F being responsible for majority of invasive pneumococcal disease (IPD) 
15
. 
The capsule is thus an important virulence factor, with different serotypes having different 
invasive disease potentials, and some serotypes such as 1, 5, 14 and 19A are associated with a 
more severe outcome 
14,15
. This is further demonstrated by the fact that un-capsulated 
pneumococci are generally not invasive 
8
.  
 
 
Figure 1.1: Structure of Streptococcus pneumoniae from Kadioglu et al 
16
. 
 
1.1.3. Carriage of S. pneumoniae 
S. pneumoniae is a common asymptomatic coloniser of the human nasopharynx in high 
income (HIC) and low-middle income (LMIC) countries
 17-22
, with carriage being a pre-
requisite to pathogenesis of all pneumococcal disease as well as transmission between 
individuals 
18,23-26
. The highest prevalence of colonisation has been observed in children <2 
years 
27
, with most children being colonised within the first year of life 
18,20,21,28
, and some 
children in LMIC countries being colonised within days after birth 
22
. Pneumococcal carriage 
prevalence varies widely, depending on age, ethnicity, socioeconomic living conditions and 
sample methods used to detect pneumococcus. However, carriage of pneumococcus increases 
gradually with age in healthy children. Syrjänen et al, reported an increase in the prevalence 
of colonisation from 9% to 43% in Finnish children 
29
, and Dagan et al, reported an increase 
from 26% to 62% in Israeli children at 2 and 24 months respectively 
30
. Furthermore, 
colonisation prevalence may remain high in African settings in both children and adults 
31
, 
3 
 
with a high prevalence of nasopharyngeal (NP) carriage in LMIC countries also being 
associated with colonisation by multiple pneumococcal serotypes 
22
.  
 
 
Children may be colonised with different pneumococcal serotypes repeatedly, with duration 
depending both on the child’s age and the serotype carried 32-34. Some serogroups such as 6, 
14, 19 and 23, are acquired frequently and carried for longer periods, while serotypes 1 and 5 
have a transient carriage 
31,35
. In addition, the duration of colonisation is longer in children 
than adults, suggesting the acquisition of natural immunity against carriage 
18,31
.  
 
1.1.4. Concurrent carriage of multiple pneumococcal serotypes 
Concurrent colonisation of multiple pneumococcal serotypes was first observed in 1933 by 
Grundel et al; however, few studies since have documented concurrent colonisation with 
prevalence varying from 1.3% to 52% according to geographical distribution and method used 
(Table 1.1). Initial studies of concurrent pneumococcal colonisation relied on mouse 
inoculation assays. While these assays were sensitive in detecting multiple serotypes, they 
were expensive, labour intensive and not practical for use in large epidemiological studies 
36
. 
Thus, the majority of subsequent studies have relied on serotyping individual dominant 
colonies isolated from culture with concurrent colonisation being reported in approximately 
10% of such studies, which is likely an underestimation of the true prevalence of this 
phenomenon due to insufficient sensitivity of culture in detecting less-abundant colonising 
serotypes 
36
. Further, Huebner et al reported that 299 colonies from each culture sample 
would need to be serotyped to have a 95% probability of detecting a second colonising 
pneumococcus which represents 1% of the colonising population, thus making culture 
impractical for detecting concurrent colonisation 
37
.  
 
Other methods have also been used to investigate concurrent carriage of multiple 
pneumococcal serotypes such as conventional PCR 
38,39
, colony blot 
40
, Restricted Fragment 
Length Polymorphism (RFLP) 
41
 and microarray 
42
. However, the majority of these methods 
rely on an initial culture step which could bias the results due to selection for better growing 
strains. Further, these tests are not-quantitative for the colonising serotypes and are thus 
unable to measure the density of colonisation and relative proportion of the individual 
colonising serotypes. Recently, Dhoubhadel et al and Messaudi et al, used quantitative real-
4 
 
time PCR assays that were able to detect concurrent carriage of 50 and 40 pneumococcal 
serotypes respectively, with the added benefit of being able to quantify the relative proportion 
of concurrent colonising serotypes without relying on an initial culture step 
43,44
. These 
methods were, however, limited in that they were not optimised to detect all known 
pneumococcal serotypes and thus concurrent carriage of multiple pneumococcal serotypes 
could still have been underestimated.  
 
Improved methods that can detect multiple pneumococcal serotypes directly from a specimen 
so that the relative proportions of the colonising serotypes are not altered; can quantitatively 
measure the density of carriage of the colonising serotypes; are validated against the Quellung 
reaction to exclude any false-positive reactions; have the capacity to detect all known 
pneumococcal serotypes; and is practical and affordable are thus still needed 
45
. 
 
 
From data available on the limited number of studies reporting concurrent carriage, 
prevalence differed by geographical regions with children in LMIC having a higher 
prevalence of concurrent colonisation than children from HIC, albeit with varying detection 
methods used (Table 1.1). Further, there is a paucity of data on concurrent colonisation in 
South Africa, with one study reporting a prevalence of 1.3% in children <5 years old 
37
. As 
this study used conventional culture to investigate concurrent colonisation, it likely under-
reported the true prevalence in a South African population, where a high prevalence of 
pneumococcal carriage has been reported 
66,67
. This is further supported by the finding that 
populations with a higher prevalence of pneumococcal carriage tend to also have a higher 
prevalence of concurrent carriage of multiple pneumococcal serotypes.  
 
 
Concurrent carriage of multiple pneumococcal serotypes has been shown to promote genetic 
recombination by horizontal gene transfer between serotypes through transformation, 
transduction or conjugate transfer 
68
. Transformation of the CPS locus can result in capsule 
switching which could affect the performance of vaccines 
69,70
. Improved methods to detect 
multiple pneumococcal serotypes with a high accuracy and efficiency can thus help us to gain 
a better understanding of the implications of concurrent colonisation, and to predict and 
monitor the emergence of new strains and thus the effectiveness of pneumococcal 
polysaccharide-protein conjugate vaccines (PCV).
5 
 
Table 1.1: Summary of studies reporting concurrent colonisation of multiple pneumococcal serotypes *  
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Dowling et al, 1971
46
 USA Culture 1.3% 
OP 
swabs 
Unvaccinated - - June 1965 - June 1969 
Gray et al, 1980 
18
 USA Culture 8.0% 
NP 
swabs 
Unvaccinated 82 0 - 24 months 
November 1974 - December 
1975 
Hansman et al, 1985 
47
 Australia Culture 7.5% 
NP 
swabs 
Unvaccinated 174 <14 years May 1981 
Montgomery et al, 1990 
20
 
Papua New 
Guinea 
Culture 33.3% 
NP 
swabs 
Unvaccinated 158 - January 1985 - March 1987 
Gratten et al, 1994 
48
 Australia Culture 20.6% 
NP 
swabs 
Unvaccinated 171 - 1990 - 1991 
García-de-Lamas et al, 1997 
49
 
Spain Culture 64.0% 
OP 
swabs 
Unvaccinated 188 1 - 13 years - 
Kellner & Ford-Jones, 1999 
50
 
Canada Culture 2.2% 
NP 
swabs 
Unvaccinated 1322 
Mean age 34 
months 
March - July 1995, and 
October 1995 - February 
1996 
Ussery et al, 1996 
51
 Alaska Culture 3.2% 
NP 
swabs 
Unvaccinated 185 <5 years 1986 - 1990 
Lloyd-Evans et al, 1996 
26
 Gambia Culture 9.8% 
NP 
swabs 
Unvaccinated 1071 <5 years June 1989 - May 1991 
Lopez et al, 1999 
52
 Spain Culture 6.7% 
NP 
swabs 
Unvaccinated 332 6 years January - June 1997 
Huebner et al, 2000 
37
 
South Africa 
Culture 
1.3% 
NP swab Unvaccinated - 1 - 60 months - 
Israel 2.4% 
6 
 
St Sauver et al, 2000 
53
 USA PFGE 5% 
OP 
swabs 
- 38 
Children 
attending day 
care 
February & June 1988 
Syrjänen et al, 2001 
29
 Finland 
Electrophoresis 
and latex 
agglutination 
3.7% 
NP 
swabs 
Unvaccinated 329 2 - 24 months April 1994 - July 1997 
3.9% 
& NP 
aspirates 
Sà-Leâo et al, 2002 
54
 Portugal PFGE 10.8% 
NP 
swabs 
Unvaccinated 37 
6 months - 6 
years 
January - March 1996 
Bogaert et al, 2004 
40
 Netherlands Colony dot blot 
6.7% 
NP swab 
Unvaccinated 
26 1 - 7 years April 1998 - January 2002 
15.4% Vaccinated 
O' Brien et al, 2007 
55
 USA Immunoblotting 8.1% 
NP 
swabs 
Unvaccinated 
and vaccinated 
852 <2 years April 1997 - October 2000 
Hare et al, 2008 
56
 Aboginease Culture 20% 
NP 
swabs 
Vaccinated 101 
Children with 
otitis media 
2004 - 2005 
Kaltoft et al, 2008 
57
 Denmark Culture 
8% 
NP 
swabs 
- 
461 
Kindergarten 
children 
Mean age 52.4 
months 
 
 
 
- 
 
12% 
123 Nursery 
children 
Mean age 23 
months 
Rivera-Olivero et al, 2009 
39
 Venezuela Multiplex PCR 20% 
NP 
swabs 
Vaccinated 50 0 - 72 months April 2004 - January 2005 
Auranen et al, 2010 
58
 Denmark Culture 20% 
NP 
swabs 
Unvaccinated 123 < 3 years April 1999 - February 2001 
Brugger et al, 2010 
41
 Switzerland RFLP 6.7% 
NP 
swabs 
Vaccinated - - 2004 - 2009 
7 
 
Turner et al,2011
42
 Thailand 
Culture 11.2% 
NP 
swabs 
Vaccinated 125 0 - 24 months 
October 2007 - November 
2008 
Sweep 
serotyping 
43.2% 
Microarray 48.8% 
Valente et al, 2012 
59
 Portugal 
plyNCR-RFLP 
and microarray 
20.1% 
NP 
swabs 
Vaccinated 492 18 - 71 months 
Winter months (January - 
March) of 2001, 2006 & 
2007 
Lee et al, 2013 
60
 Korea 
Culture and 
multiplex PCR 
11.9% 
NP 
swabs 
Status not 
known 
582 - June 2006 - February 2007 
Dhoubhadel et al, 2014 
43
 Vietnam 
Nanofludic real 
time PCR 
18.5% 
NP swab vaccinated 
595 with 
ARI 
<5 years April 2008 - March 2009 
7.1% 
350 healthy 
children 
Wyllie et al, 2014 
61
 Netherlands 
Culture 
enriched qPCR 
52% Saliva Vaccinated 50 5 - 10 years June 2012 
Kamng'ana et al, 2015
 62
 Malawi Microarray 40 % 
NP 
swabs 
Unvaccinated 189 0 - 13 Years 2008 - 2012 
Kandasamy et al, 2015 
63
 Nepal Microarray 20.2% 
NP 
swabs 
Unvaccinated 600 
6 weeks - 24 
months 
May - October 2012 
Saha et al, 2015 
38
 Bangladesh 
culture and 
PCR 
22% 
NP 
swabs 
- 212 <5 years - 
Hjálmarsdóttir et al, 2016 
64
 Iceland 
Culture 8.1% NP 
swabs 
Unvaccinated 514 1.2 - 6.3 years March - April 2009 
Multiplex PCR 23.5% 
Wyllie et al, 2016 
65
 Netherlands 
Culture 
enriched qPCR 
22% 
NP 
swabs 
Vaccinated 1169 11 - 24 months 
Autumn/winter 2010- 
Autumn/winter 2013 
*Pubmed and Scopus were used to search for studies reporting concurrent colonisation of multiple pneumococcal serotypes. ARI, acute 
respiratory infection. NP, nasopharyngeal. OP, oropharyngeal. PCV, pneumococcal conjugate vaccine. PCR, polymerase chain reaction. PFGE, 
Pulsed-field gel electrophoresis. qPCR, quantitative PCR. -, information not provided in publication.
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1.2. INTERACTIONS BETWEEN PNEUMOCOCCUS AND OTHER 
NASOPHARYNGEAL COLONISING BACTERIA 
Colonisation of the nasopharynx is a dynamic process where organisms are continuously 
acquired and eliminated, with clearance influenced by host immune responses 
71
. Bacterial 
species, besides the pneumococcus that reside in the nasopharynx include H. influenzae, M. 
catarrhalis, S. aureus, and N. meningitidis 
72
. Although there is emerging understanding of 
the interactions between these bacteria and the establishment of carriage and disease 
73,74
, the 
relevant mechanisms of such interactions remain unclear 
74-77
. 
 
Association between colonising bacteria can be synergistic or competitive. Competition 
between residing nasopharyngeal flora can provide an opportunity for other species to occupy 
the vacated niche after antimicrobial treatment or vaccination targeted at specific bacterial 
species. Further, enzymes produced by one bacterial species might affect the growth or 
survival of other bacteria, and also horizontal gene transfer might occur between concurrently 
colonising organisms 
78
.  
 
1.2.1. Association between S. pneumoniae and S. aureus 
There is conflicting data with respect to the association between S. pneumoniae and S. aureus 
colonisation, with some studies showing a negative association, especially with respect to 7-
valent pneumococcal serotypes (4, 6B, 9V, 14, 18C, and 23F) 
77,79-81
, whereas other studies 
have not established any such association or described the association to be independent of 
PCV7-serotypes 
82,83
. The negative association between these bacteria is thought to be due to 
S. pneumoniae producing hydrogen peroxide which has a bactericidal effect on S. aureus 
84
.  
 
1.2.2. Association between S. pneumoniae and H. influenzae 
A synergistic relationship between S. pneumoniae and H. influenzae has been reported, with 
children colonised with pneumococcus being more likely to be colonised with H. influenzae 
77,81
. Further, pneumococcus and H. influenzae have been shown to form biofilms which 
facilitates their survival, persistence and disease outcome after colonisation 
85
.  
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1.2.3. Biofilm formation  
Biofilms are bacterial communities that aggregate on cell surfaces, and could be responsible 
for the conflicting data with respect to bacterial associations. Bacteria organised in biofilms, 
have different growth rates, metabolism, gene expression, and protein production than those 
of planktonic cultures 
86
. Further, biofilms have been shown to result in weaker inflammatory 
responses and bacteria are more resistant to host defences and other environmental changes, 
thus having an increased capacity to evade the host immune system. Recently, pneumococci 
have been shown to form biofilms during carriage in animal studies, with colonisation 
associated with enhanced adhesive, increase resistance to antibiotic treatment, persistent 
carriage and decreased virulence 
87-89
. In addition, carriage of H. influenzae has been shown to 
increase pneumococcal biofilm formations both in vivo and in vitro 
90
. 
 
1.3. MECHANISM OF COLONISATION  
S. pneumoniae encounters the mucosa of the host nasopharynx, which is covered with a 
mucus layer and epithelial cells. In healthy individuals, the mucosa inhibits the attachment of 
the bacteria by acting as a physical barrier and releasing antimicrobial substances such as 
lysozyme and lactoferrin which will either kill the bacteria or inhibit its growth 
91
. If the 
pneumococcus is able to overcome these host defences, it attaches itself to the cell surface 
carbohydrate (N-acetyl glucosamine) receptors on non-inflamed epithelium of the respiratory 
tract 
72
, a process mediated by specific bacterial adhesion molecules such as PsaA and 
choline-binding proteins that form a bridge between the bacterial surface components and 
epithelial cell receptors 
71,92-95
 (Figure 1.2). 
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Figure 1.2: Interaction between S. pneumoniae and epithelial cells from Bogaert et al 
72 
 
Pneumococcal enzyme Neuraminidase (NanA) decreases the viscosity of the mucus and 
exposes the N-acetyl-glycosamine (GlcNAc) receptors on the epithelial cells, thus facilitating 
its interaction with pneumococcal surface-associated proteins 
72
. Other functions of 
pneumococcal enzymes include cell lysis, cell wall degradation, inhibiting ciliary function, 
providing nutrients to the bacteria and inhibiting opsonophagosytosis by human neutrophils 
6,8,96
. Further, a thick capsule polysaccharide has an inhibitory effect on adherence and thus 
most pneumococcal isolates display phase variation between two forms distinguishable by 
their opaque or transparent colony morphologies. During the initial stages of colonisation, 
thinner capsules that are transparent and promote binding to host tissues dominate over 
thicker opaque capsules 
16
. 
 
1.4. THE RELATIONSHIP BETWEEN COLONISATION AND MUCOSAL 
DISEASE 
The human nasopharynx is constantly exposed to the outside environment, and as a result is 
colonised with multiple commensal bacterial pathogens that adhere to the mucosal epithelium 
such as S. pneumoniae, S. aureus and H. influenzae that are embedded in a complex 
11 
 
microbiota. Despite colonisation being asymptomatic, disruptions to the host immune 
defences, infection with respiratory viruses or underlying medical conditions such as chronic 
obstructive pulmonary disease (COPD), can result in a shift from nasopharyngeal commensal 
to causing mucosal or invasive disease 
97
 (Figure 1.3).  
 
The nasopharyngeal niche is a major ecological reservoir of bacterial species and provides a 
source of potential opportunistic pathogens. Bacterial overgrowth and contiguous spread to 
the eustachian tube can result in negative middle ear pressure and capillary leakage of fluid 
into the middle ear resulting in otitis media 
98
. Bacterial spread into sinus spaces result in 
sinusitis, while spread to the large airways could cause bronchitis and that of the lower 
airways present as pneumonia. High density colonisation of the nasopharynx can result in 
micro-aspiration of the organisms into the airways and into the lungs, resulting in pneumonia 
72
. 
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Figure 1.3: Pathogenic route for respiratory pathogens adapted from Bogaert et al 
72
 
Mucosal and invasive diseases are represented by blue and red dots respectively. 
  
13 
 
1.5. COMMENSAL BACTERIA AND INVASIVE DISEASE 
Sub-optimal host immunity can result in high density colonisation of the nasopharynx, 
including due to host conditions such as young age and malnutrition that weaken the immune 
function; or disruption to the host mucosal barriers by infections such as influenza virus, HIV, 
and some cancers. Increase in nasopharyngeal density may result in the bacteria successfully 
breaching the mucosal barrier and causing invasion of sterile sites such as the blood and 
meninges, resulting in invasive diseases such as septicaemia, bacteraemia and meningitis. 
 
The majority of invasive diseases are caused by immuno-evasive encapsulated organisms 
such as S. pneumoniae and H. influenzae type b; whereas un-encapsulated organisms such as 
non-typable H. influenzae and M. catarrhalis rarely cause invasive bacterial diseases. Further, 
isolates with some capsule structures are more efficient at causing invasive disease than 
others, as they are less susceptible to the hosts’ immune response and thus pathogenesis of 
pneumococcal infections depends on the virulence of the bacteria 
16
.  
 
1.6. INVASIVE DISEASE POTENTIAL OF PNEUMOCOCCAL SEROTYPES  
Pneumococcal serotypes differ in their invasive disease potential with the majority of 
serotypes rarely causing serious disease 
99
. A limited number of serotypes that differ 
according to temporal and geographical variations are responsible for the majority (~80%) of 
all invasive pneumococcal disease (IPD) 
15
, with serotype/groups 14, 16, 19, 18 and 23 
causing the majority of IPD in Europe and the USA, and serotypes 1 and 5 being important in 
Africa and Asia 
13,100
.  
 
Both the invasive disease potential and carriage prevalence of a serotype play a role in IPD. 
Although some serotypes have a low invasive disease potential, but a high prevalence of 
colonisation, they may contribute substantially to the burden of IPD, while other serotypes 
have high invasive potential but low carriage prevalence, with disease from these serotypes 
occurring in epidemics, in between which they are less common causes of IPD 
101
. A limited 
number of studies which evaluated serotype invasiveness, by comparing prevalence of 
colonisation of specific serotypes in relation to their representation in IPD, identified 
serotypes 1, 4, 7F, 18C and 14 as having high invasive disease potential, and serotypes 3, 6A, 
6B, 9V and 23F to have low invasive disease potential. Thus, as an example, even though 
14 
 
serotype 6B is responsible for a large percentage of IPD, in relation to carriage prevalence it is 
less likely to cause disease than serotype 14 
14,102,103
. This observation is further supported by 
Bruggerman et al, who found an inverse association between carriage prevalence and invasive 
disease potential, with the most commonly carried serotypes less likely to cause disease than 
the less commonly carried serotypes 
101,104
.  
 
1.7. CHILDHOOD RISK FACTORS FOR IPD  
Children <2 years are at the greatest risk for IPD , with risk factors including number of 
household contacts, lower socioeconomic status and host immunodeficiency 
105
. Also, 
children attending day care, or who have siblings attending day care have a higher incidence 
of IPD, due to the close interactions between children that facilitate the transmission of the 
pneumococcus from one child to another 
30,106-108
, with the risk being highest in the first two 
months after day care is commenced 
109
. Further, high rates of acute otitis media (AOM) in 
day care centre attendees mainly caused by the pneumococcus and H. influenzae, promotes an 
increase in antibiotic usage thus selecting for resistant pneumococci 
110,111
. Several studies 
have shown an increasing number of household contacts to be associated with an increased 
incidence of pneumococcal carriage, transmission and disease 
46,112,113
, with young children 
being primarily responsible for the introduction of new serotypes into a household 
112
.  
 
Low socioeconomic status, which is linked to low income, lower levels of education, and 
overcrowding has also been found to be a risk factor associated with an increased 
susceptibility of IPD. Further, asplenic children who are unable to clear opsonised bacteria 
from the host, as well as HIV-infected children who have defective antibody production and 
mucosal clearance, facilitates opportunistic infections with the pneumococcus and are thus at 
an increased risk of developing IPD 
100,105,114
. Cases of IPD are more common in the winter 
months, which coincide with the cyclic pattern of respiratory viruses such as influenza and 
RSV, which act synergistically with the pneumococcus to disrupt the local immune defences 
and promote adherence to the respiratory epithelium 
115-117
.  
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1.8. PREVENTION AND TREATMENT OF UPPER AND LOWER 
RESPIRATORY TRACT INFECTIONS 
Despite the effectiveness of antibiotics in treating mucosal and invasive infections, there 
remains a high morbidity and mortality rate. This is due to poor access to healthcare facilities, 
antibiotic resistance and the rapid onset of certain conditions such as meningitis and 
septicaemia in young infants, with insufficient time for treatment and intervention. This has 
led to an interest in preventative measures such as vaccination 
118,119
. 
 
1.8.1. Pneumococcal polysaccharide vaccine (PPV) 
To date, several vaccines have been developed and introduced. The pneumococcal 
polysaccharide vaccine (PPV; Pneumovax) was the first pneumococcal vaccine to be 
developed and was licensed for use in the United States in 1977. PPV is derived from 23 
unique purified antigens directed against the most invasive capsular polysaccharides of S. 
pneumoniae (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 
20, 22F, 23F, and 33F). Immunity is induced primarily through stimulation of B cells which 
releases IgM, without the assistance of T-cells, and thus does not induce memory responses 
and is poorly immunogenic in young children whose T-cell independent immune system is 
still immature 
120
. Although this vaccine is effective in adults and older children, it is not 
effective in children under the age of two years 
121,122
.  
 
1.8.2. Pneumococcal conjugate vaccines  
Conjugate vaccines were then developed to improve the immunogenicity to the 
polysaccharide epitopes in children under the age of two years 
123
. The conjugation of a 
protein molecule to the polysaccharides enhances the immunogenicity to the polysaccharide 
epitope by eliciting a T-cell dependent immune response, thus allowing for the development 
of an immunological memory and maturation of the immune response 
124
. The first 
polysaccharide-protein conjugate vaccine to be licensed was HiB conjugate vaccine, which 
resulted in an elimination of HiB invasive disease in some countries 
125
.  
 
This was followed by the introduction of a 7-valent pneumococcal conjugate vaccine (PCV7) 
which targeted seven of the most invasive serotypes namely; 4, 6B, 9V, 14, 18C, 19F and 23F 
126,127
. PCV7 was licensed for use in the United States in 2000, but only introduced for routine 
16 
 
administration to young infants and children in South Africa in 2009 
126
. Since then, PCV7 
has been effective at decreasing the incidence of vaccine-serotype IPD; however, some non-
vaccine serotypes (NVT) still cause pneumococcal disease, and in some countries appear to 
be on the increase 
128-132
. In order to prevent this shift, the repertoire of pneumococcal 
serotypes in the vaccine was expanded to include 13 serotypes 
133
. By June 2016, 137 
countries have introduced PCV into their national immunisation program, including 128 
universal, 4 subnational and 5 high risk programs as shown in Figure 1.4 [International 
Vaccine Access Centre (IVAC)]. 
 
 
Figure 1.4: Geographical distribution of PCV  
International Vaccine Access Centre (IVAC), Johns Hopkins Bloomberg School of Public Health, 
Vaccine Information Management system (VIMS). Global vaccine Introduction Report, June 2016. 
 
 
1.9. EFFECT OF IMMUNISATION ON PNEUMOCOCCAL CARRIAGE AND 
SEROTYPE REPLACEMENT DISEASE 
Pneumococcal vaccination has had an enormous impact on reducing nasopharyngeal carriage 
of vaccine targeted serotype (VTs) pneumococci and has resulted in an increase in the 
detection of carriage of NVTs 
134. This phenomenon has been referred to as the “serotype 
17 
 
replacement effect”, whereby VTs appear to have disappeared from the host nasopharynx and 
been largely replaced by NVTs 
135-137
. However, it remains unclear whether this apparent 
increase in NVT was due exclusively to serotype replacement of VT by NVT as a response to 
a vacant niche in the nasopharynx, or whether this process was due to the unmasking of 
underlying non-vaccine serotype pneumococci which previously colonised the NP at low 
levels and were undetectable by the standard methods recommended for carriage studies by 
WHO; Figure 1.5 
138,139
. 
 
 
 
 
Figure 1.5: Simulation of the two possible mechanisms by which serotype replacement in the 
nasopharynx can occur following vaccination 
Blue dots represent vaccine serotypes, while green, pink and yellow dots represent non-vaccine 
serotypes.  
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This vaccine effect has been observed in most studies investigating pneumococcal carriage 
post PCV-vaccination (Table 1.2), with serotypes 19A emerging as dominant NVT serotype 
following childhood immunisation with the 7-valent PCV 
30,131,140
. In a study by Haung et al 
in USA, carriage of NVT was found to increase from 15% in 2000 to 29% in 2007, with 
serotypes 19A, 6A, 15B/C, 35B, and 11A being the most dominant NVTs isolated 
141
, while 
in a study by Nunes et al in South Africa, carriage of NVT was found to increase from 33.9% 
to 45%, with serotypes 6A and 19A being the most dominant NVTs isolated 
142
. While these 
studies have been meaningful to some extent, the majority have relied on traditional culture 
methods that are non-quantitative for these colonising serotypes and thus the effect that PCV 
has on pneumococcal carriage density is not well understood, with available data from the 
limited number of studies being contradictory (Table 1.3); including O’Brien et al, reporting 
only a decrease in NVT carriage density in Navajo Indians 
55
; Roca et al, reporting a decrease 
in both VT and NVT carriage density in The Gambia 
143
; and Hanke et al reported an increase 
in NVT carriage density alone in Peru 
144
. Further investigation is thus needed with more 
sensitive molecular methods to clarify these findings.  
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Table 1.2: Summary of studies evaluating the effect of infant vaccination with PCV on the prevalence of serotype-specific nasopharyngeal 
colonisation in children *. 
Reference 
Study 
vaccine 
Study design Country Assay(s) used 
Specimen 
type 
Study period Participants Main Findings 
Dagan et 
al, 1996 
30
 
PCV7 
Randomized 
control study 
Israel Culture NP swabs 
February - June 
1994 
12 - 18 
months 
Carriage of NVT was found to increase from 
15% to 38% and from 22% to 32% in 
children who received 1 or 2 doses of PCV7 
respectively, one year after PCV 
immunisation. 
Serotypes 6A and 19A were the most 
dominant NVTs isolated. 
Mbelle et 
al, 1999 
145
 
PCV9 
Double-blind, 
randomized, 
placebo-controlled 
study 
South 
Africa 
Culture 
Blood and 
NP swabs 
- 
Infants <6 
weeks 
n = 500 
Carriage of NVT was found to increase from 
25% to 36%. 
Serotypes/groups 15, 6A and 19A were the 
most dominant NVTs isolated. 
Dagan et 
al, 2002 
108
 
PCV9 
Double-blind, 
randomized study 
Israel Culture NP swabs 
August 1996 -
February 1997 
12-35 
months 
n = 264 
 
Carriage of NVT was found to increase from 
34.1% to 43.7%. 
No data on carriage of serotypes/groups. 
Lakshman 
et al, 2003 
146
 
PCV7 
Non-randomized, 
unblinded control 
study 
UK Culture NP swabs 
June 2000 - 
March 2001 
2-5 years      
n = 607 
Carriage of NVT increased in both summer 
and winter months. 
No data on carriage of serotypes/groups. 
 
Ghaffar et 
al, 2004 
147
 
PCV7 - USA Culture NP swabs 
September 
2000-August 
2001 
2 - 18 
months        
n = 278 
Carriage of NVT was found to increase from 
6% (2 month old children) to 18% (15 - 18 
month old children). 
Serogroup 15 was the most dominant NVT 
isolated. 
20 
 
Pelton et al, 
2004 
148
 
PCV7 Surveillance study USA Culture NP swabs 
October 2000 -
September 2003 
2 - 24 
months        
n = 1736 
Carriage of NVT was found to increase from 
7% to 16% in a 3 year period. 
Serogroups 15 (15A, 15B, 15C and 15F) and 
11 (11A, 11C and 11D) were the most 
dominant NVTs isolated. 
Huang et 
al, 2005 
149
 
PCV7 - USA Culture NP swabs 
March 2001 - 
April 2004 
<7 years      
n = 1736 
Carriage of NVT was found to increase from 
34% in 2001 to 55% in 2004. 
Serotypes/groups 11, 15 & 29 were the most 
dominant NVTs isolated. 
O'Brien et 
al, 2007 
55
 
PCV7 
Group-randomized 
efficacy trial 
USA 
Culture and 
Immunoblot 
NP swabs 
April 1997 -
October 2000 
<2 years      
n = 8292 
Increased risk of NVT colonisation among 
vaccinees. 
Huang et 
al, 2009 
141
 
PCV7 - USA Culture NP swabs 
winter season 
(2000 -2001; 
2003 - 2004; 
2006 - 2007) 
3 months - 7 
years 
n = 2638 
Carriage of NVT increased from 15% in 
2000 to 29% in 2007. 
Serotypes 19A, 6A, 15B/C, 35B, and 11A 
were the most dominant NVTs isolated. 
Rodrigues 
et al, 2012 
150
 
PCV7 
Cross-sectional 
study 
Portugal Culture NP swabs 
February 2008 
and 2009 
3 months - 
<7 years 
n = 1142 
 
No increase in overall NVT serotypes. 
Serotypes 3, 6C, 15B/C, 23A, 23B, 11A, 21, 
16F, 35F and 24F were frequently isolated. 
 
Roca et al, 
2013 
151
 
 
PCV7 
Village-randomized 
study 
Gambia 
Culture, PCR(to 
differentiate 
6A/C) and 
MILST (6A and 
19A genotyping) 
NP swabs 
December 2003 
-June 2008 
<30 months 
n = 4792 
Overall prevalence of NVT carriage was 
31.2% and decreased with age. 
Serotype 19A being the most dominant NVT 
isolated, followed by 21 and 35B. 
21 
 
Grivea et 
al, 2014 
152
 
PCV7 
Cross-sectional 
study 
Athens Culture NP swabs 
December 2010 
- June 2011 
24 - 59 
months        
n = 233 
Serotypes 19A, 23B, 15B/C, 16F, 21, 11A, 
15A, 6C, 10A, 22F, and 23A were the most 
dominant serotypes isolated. 
Hammit et 
al, 2014 
153
 
PCV10 
Cross-sectional 
study 
Kenya Culture & qPCR NP swabs 2009 - 2012 
All ages       
n = 2031 
Among children <5 years, carriage of NVT 
increased from 41% to 57% in 4 years. 
Serotypes 6A, 11A, 19A and 35B were the 
most dominant NVTs to be isolated in 
vaccinated groups. 
Ueno et al, 
2014 
154
 
PCV7 Prospective study Japan 
Culture & PCR 
(lytA) 
NP swabs 
July 2010 - 
November 2012 
<6 years 
n = 137 
No difference in carriage of NVT (24.1% vs 
23.4%) between unvaccinated and 
vaccinated groups respectively. 
Serotypes 6C was, however, the dominant 
NVT isolated. 
Cohen et 
al, 2015 
155
 
PCV7 & 
PCV13 
Cross-sectional 
carriage study 
France Culture NP swabs 
October 2001 -
June 2014 
6 - 24 
months        
n = 7991 
Carriage of NVT increased from 17.2% to 
24.3% from 2001 - 2012, but this effect 
greatly decreased after the implementation 
of PCV13 (21.4% - 3.8%). 
Serotype 19A was the most dominant NVT 
after PCV7, while serotypes 15B/C, 11A, 
15A and 35B were the most dominant NVTs 
after PCV13 immunisation. 
Daana et al, 
2015 
156
 
PCV7 
Cross-sectional 
surveillance study 
Palestine Culture NP swabs 
May-July (2009 
-2011) 
<5 years      
n = 2755 
Carriage of NVTs increased from 34% to 
65%. 
Serotypes/groups 15B/C, 19B & 35B were 
the most dominant NVTs isolated. 
Desai et al, 
2015 
157
 
PCV13 - USA Culture NP swabs 
July 2010 - June 
2013 
6 - 59 
months        
n = 2048 
Carriage of non-PCV13 serotypes increased 
from 68.4% to 97%. 
Serotypes 35B, 15B/C, 19A, 11A, 23B, 6C, 
21 and 15A were the most dominant 
serotypes to be isolated during the entire 
study period. 
22 
 
Gladston et 
al, 2015 
158
 
PCV7 and 
PCV13 
- UK 
Culture and 
whole genome 
sequencing 
NP swabs 
October - march 
(2006/7 & 
2010/11) 
<4 years       
n = 1712 
Carriage of NVT increased. 
Increase in the carriage prevalence of NVTs 
21, 23B, 33F and 35F. 
Gounder et 
al, 2015 
159
 
PCV7 
Cross-sectional 
study 
Alaska Culture NP swabs 
2000 - 2004 & 
2008 - 2010 
<5 years      
n = 3496 
Carriage of NVTs increased from 43% to 
95%. 
Serotype 19A was the most dominant NVT 
isolate. 
Nunes et al, 
2015 
66
 
PCV7 
Longitudinal 
prospective study 
South 
Africa 
Culture NP swabs 
December 2009 
-April 2010 
6-12 weeks 
n = 255 
Carriage of NVT increased from 33.9 % to 
45 %. 
Carriage of serotypes 6A and 19A was 
higher in vaccinated groups, but colonisation 
by other serotypes was not elaborated on. 
Tòthpal et 
al, 2015 
160
 
PCV7 - Hungary Culture NP swabs 
February 2010 - 
February 2012 
3-6 years      
n = 1022 
Carriage of NVT increased from 32.8 % to 
41.7 %. 
Carriage of serotypes 11A, 35F, 19A, 6B, 
15B, 3 and 28 were the most dominant 
NVTs isolated. 
Bosch et al, 
2016 
161
 
PCV7 & 
PCV10 
Surveillance study Netherlands Culture NP swabs 
October 2012 - 
March 2013 
11 & 24 
months old   
n = 660 
Carriage of NVT increased from 29% to 
50% (post-PCV7) and to 57% (post-PCV10) 
in 11 month old children. 
Carriage of NVT increased from 30% to 
61% (post-PCV7) and to 55% (post-PCV10) 
in 24 month old children. 
Carriage of serotypes 19A, 6C, 23B, 23A 
and 11A were the most dominant serotypes 
to be isolated. 
Chan et al, 
2016 
162
 
PCV13 
Cross-sectional 
surveillance study 
Hong-Kong 
Culture & 
Multiplex PCR 
(40 
serotypes/groups) 
NP swabs 
June 2013 - June 
2014 
2,12 & 18 
month old 
children      
n = 1541 
Pneumococcal carriage was low compared 
to other countries. 
Serotypes 15B/C, 6C, 23A and 15AF were 
the most dominant serotypes to be isolated. 
23 
 
Hamaluba 
et al, 2015 
163
 
PCV7 
Cross-sectional 
observational study 
UK 
Culture & 
Microarray 
NP swabs 
November 2010 
- September 
2011 
22-55 
months        
n = 575 
Carriage of NVTs increased. 
Serotypes 6B, 3, 19A, 6C, 11A and 23B 
were dominant NVTs isolated. 
Hanke et 
al, 2016 
144
 
PCV7 
Cross-sectional 
study 
Peru 
Culture and 
qPCR (Density 
based on lytA) 
NP swabs 
May - 
September 
(2009 & 2011) 
<3 years 
n = 125 
Carriage of NVT increased from 52 % to 
71.2 %. 
Serotype 6C was the dominant NVT 
isolated. 
Nunes et al, 
2016 
164
 
PCV7 
Cross-sectional 
study 
Portugal 
Culture & 
Multiplex PCR 
(40 
serotypes/groups) 
NP swabs 
January- March 
(1999 - 1999; 
2001 - 2003; 
2006 - 2007) 
0-6 years      
n = 1092 
Carriage of NVT increased from 35.7 % to 
46.6 %. 
Serotypes 19A, 6C, 15A, 16F, 21, 23A and 
23B were the most dominant isolates 
identified. 
Soysal et 
al, 2016 
165
 
PCV13 
Retrospective 
surveillance study 
Turkey 
Culture & 
Multiplex PCR 
(40 
serotypes/groups) 
NP swabs 
September 2011 
- September 
2013 
0-18 years   
n = 2165 
Decrease in PCV13 serotypes and a slight 
shift towards non-PCV13 serotypes. 
Serotypes/groups 6AB, 19F, 23F, 9AV, 12F, 
15A/F and 22A/F most common isolates 
identified. 
* Pubmed and Scopus were used to search for studies evaluating the effect of infant vaccination with PCV on the prevalence of serotype-specific 
nasopharyngeal colonisation. MILST, multi-invasive-locus sequencing typing. NP, nasopharyngeal. NVT, non-vaccine serotypes. PCV, 
pneumococcal conjugate vaccine. PCV7, 7-valent pneumococcal conjugate vaccine. PCV10, 10-valent pneumococcal conjugate vaccine. PCV13, 
13-valent pneumococcal conjugate vaccine. PCR, polymerase chain reaction. qPCR, quantitative PCR. VT, vaccine serotypes. -, information not 
provided in publication. 
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Table 1.3: Summary of studies evaluating the effect of infant vaccination with PCV on the density of carriage of serotype-specific 
nasopharyngeal colonisation in children *. 
Reference 
Study 
vaccine 
Study design Country Assay(s) used 
Specimen 
type 
Study period Participants Main Findings 
O'Brien et al, 
2007 (55) 
PCV7 
Group-randomized 
efficacy trial 
USA 
Culture and 
Immunoblot 
NP swabs 
April 1997 -
October 2000 
<2 years       
n = 8292 
Density of VT decreased, no difference in the 
density of NVT (Note: Semi-quantitative culture 
used to determine carriage density). 
Roca et al, 
2012 (143) 
PCV7 
Clustered-
randomized trial 
Gambia Culture NP swabs 
December 2003 
-June 2008 
<30 months  
n = 4792 
Decrease in density of VT carriage following 
vaccination. 
 
Decrease in density of NVT carriage following 
vaccination. 
 
(Note: Semi-quantitative culture used to 
determine carriage density). 
Hanke et al, 
2016 (144) 
PCV7 Cross-sectional study Peru 
Culture and 
qPCR (Density 
based on lytA) 
NP swabs 
May - 
September 
(2009 & 2011) 
 
<3 years  
n = 125 
No different in density of VT serotypes, carriage 
density of NVT increased. 
  
*Pubmed and Scopus were used to search for studies evaluating the effect of infant vaccination with PCV on the density of carriage of serotype-
specific nasopharyngeal colonisation. NP, nasopharyngeal. NVT, non-vaccine serotypes. PCV, pneumococcal conjugate vaccine. PCV7, 7-valent 
pneumococcal conjugate vaccine. qPCR, quantitative PCR. VT, vaccine serotypes.  
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1.10. EFFECT OF PCV IMMUNISATION ON CO-COLONISING BACTERIA 
The human nasopharynx is colonised by a multitude of bacterial species embedded in a 
complex microbiota and shifts in colonising species may disrupt the natural balance. PCV 
induced effect on colonising bacterial species such as M. catarrhalis, H. influenzae, and S. 
aureus has not been fully investigated, especially with respect to changes in the microbiome, 
and its attribution to extended pressure or vaccine introduction 
166 
(Table 1.4). Wiertsema et 
al, found an increase in non-typable H. influenzae post-vaccination in Western Australia in 
children with otitis media 
167
, while another study by Xu et al, found that carriage of 19A was 
associated with a decrease in carriage of H. influenzae 
74
. Further, there is contrasting data 
with respect to the effect that PCV has on S. aureus carriage, with most studies 
168,169
 
reporting no change and others reporting a temporary increase in prevalence 
170
. It is thus 
important not only to monitor changes in pneumococcal colonisation following PCV 
immunisation, but also monitor the epidemiology of colonisation by other bacteria in the 
nasopharynx, which could impact on changes in risk of disease by these bacteria and future 
strategies for vaccine development 
166
. In addition, most of these NP studies on bacterial 
colonisation have used traditional culture methods and thus the effect that PCV has on the 
carriage density of common bacterial colonisers is still unknown, thus justifying further 
research with more sensitive molecular methods.  
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Table 1.4: Summary of studies investigating the effect of PCV immunisation on co-colonising bacteria* 
Reference Country Study design 
 Study 
vaccine 
Assay(s) 
used 
Specimen 
type 
Study period Participants 
Bacterial 
targets 
Main findings 
Block et al, 
2004 
171
 
USA - 
 
 
PCV7 
Culture 
Middle ear 
swabs 
January 1992 -
January 1998 
& July 2000 -
April2003 
7 - 24 months        
n = 379 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. pyogenes. 
Vaccination decreased 
pneumococcal carriage and 
increased non-typable H. influenzae 
carriage prevalence. 
Revai et al, 
2006 
172
 
USA 
Retrospective 
cross-sectional 
study 
 
PCV7 
Culture NP swabs 
October 1995 -
December 
2004 
6 months - 4 
years 
n = 580 
S. pneumoniae, 
H. influenzae & 
M. catarrhalis 
Vaccination increased the carriage 
prevalence of both H. influenzae 
and M. catarrhalis. 
Cohen et al, 
2007 
168
 
France 
Prospective 
study 
 
PCV7 
Culture NP swabs 
December 
2003 -June 
2006 
6 - 24 months        
n = 1783 
S. pneumoniae 
& S. aureus. 
PCV had no effect on S. aureus 
carriage prevalence. 
Madhi et al, 
2007 
77
 
South Africa 
Randomized 
control trial 
 
 
PCV9 
Culture NP swabs 
March 2001 - 
April 2005 
Mean age = 
5.64 years 
n = 352 
S. pneumoniae, 
H. influenzae & 
S. aureus. 
No difference in the carriage 
prevalence of S. aureus and H. 
influenzae between vaccinated and 
unvaccinated groups 5.3 years after 
primary series and prior to general 
PCV immunisation. 
Pymula et al, 
2011 
173
 
Czech 
Republic & 
Slovakia 
Prospective 
randomized 
double-blind 
controlled study 
 
PCV10 
Culture, 
PCR & 
Immunoblo
t 
NP swabs - 
6 - 24 months        
n = 381 
S. pneumoniae 
& H. influenzae 
Vaccination decreased the carriage 
prevalence of non-typable H. 
influenzae. 
van Gils et 
al, 2011 
170
 
Netherlands 
Randomized 
control trial 
PCV7 Culture NP swabs 
July 2005 - 
February 2008 
New-borns     
n = 1005 
S. pneumoniae 
& S. aureus. 
A trend towards higher colonisation 
of S. aureus after vaccination was 
observed. 
Wiertsema et 
al, 2011 
167
 
Australia Carriage study PCV7 
Culture and 
PCR 
NP swabs & 
MEE(middle 
ear effusion) 
November 
2007 -May 
2009 
<36 months    
n = 186 
S. pneumoniae, 
H. influenzae & 
M. catarrhalis 
Vaccination increased the carriage 
prevalence of non-typable H. 
influenzae in children with AOM. 
27 
 
Cohen et al, 
2012 
174
 
France 
Prospective 
surveillance 
study 
PCV7 Culture NP swabs 
1933 - 2000 & 
2006 - 2009 
6 - 30 months        
n = 4405 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. aureus 
Vaccination decreased S. 
pneumoniae, H. influenzae and S. 
aureus carriage (Although not 
significant) and increased the 
carriage prevalence of M. 
catarrhalis. 
Dunne et al, 
2012 
175
 
Fiji 
Phase II 
pneumococcal 
vaccine trial 
PCV7 
Multiplex 
qPCR 
NP swabs 2006 - 2007 
17 months      
n = 161 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. aureus 
Vaccination increased the carriage 
prevalence of NVT, while 
prevalence of other bacteria 
remained the same. 
The carriage densities of S. 
pneumoniae and H. influenzae 
remained the same, but density of 
M. catarrhalis was higher in 
indigenous children as a result of 
PCV immunisation. 
Ho et al, 
2012 
176
 
Hong Kong - PCV7 
Culture and 
PCR 
NP swabs 
September 
2009 -
April2010 
2 - 5 years      
n = 2211 
S. pneumoniae 
& S. aureus. 
No difference in the carriage 
prevalence of S. aureus was found 
between vaccinated and control 
groups. 
Spijkerman et 
al, 2012 
177
 
Netherlands 
Cross-sectional 
carriage study 
PCV7 Culture NP swabs 
March 2006 -
January 2011 
11 & 24 
months           
n ≈ 660 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. aureus 
Vaccination decreased overall 
pneumococcal carriage at 11 
months, but by 24 months the rates 
were similar between cohorts. 
A persistently higher rate of S. 
aureus and H. influenzae was 
observed after PCV immunisation. 
Dukers -
Muijrers et 
al, 2013 
178
 
Netherlands 
Cross-sectional 
study 
 PCV7 Culture NP swabs - 
6 weeks-4 
years              
n = 620 
S. pneumoniae 
& S. aureus. 
Vaccination increased the carriage 
prevalence of non-vaccine type 
pneumococci and S. aureus. 
28 
 
Hare et al, 
2013 
179
 
Australia and 
Alaska 
Prospective 
cohort study 
  PCV7 culture NP swabs 2004 - 2010 
0.5 - 8.9 years            
n = 120 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. aureus 
Vaccination increased the carriage 
prevalence of S. aureus and 
decreased the carriage prevalence of 
H. influenza in both cohorts. 
M. catarrhalis Carriage decline in 
Australian children only. 
Biesbroek et 
al, 2014 
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Netherlands 
Randomized 
control trial 
 
 
 
PCV7 
Culture and 
sequencing 
NP swabs - 
12 and 24 
months 
n = 200 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. aureus 
Temporary shift in microbial 
community composition and 
increased bacterial diversity. 
Vaccination increased the relative 
abundance of non-pneumococcal 
streptococci and anaerobic bacteria. 
Vaccination increased the carriage 
prevalence of H. influenzae and S. 
aureus. 
Hammit et al, 
2014 
181
 
Kenya 
cross-sectional 
carriage study 
 
 
PCV10 
Culture and 
multiplex 
PCR 
NP swabs 2009 - 2012 
<5 years 
n = 2031 
S. pneumoniae, 
H. influenzae & 
S. aureus 
Vaccination decreased carriage 
prevalence of vaccine-type 
pneumococci & non-typable H. 
influenzae. 
No change in S. aureus carriage 
prevalence. 
Nzenze et al, 
2014 
182
 
South Africa 
Cross-sectional 
study 
 
PCV7 
Culture NP swabs 
May - October 
2009 & 2011 
0-2 years & 3-
12 years 
n = 5669 
S. pneumoniae, 
H. influenzae & 
S. aureus 
Prevalence of S. pneumoniae and H. 
influenzae carriage prevalence 
decrease between the two study 
periods, while the prevalence of S. 
aureus remained unchanged. 
Camilli et al, 
2015 
183
 
Italy 
Cross-sectional 
study 
PCV7 & 
PCV13 
Culture and 
PCR 
NP swabs 
January - April 
2012 
<6 years 
n = 301 
S. pneumoniae 
& H. influenzae 
Vaccination increased H. influenzae 
nasopharyngeal carriage. 
29 
 
Bosch et al, 
2016 
161
 
Netherlands 
Surveillance 
study 
PCV10 Culture NP swabs 
October 2012 - 
March 2013 
11& 24 
months old 
n = 660 
S. pneumoniae, 
H. influenzae, 
M. catarrhalis, 
& S. aureus 
Vaccination decreased the overall 
pneumococcal carriage prevalence. 
While a temporary increase in the 
carriage prevalence of S. aureus was 
observed at 11 months but not at 24 
months. 
The carriage prevalence of H. 
influenzae also increased while the 
prevalence of M. catarrhalis 
remained constant after vaccination. 
* Pubmed and Scopus were used to search for studies evaluating the effect of PCV immunisation on co-colonising bacteria. AOM, acute otitis 
media. MEE, middle ear effusion. NP, nasopharyngeal. NVT, non-vaccine serotypes. OP, oropharyngeal swabs. PCV, pneumococcal conjugate 
vaccine. PCR, polymerase chain reaction. qPCR, quantitative PCR. VT, vaccine serotypes. -, information not provided in publication. 
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1.11. EFFECT OF IMMUNISATION ON INVASIVE PNEUMOCOCCAL DISEASE 
PCV has greatly reduced the incidence of pneumococcal disease in both vaccinated and 
unvaccinated groups by reducing vaccine serotype transmission within the population, thus 
leading to heard immunity or indirect protection 
134
. CDC has reported that the incidence of 
IPD caused by vaccine serotypes decreased by 94% within 7 years of PCV7 introduction, 
although the clinical impact of serotype replacement may not yet be fully established as it 
could lag behind the reduction in VT disease and will also depend on the invasiveness of the 
NVT 
(30)
. 
 
 
Figure 1.6: Rates of invasive pneumococcal disease amongst children aged <5years, 1988 - 
2010 
(CDC )
 
 
1.12. EPIDEMIOLOGY OF INVASIVE STREPTOCOCCUS PNEUMONIAE IN HIV-
INFECTED INFANTS IN SOUTH AFRICA 
In South Africa it is estimated that approximately 5% of children under the age of 5 years are 
infected with HIV. Among these children, 85% will develop a lower respiratory tract 
infection, with pneumonia being the most common cause of hospitalisation in HIV-infected 
children 
119
. S. pneumoniae is the most important cause of invasive bacterial disease, with the 
burden of disease being 37 to 49 fold higher in HIV-infected compared to HIV-uninfected 
children 
184,185
. This is most likely a result of decrease in the mucosal immunity (IgA and IgG) 
which allows for the persistent colonisation of pneumococcus and other bacteria, or decreased 
31 
 
immunological responsiveness to natural exposure and vaccination in the absence of 
antiretroviral treatment 
71
.  
 
There are a limited number of comparative studies that have investigated the association 
between HIV-infection and pneumococcal colonisation, with results from these studies being 
contradictory with respect to the effect that HIV has on the overall carriage prevalence of 
pneumococcus (Table 1.5), with some studies showing no differences in the carriage 
prevalence between HIV-infected and HIV-uninfected children 
186
, and others studies from 
South Africa and The Gambia reporting that HIV-infected children have a higher prevalence 
of pneumococcal colonisation then their HIV-uninfected counterparts 
77,187
. These studies 
were, however, all limited in that they relied on non-quantitative culture-based methods and 
thus the effect that HIV-infection has on pneumococcal carriage density is still unknown. 
Further, the majority of these studies involved populations that were not immunised with PCV 
and thus further investigation with more sensitive molecular methods on the association 
between HIV-infection and pneumococcal carriage prevalence and density in a PCV-
vaccinated cohort is still needed. 
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Table 1.5: Summary of studies investigating the association between HIV-infection and bacterial colonisation in children * 
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Rusen et al, 
1997 
188
 
Kenya 
Cross-
sectional 
Culture 
January 1990 
-November 
1990 
S. pneumoniae No 
Pneumococcal carriage prevalence was higher in HIV-
infected than HIV-uninfected children. 
Leibovitz et 
al, 1999 
189
 
Romania 
Cross-
sectional 
Culture May 1996 S. pneumoniae No 
Pneumococcal carriage prevalence was lower in HIV-
infected than HIV-uninfected children. 
Polack et al, 
2000 
190
 
USA 
Cross-
sectional 
Culture 
March - June 
1997 
S. pneumoniae No 
No difference in the carriage prevalence of 
pneumococcus between HIV-infected and HIV-
uninfected children. 
Zar et al, 
2003 
191
 
South 
Africa 
Cross-
sectional 
Culture 1998 
S. pneumoniae, H. 
influenzae, S. aureus, K. 
pneumoniae, M. 
catarrhalis & M. 
tuberculosis 
No 
No difference in the carriage prevalence of 
pneumococcus between HIV-infected and HIV-
uninfected children. 
Carriage prevalence of S. aureus was higher in HIV-
infected children. 
Cardoso et al, 
2006 
192
 
Portugal 
Observational 
& cross-
sectional 
Culture 
November 
2002 - May 
2003 
S. pneumoniae No 
No difference in the carriage prevalence of 
pneumococcus between HIV-infected and HIV-
uninfected children. 
McNally et 
al, 2006 
193
 
South 
Africa 
Cross-
sectional 
Culture 
January 2001 
-December 
2002 
S. pneumoniae & S. aureus No 
No difference in the carriage prevalence of 
pneumococcus between HIV-infected & HIV-
uninfected children. 
Carriage prevalence of S. aureus was higher in HIV-
infected children. 
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Madhi et al, 
2007 
77
 
South 
Africa 
Cross-
sectional 
Culture 
March 2001 - 
April 2005 
S. pneumoniae, H. 
influenzae & S. aureus 
Yes 
HIV-infected children had a higher carriage prevalence 
of S. pneumoniae and H. influenzae. 
No difference in the carriage prevalence of S. aureus 
was found between HIV-infected and HIV-uninfected 
children. 
Gill et al, 
2008 
194
 
Zambia Longitudinal Culture 
December 
2003 - 
September 
2004 
S. pneumoniae No 
Pneumococcal carriage prevalence was higher in HIV-
exposed than HIV-unexposed infants. 
Abdullahi et 
al, 2012 
195
 
Kenya 
Cross-
sectional 
Culture 
October 2006 
-December 
2008 
S. pneumoniae Yes 
Pneumococcal carriage prevalence was higher in HIV-
infected than HIV-uninfected children. 
Kinabo et al, 
2013 
196
 
Tanzania Longitudinal 
Culture 
& PCR 
September 
2005 - 
December 
2009 
S. pneumoniae, H. 
influenzae & S. aureus 
No 
Carriage with S. aureus was more common in HIV-
infected children, while carriage of S. pneumoniae & 
H. influenzae was more common in HIV-uninfected 
children. 
Nzenze et al, 
2013 
197
 
South 
Africa 
Cross-
sectional 
culture 
May - 
October 2009 
& 2011 
S. pneumoniae Yes 
No difference in the carriage prevalence of 
pneumococcus between HIV-infected and HIV-
uninfected children. 
Madhi et al, 
2015 
198
 
South 
Africa 
Longitudinal Culture 
April 2005 - 
June 2006 
S. pneumoniae, H. 
influenzae & S. aureus 
Yes 
Vaccine serotype colonisation was similar in PCV-
immunised HIV-infected and HIV-uninfected children; 
however, a lower prevalence of overall pneumococcus, 
non-vaccine serotypes and H. influenzae in HIV-
infected children was observed. 
*Pubmed and Scopus were used to search for studies investigating the association between HIV-infection and bacterial colonisation in children. 
HIV, human immunodeficiency virus. PCV, pneumococcal conjugate vaccine. PCR, polymerase chain reaction. 
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1.13. ASSOCIATION BETWEEN HIV-1 INFECTION AND COMMON 
BACTERIAL NASOPHARYNGEAL COLONISERS SUCH AS S. AUREUS 
AND H. INFLUENZAE 
The effect of HIV-infection on other common nasopharyngeal colonisers such as S. aureus 
and H. influenzae is not clear, as a result of a limited number of studies that have focused only 
on non-quantitative culture based methods, predominantly in a PCV-unvaccinated population 
(Table 1.4). Further, results from these studies have been contradictory in that some studies 
have shown no difference in the carriage prevalence of S. aureus between HIV-infected and 
HIV-uninfected children 
77
, and others reported that HIV-infected children have a higher 
prevalence of S. aureus colonisation 
191,193,196
. Also, while some studies have reported HIV-
infected children to have a higher carriage prevalence of H. influenzae 
77
, others have rather 
reported a lower carriage prevalence of H. influenzae 
196,198
 or no difference between HIV-
infected and HIV-uninfected groups 
191
.  
 
1.14. INVESTIGATION OF SEROTYPE DISTRIBUTION 
 
1.14.1. Quellung method for serotyping Streptococcus pneumoniae 
Pneumococcal colonisation and serotype distribution is normally investigated by culture of 
the dominant colony on blood-agar media, followed by serotyping with specific antisera 
199
. 
Despite the ubiquitous use of culture based methods for NP colonisation studies, there are 
several fundamental limitations with this method. These include that this traditional method 
generally detects only the dominant colonising serotype, and in the case of multiple serotype 
carriage, the minor serotypes will go undetected 
200
. Further, these methods are not 
quantitative for the dominant serotype, and will not provide information of the relative 
quantitative distribution of the minor serotypes. Also, culture based methods tend to favour 
organisms which are more able to grow on laboratory media 
127,133,134
. These limitations of 
culture-based methods, limit their ability to determine the true underlying mechanism of the 
increase in NVT colonisation following introduction of PCV 
201
. 
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1.14.2. Molecular methods: Real time qPCR 
Real-time PCR has recently been developed not only to detect multiple S. pneumoniae 
serotypes that colonise the nasopharynx niche, but also to detect other respiratory pathogens 
such as S. aureus and H. influenzae directly from nasopharyngeal secretions. Quantitative 
real-time PCR has become an increasingly important platform in which multiple respiratory 
organisms can be detected from clinical specimens, with an increased sensitivity and 
specificity compared to standard culture methods. Several studies have illustrated the 
usefulness of qPCR. Stralin et al, developed a successful multiplex real-time PCR assay to 
simultaneously detect four respiratory pathogens, including S. pneumoniae and H. influenzae 
from a single sputum sample 
202
, while results from Corless et al, showed real-time PCR 
improved the diagnosis and detection of multiple causative agents of bacterial meningitis 
203
.  
 
The ability to quantitatively detect multiple serotypes from a single nasopharyngeal specimen 
in both PCV-vaccinated and PCV-unvaccinated infants, enables better understanding of the 
dynamics of pneumococcal carriage and its relationship to disease. Serotyping pneumococci 
by qPCR, however, has two main shortcomings, including that a large sample volume is 
required to distribute across all the reactions, and that it is expensive. Further, processing 
multiple qPCR reactions is labour intensive and time consuming. 
 
1.14.3. Molecular methods: Fluidigm  
Fluidigm is a nanofluidic automated real-time PCR system that relies on microfluidic 
technology in which dynamic arrays of integrated fluidic circuits (IFCs) are used. These IFC’s 
contain thousands of controlled valves and interconnected channels in which molecules of 
biological samples and reagents can be automatically mixed in a variety of grid like matrices. 
The instrument uses an array of non-fluidic chips called dynamic arrays for qPCR, in which a 
typical chip format allows for 9 216 PCR reactions (96.96 chip format; 96 samples x 96 
assays) in a single qPCR run (www.fluidigm.co.za)
 204
.  
 
Fluidigm has several advantages over standard qPCR in that it allows for a larger number of 
reactions per plate, thus making it more cost effective and less time consuming. Further, IFCs 
not only reduces the reaction volume from 10µL – 20µL down to 10nL scale, but the 
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technology also allows for validations as well as increased parallelism and throughput of 
qPCR reactions 
204
. Fluidigm has a number of applications in biological automation including 
gene expression and genotyping, and has also recently been used to detect pneumococcal 
serotypes from nasopharyngeal samples. Dhoubhadel et al, showed this method to be specific 
with respect to detecting 50 different pneumococcal serotypes (17 individual serotypes and 33 
serotypes in 12 groups), with good repeatability, accuracy and reproducibility
 205
. 
 
Improved methods of detection of respiratory pathogens has provided a means to improve the 
health care of patients as optimal therapy can be initiated sooner, effectiveness of the 
treatment is improved and spread of disease can be reduced or even prevented 
206
. A high 
bacterial load detected by real-time PCR in nasopharyngeal specimens can help predict the 
etiological role for S. pneumoniae in disease states 
207
. 
 
1.15. RATIONAL FOR THE STUDY  
The burden of HIV-infection in children in South Africa is high, with 1 in 8 children infected 
with HIV globally living in South Africa. Of these infants, 85% will develop a respiratory 
tract infection during the course of their HIV disease, with pneumonia being the most 
common cause of hospitalisation. S. pneumoniae is the most common cause of bacterial 
disease, with the burden of IPD being 37-49 fold higher in HIV-infected compared to HIV-
uninfected children. While PCV has been effective in reducing serotype specific IPD by more 
than 80% in most countries, it is more effective in HIV-uninfected than HIV-infected infants 
185,208
. Further, there is conflicting data with respect to the effect HIV-infection has on the 
overall carriage prevalence of pneumococcus, with some studies showing no difference in 
prevalence of pneumococcal carriage between HIV-infected and HIV-uninfected children, 
whilst other studies report that HIV-infected children have a higher prevalence of colonisation 
209
.  
 
Concerns have also been raised about the long term effectiveness of PCV with limited 
serotypes, to sustain reduction in overall pneumococcal mucosal and invasive disease. There 
have already been reports of increase in disease from NVT pneumococcal serotypes and other 
bacteria such as H. influenzae 
167,210
. Whilst these epidemiological studies provide some 
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insight as to what may be happening in the nasopharynx in response to PCV introduction, 
there are several shortcomings. The numbers of cases reported are often too few to make 
meaningful conclusions, especially when one stratifies into specific serotypes. In addition, the 
periods of analysis are often short, and could be influenced by factors such as fluctuations in 
the circulating respiratory viruses within a particular year. 
 
Since NP colonisation is the precursor to diseases of the upper and lower respiratory tract, 
analysis of the NP tract flora can provide a simple means to signal changes, which could 
inform future trends in the long term effectiveness of these vaccines. The majority of studies 
of NP colonisation have focused on non-quantitative culture based methods, and compared 
changes in the dominant pneumococcal serotype. Whilst this has been meaningful to some 
extent, the lack of quantitative data has hindered our understanding of these dynamics. By 
applying quantitative real-time PCR and Fluidigm to quantitatively detect carriage of the most 
frequently isolated pathogens in the nasopharynx and in the case of the pneumococcus, down 
to serotype level, we can gain a better understanding of the impact of PCV on nasopharyngeal 
carriage and its potential relationship to pneumococcal disease. 
 
1.16. STUDY OBJECTIVES  
 
1. To develop a quantitative multiplex real-time PCR assay for the detection and density 
characterisation of multiple pneumococcal serotypes (44 serotypes/groups; 13 
individual serotypes and 31 serotypes in 11 groups) on nasopharyngeal swabs, 
previously investigated by traditional culture methods. 
 
2. To evaluate the effect of infant vaccination with 7-valent PCV (PCV7) on the 
density of serotype-specific nasopharyngeal colonisation, and also delineate the 
relative role of serotype replacement versus unmasking as the cause for the 
increase in non-vaccine serotype colonisation in PCV7-vaccinated children. 
 
3. To evaluated the association of PCV7 immunisation of infants on the prevalence and 
density of nasopharyngeal colonisation by common, potentially pathogenic bacteria 
including PCV7 serotypes, non-vaccine serotypes, Haemophilus influenzae, 
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Staphylococcus aureus, Moraxella catarrhalis, Streptococcus pyogenes and Neisseria 
meningitidis using the qPCR assay. 
 
4. To develop a novel Nanofludic real-time PCR assay that could simultaneously detect 
and quantify 11 bacterial pathogens, 53pneumococcal serotypes (16 individual 
serotypes and 37 serotypes in 13 groups) and 6 serotypes of H. influenzae (serotypes 
a-f). 
 
5. To compare results from traditional qPCR and Fluidigm for the detection of bacterial 
colonisation and pneumococcal serotyping in PCV-vaccinated children. 
 
6. To evaluate the association between HIV-infection and HIV-exposure on the 
prevalence and density of nasopharyngeal colonisation by common, potentially 
pathogenic bacteria including PCV7 serotypes, non-vaccine serotypes, Haemophilus 
influenzae, Non-typable Haemophilus influenzae, Staphylococcus aureus, Moraxella 
catarrhalis, Streptococcus pyogenes, Neisseria meningitidis, Neisseria lactamica, 
Bordetella pertussis, Bordetella parapertusis, Bordetella bronchiseptica and 
Bordetella holmesii, in PCV7-vaccinated children with the Biomark HD Nanofludic 
qPCR instrument.  
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CHAPTER 2: COMPARISON OF TRADITIONAL CULTURE AND 
MOLECULAR QPCR FOR DETECTION OF SIMULTANEOUS 
CARRIAGE OF MULTIPLE PNEUMOCOCCAL SEROTYPES IN 
AFRICAN CHILDREN 
 
Streptococcus pneumoniae is a common coloniser of the human nasopharynx in both HIC and 
LMIC countries, with carriage being a pre-requisite to pathogenesis of pneumococcal disease 
as well as transmission between hosts 
18,23-26
. To date almost 100 serotypes have been 
identified through their capsular polysaccharide and there is a paucity of data on concurrent 
carriage of multiple pneumococcal serotypes due to limitations of traditional recommended 
culture methods 
139
. 
 
Pneumococcal colonisation and serotype characterisation is normally investigated by culture 
of the dominant organism followed by serotyping with specific antisera 
199
. Despite the 
ubiquitous use of culture-based methods for nasopharyngeal colonisation studies, detection of 
concurrent colonisation by other serotypes of a lower density are often missed 
200
. Further, 
traditional culture methods are not quantitative for the colonising serotypes. Molecular 
detection of pneumococci in the nasopharynx have several potential advantages over culture 
based methods, including detection of multiple serotypes from a single sample with high 
sensitivity, as well as quantitative PCR methods being able to measure the density of 
colonisation and relative proportion of colonising serotypes
 211
. Interrogating beyond 
identification of only the dominant serotype colonising children, could also help inform the 
extent to which the increase in nasopharyngeal non-vaccine serotype colonisation following 
pneumococcal conjugate vaccine (PCV) immunisation is driven by unmasking of previously 
minor colonising serotypes or replacement acquisition by new serotypes. 
 
In this chapter we aimed to evaluate the use of multiplex quantitative PCR (qPCR) for the 
detection and density characterisation of multiple pneumococcal serotypes on nasopharyngeal 
swabs, from PCV naive black-African children previously investigated by traditional culture 
methods. 
 
40 
 
2.1. MATERIAL AND METHODS 
 
2.1.1. Study population 
We retrospectively analysed archived nasopharyngeal swab samples collected from a cohort 
of PCV-unvaccinated, HIV-uninfected infants in Soweto, South Africa, who had previously 
been investigated by standard culture methods 
142,185
. The parent study was a longitudinal, 
prospective study in which black-African HIV-infected and HIV-uninfected mothers and their 
infants were enrolled from January 2007 through to October 2007. The cohort included 250 
PCV naïve infants and their mothers, including 125 infants born to HIV-infected women but 
who were HIV-uninfected (HEU); and 126 infants born to HIV-uninfected mothers. All 
infants born to HIV-infected mothers had a nonreactive HIV-polymerase chain reaction at 
enrolment and were not breastfed. Participants had five scheduled visits dictated by the 
child’s age and a standardised questionnaire was administered at each study visit to gather 
demographic and clinical characteristics and to determine possible risk factors for S. 
pneumoniae carriage. The pneumococcal conjugate vaccine (PCV) immunisation of children 
was not available as standard-of-care during the study period.  
 
One nasopharyngeal (NP) swabs were taken from each participant at each study visit, 
including at 9 and 15-16 months of age. Swabs were stored in skim milk-tryptone-glucose-
glycerol (STGG) transport media at -70ºC at the Respiratory and Meningeal Pathogen 
Research Unit (RMPRU) in South Africa, as recommended by WHO 
212
. The samples were 
previously cultured for S. pneumoniae using standard culture methods and pneumococcal 
serotyping undertaken using the Quellung method as described 
36. 
If pneumococcal colonies 
presented with different morphologies on the same plate, one colony representative of each 
was sub-cultured and serotyped.  
 
2.1.2.  Multiplex qPCR methods 
Stored nasopharyngeal swab samples were thawed and processed. Briefly, NP swabs were 
vortexed for 30 seconds to release bacteria into the transport media and total nucleic acids 
were automatically extracted from STGG with the NucliSens ® easyMAG ® extraction 
system (BioMérieux, Marcy l’Etoile, France) according to manufactures instructions. 
Similarly, total nucleic acids were also extracted from pneumococcal reference strains 
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(positive control strains) grown in Todd-Hewitt broth supplemented with 5% yeast, with the 
NucliSens ® easyMAG ® extraction system according to manufactures instructions. Samples 
and pneumococcal reference strains were stored at – 20 °C. 
 
Control strains for the pneumococcal serotypes 1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7C, 9A, 9L, 9N, 
9V, 10A, 10B, 11A, 11B, 11C, 11D, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 15F, 16F, 
17A. 17F, 18A, 18B, 18C, 19A, 19B, 19F, 20, 21, 23A, 23B, 23F, 34 and 37 were obtained 
from the National Institute for Communicable Diseases (NICD). DNA from these strains were 
used to optimise PCR assays and as positive controls. 
 
The sequences for oligonucleotide primers and dye-labelled MGB probes were taken from 
previously published sequences, or designed with the ABI primer express software package, 
version 3.0 (Applied Biosystems, ABI, Foster City, USA). All primers and probes were 
designed based on previously published CpsA (Capsular polysaccharide) genes; in which all 
sequences were obtained from the Gene Bank database 
http://www.ncbi.nlm.nih.gov/genbank/). Primer and Probe sequences are described in Table 
2.1. Due to the high genotypic similarities between the capsule loci of certain serotypes, the 
qPCR method was unable to discriminate between some serotypes within a particular 
serogroup (i.e. 6A/B, 6C/D, 9A/L/N/V, 10A/B, 11A/B/C/F, 12A/B/F, 15A/B/C/F, 18A/B/C, 
19B/F, 23A/B and 34/37/17A), but was able to identify serotypes 1, 3, 4, 5, 7C, 13, 14, 16F, 
17F, 19A, 20, 21 and 23F individually. 
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Table 2.1: Primers and probe sequences for the qPCR detection of pneumococcal serotypes 
Primers/Probe
a
 name    Sequence (5′ - 3′) serotype/serogroup Source 
lytA-Fwd TCTTACGCAATCTAGCAGATGAAGC 
Streptococcus pneumoniae McAvin et al, 2001 lytA-Rev GTTGTTTGGTTGGTTATTCGTGC 
lytA-Probe (VIC)-TTTGCCGAAAACGCTTGATACAGGG-(MGB) 
    1-Fwd CGTGCGGTAATTGAAGCTATGA  
Streptococcus pneumoniae_serotype 1 Azzari et al, 2010 1-Rev  TGTGGCCCCAGCAACTCT  
1-Probe  (FAM)-TGCTTGCCCTTGTATAGGGT-(MGB) 
    3-Fwd GGTCAGCAGAAAGTATGCATTGG 
Streptococcus pneumoniae_serotype 3 Azzari et al, 2010 3-Rev  TCGTTTATCCAGGGTCTGATGA 
3-Probe  (VIC)-TATTGGATGTGGTTTATCGTGAAGA-(MGB)  
    4-Fwd TGGGATGACATTTCTACGCACTA 
Streptococcus pneumoniae_serotype 4 Azzari et al, 2010 4-Rev  CCGTCGCTGATGCTTTATCA 
4-Probe  (FAM)-TCCTATTGGATGGTTAGTTGGTGA-(MGB)  
    5-Fwd TTACGGGAGTATCTTATGTCTTTAATGG 
Streptococcus pneumoniae_serotype 5 Azzari et al, 2010 5-Rev  CAGCATTCCAGTAGCCTAAAACTAGA 
5-Probe  (VIC)-TTGTCTCAGCAACTCTATTTGGCTGTGGG-(MGB)  
    6A/B/C/D-Fwd AAGTTTGCACTAGAGTATGGGAAGGT 
Streptococcus pneumoniae_serogroup 6A/B/C/D Azzari et al, 2010 6A/B/C/D-Rev  ACATTATGTCCRTGTCTTCGATACAAG 
6A/B/C/D-Probe  (VIC)-TGTTCTGCCCTGAGCAACTGG-(MGB)  
 
 
  6C/D-Fwd TTGGGATGATTGGTCGTATTAG 
Streptococcus pneumoniae_serogroup 6C/D Azzari et al, 2010 6C/D-Rev  CTCTTCAATTAGTTCTTCAGTTCG 
6C/D-Probe  (FAM)-CCACGCAATTCGCCATC-(MGB) 
    7C-Fwd CGTCAGGAATAGGTGCAATCTCT 
Streptococcus pneumoniae_serotype 7C This Study 7C-Rev  TGAAATTCCAAGCGAAGCAA 
7C-Probe  (VIC)-TTCATCTATTGGTTCTTATGGTGTT-(MGB)  
    9A/L/N/V-Fwd TGGAATGGGCAAAGGGTAGTA 
Streptococcus pneumoniae_serogroup 9A/L/N/V Azzari et al, 2010 9A/L/N/V-Rev  TCGGTTCCCCAAGATTTTCTC 
9A/L/N/V-Probe  (FAM)-TTAATCATGCTAACGGCTCATCGA-(MGB) 
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    10A/B-Fwd CCTCTCCTATCAACTATTACTCATTATACTACCT 
Streptococcus pneumoniae_serotype 10A/B Azzari et al, 2010 
10A/B-Rev  AATAACCATAAGTCCCTAGATCATTCAAAG 
10A/B-Probe  
(VIC)-TCATTACAACTCCCTATGTGACACGGGTCTTTT-
(MGB)  
 
 
  11A/B/C/D/F-Fwd ACCGCATTTCTTATCGCACTATATT 
Streptococcus pneumoniae_serogroup 11A/B/C/D/F This Study 11A/B/C/D/F-Rev  TCTCCTTACCATCAAACATGTTAATCA 
11A/B/C/D/F-Probe  (FAM)-TGAATCAGTCTGACCGTTT-(MGB) 
    12A/B/F-Fwd GATTATTCGCTTGCCTCTTCATG 
Streptococcus pneumoniae_serogroup 12A/B/F Azzari et al, 2010* 12A/B/F-Rev ATAGCCGAAATAAGCTTTCCAGAA 
12A/B/F-Probe  (FAM)-ATTTGTAAGCGGACGTGCGATT-(MGB)  
 
 
  13-Fwd TCGGATTTAGTAGTAACCCCATTGA 
Streptococcus pneumoniae_serotype 13 This Study 13-Rev TTCTTGATTGAGGATGCATTTCC 
13-Probe  (VIC)-AGTAGTAAGAGATCATATTCAAG-(MGB)  
 
 
  14-Fwd CGACTGAAATGTCACTAGGAGAAGAT 
Streptococcus pneumoniae_serotype 14 Azzari et al, 2010 14-Rev AATACAGTCCATCAATTACTGCAATACTC 
14-Probe  (VIC)-TGTCATTCGTTTGCCAATACTTGATGGTCTC-(MGB)  
 
 
  15A/B/C/F-Fwd TTGAATCAGGTAGATTGATTTCTGCTA 
Streptococcus pneumoniae_serogroup 15A/B/C/F Azzari et al, 2010 15A/B/C/F-Rev  CTCTAGGAATCAAATACTGAGTCCTAATGA 
15A/B/C/F-Probe  (FAM)-CTCCGGCTTTTGTCTTCTCTGT-(MGB) 
    16F-Fwd GCAACTGGTATTTTTGATATTGGAGAA 
Streptococcus pneumoniae_serotype 16F This Study 16F-Rev  CAAAGGAATGCCATGCCATA 
16F-Probe  (NED)-AAAATGCTAACTTCGTTGGAGG-(MGB)  
    17F-Fwd GTAAAGATTTCATGTCCTATAAGGGAGAA 
Streptococcus pneumoniae_serotype 17F This Study 17F-Rev AGGCGTCCCTGTTTATGAGAAG 
17F-Probe  (FAM)-TTGTACATGGTCTGGATTT-(MGB) 
 
 
  18A/B/C-Fwd CCTGTTGTTATTCACGCCTTACG 
Streptococcus pneumoniae_serogroup 18A/B/C Azzari et al, 2010 18A/B/C-Rev TTGCACTTCTCGAATAGCCTTACTC 
18A/B/C-Probe  (FAM)-AACCGTTGGCCCTTGTGGTGGA-(MGB) 
 
 
  19A-Fwd TTCGACGACGTATCAGCTTCA Streptococcus pneumoniae_serotype 19A Azzari et al, 2010 
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19A-Rev TCATTGAGAGCCTTAACCTCTTCA 
19A-Probe  (VIC)-ACCCAAAACGGTTGACGCATTATACT-(MGB)  
 
 
  19B/F-Fwd GGTCATGCGAGATACGACAGAA 
Streptococcus pneumoniae_serogroup 19B/F Azzari et al, 2010 19B/F-Rev TCCTCATCAGTCCCAACCAATT 
19B/F-Probe  (VIC)-ACCTGAAGGAGTAGCTGCTGGAACGTTG-(MGB)  
 
 
  20-Fwd AAAGATACTGGCTGAGGAGCTATCTATT 
Streptococcus pneumoniae_serotype 20 Azzari et al, 2010 20-Rev AGTCAAAAGTACTCAACCATTCTGATATATTC 
20-Probe  (VIC)-AGGATAAGGTCTACTTTGTGGGAGTTC-(MGB)  
 
 
  21-Fwd CCATTTGAAGGACCAGTTGTTG 
Streptococcus pneumoniae_serotype 21 This Study 21-Rev AAAAAGCCACTATCAGGAATACCAA 
21-Probe  (FAM)-AATGGCATTGCTTCGTAAA-(MGB)  
 
 
  23A/B/F-Fwd GGTGGACTTTCCGATGCAA 
Streptococcus pneumoniae_serogroup 23A/B/F This Study 23A/B/F-Rev CACTGTCAACAAAAATGAGGTAATCTC 
23A/B/F-Probe  (VIC)-AAATGTCGGTATAGATAAAG-(MGB)  
 
 
  23F-Fwd TGCTATTTGCGATCCTGTTCAT 
Streptococcus pneumoniae_serotype 23F Azzari et al, 2010 23F-Rev AGAGCCTCCGTTGTTTCGTAAA 
23F-Probe  (FAM)-TTTCTCCGGCATCAAACGTTAAG-(MGB)  
 
 
  34/37/17A-Fwd GGATACTATGTACGAACAGATGGACTTG 
Streptococcus pneumoniae_serogroup 34/37/17A This Study 34/37/17A-Rev  CTCACTAACTCGCCCGAATAAAC 
34/37/17A-Probe  (FAM)-CCGACTATACTCCATTTGA-(MGB)  
        
Probe
a
: Minor Grove Binding (MGB) dye labelled TaqMan probe.
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2.1.3.  Primer optimisation, standard curves and quantification of the real-time PCR 
assays 
The qPCR’s was optimised in 25µL reaction volumes containing 12.5µL 2x TaqMan gene 
expression master mix (ABI) and 0.25mM MGB dye labelled probe (ABI) in a primer 
concentration matrix. Reactions were amplified with the ABI 7500 Real Time PCR system 
(Applied Biosystems, ABI, Foster City, USA) as per standard manufactures instructions with 
standard cycling times. Standard concentration curves and lower limits of detection (LLD) for 
each target serotype was determined by amplifying serial dilutions of purified genomic DNA 
extracted from reference strains with the linear dynamic range being 10
1
 – 107 copies per 
standard curve. Target control DNA was harvested from early exponential phase cultures 
(OD600 =0.1), and the number of CFU/swab was estimated from Cq values relative to the 
standard curve, which is based on the quantitative culture of the control DNA. 
 
The correlation coefficients (r
2
) of each standard curve was determined and the amplification 
efficiency (e) of a given primer pair was calculated by e = 10
–1/m
 -1, where m is the slope of 
the standard curve. Lower limits of detection (LLD) or analytical sensitivity was determined 
by the minimum number of copies of DNA that could be measured repeatedly by the primers 
in the 10-fold serial dilutions. All primer pairs were tested with genomic DNA from all 
bacterial controls to determine the analytical specificity. Further, intra-assay variation 
(repeatability) was determined by running the same samples four times in the same assay run 
and presented as standard deviation (SD) for the copy number of the samples. A ratio of the 
difference between the observed copy number and the expected copy number was calculated 
to determine the accuracy of the assays, while the inter-assay variation (reproducibility) was 
determined by the SD of the copy number of the same sample tested in different runs.  
 
Serotype targets were duplexed (Table 2.2) and paired reactions were tested to ensure that 
their Cq values did not shift by >1 Cq value, and that sensitivity and specificity remained the 
same as for singleplex reactions. 
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Table 2.2: Primer/probe duplex combinations  
Primmer/probe combinations Duplex reaction 
5 & 21 A 
20 & 23F B 
4 & 14 C 
3 &17F D 
1 &23A/B/F E 
6A/B/C/D & 6C/D F 
10A/B & 15A/B/C/F G 
13 & 9A/L/N/V H 
19A & 18A/B/C I 
19B/F & 12A/B/F J 
11A/B/C/F & 16F K 
7C & 34/37/17A L 
 
2.1.3.  Real-time PCR multiplex assay 
Target DNA was pre-screened for pneumococcus by PCR for the LytA gene as described
 213
. 
All LytA positive samples (Cq <35) were regarded as positive for pneumococci and tested for 
serotypes. Amplification data was analysed with the Applied Biosystems 7500 software, 
version 2.3 (Foster City, USA) with manually defined thresholds. Negative samples were 
defined as those with Cq values <35. Further, all LytA negative samples were tested for 
human GAPDH target to confirm the efficiency of the DNA extraction with all qPCR 
negative samples being positive for GAPDH.  
 
2.1.4.  Statistical analysis 
Statistical analysis was performed with STATA Version 11.0 (Statacorp, Texas, USA). All 
LytA positive samples in which no serotype was identified were omitted in the multiple 
carriage analysis. The sensitivities of the qPCR assay and culture were tested with 
McNemar’s test using culture as a reference, and when analysed for concordance, all 
serogroups were included as serotypes detected by qPCR vs. serotypes identified by culture. 
In the case of non-typable (NT) pneumococcus, we did not compare findings by culture and 
qPCR, as the qPCR method was not optimised to test for all pneumococcal serotypes and thus 
analysis could be misleading as a proportion of the NT detected by qPCR could belong to 
untested serotypes. For density of carriage, geometric mean densities (GMD) and 95% 
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confidence intervals (95%CI) of pneumococcal mean concentrations were calculated 
following log10 transformation on the data positive by qPCR. Further, the serotype specific 
propensity of whether a given serotype/serogroup was more likely to be found as a primary or 
non-primary isolate, was analysed using a two-tail Binomial test, in which the observed 
proportion of primary to non-primary isolates were compared. Results were considered 
significant when the p-value was < 0.05. 
 
2.1.5.  Ethical consent 
Ethical consent for the initial enrolment was obtained from the Medical Human Research 
Ethics Committee (HREC) of the University of Witwatersrand (HREC: 050705). Approval 
for further testing of samples was obtained from the HREC (M120972). Written, informed 
consent had been obtained from the parents/guardians of all the study participants at the time 
of initial enrolment. 
 
2.2.  RESULTS 
Molecular qPCR analysis involved 374 (83%) of the initial 450 nasopharyngeal swabs 
collected at either 9 or 15-16 months of age (Figure 2.1). Within the cohort, there were no 
differences in the prevalence of serotype colonisation detected by traditional culture methods 
between those in whom samples were and were not available (Appendix A). All children, in 
whom samples were available, were black-African, and 49.7% were male. Due to high 
similarities in findings at both 9 and 15-16 months of age, data was combined for the main 
analysis. 
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Figure 2.1: Schematic diagram of study population and sample availability  
Diagram indicating the number of children initially enrolled in a PCV-unvaccinated cohort of HIV-uninfected 
children, as well as the number of nasopharyngeal (NP) swabs available for subsequent molecular qPCR 
analysis. No swabs were collected due to a missed study visit and the number of NP swabs available for 
molecular testing was defined by whether there was an adequate volume of sample remaining. 
 
2.2.1.  Performance of the real-time qPCR assay 
All assays were effective in amplifying their respective targets with a high sensitivity, 
specificity and linearity with the exception of assay 10A/B in which only 10A was detected 
by the assay. The efficiency of all the assays ranged from 90% to 105% (Table 2.3). Within 
the linear dynamic range, the correlation coefficients (r
2
) of all the assays were 0.99. Further, 
all assays showed high analytical sensitivities with their respective primer and probe pairs 
with the limit of detection being equivalent 10 copies per PCR for all respective assays, with 
exception to primers/probes that detected serotypes/serogroups 5, 23F, 14, 6A/B/C/D, 13 and 
10A in which the LLD was 10 fold less sensitive (100 copies per PCR). All primer pairs and 
probes were tested with genomic DNA from all pneumococcal and bacterial controls, and no 
cross reactions occurred (Table 2.4). Both the inter-assay variation (repeatability) and inter-
assay variation (reproducibility) for all respective assays was <0.1, while the accuracy for all 
respective assays was within ±0.1 (Table 2.3).  
 
 
251 Children enrolled 
Nasopharyngeal (NP) swabs collected = 450 
9 months = 229 NP swabs 
16 months = 221 NP swabs 
 
Nasopharyngeal (NP) swabs available for subsequent molecular testing = 374 
9 months = 181 NP swabs 
16 months = 193 NP swabs 
 
       No swabs available = 52  
9 months = 20 NP swabs 
16 months = 32 NP swabs 
 
No sample available = 76 
9 months = 48 NP swabs 
16 months = 28 NP swabs  
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Table 2.3: Performance of the quantitative real-time PCR assay  
 
 
Bacterial target 
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Streptococcus pneumoniae (lytA) 97 0.99 10 0.02 0.043 0.025 
Streptococcus pneumoniae serotype 1 105 0.99 10 0.011 0.025 0.032 
Streptococcus pneumoniae serotype 3 94 0.99 10 0.025 -0.013 0.025 
Streptococcus pneumoniae serotype 4 91 0.99 10 0.074 -0.01 0.015 
Streptococcus pneumoniae serotype 5 95 0.99 100 0.018 0.048 0.047 
Streptococcus pneumoniae serogroup 6A/B/C/D 97 0.99 100 0.013 -0.26 0.023 
Streptococcus pneumoniae serogroup 6C/D 92 0.99 10 0.011 -0.078 0.041 
Streptococcus pneumoniae serotype 7C 102 0.99 10 0.008 -0.076 0.041 
Streptococcus pneumoniae serogroup 9A/L/N/V 97 0.99 10 0.019 -0.059 0.023 
Streptococcus pneumoniae serotype 10A/B 91 0.99 10 0.006 0.001 0.008 
Streptococcus pneumoniae serogroup 11A/B/C/D/F 98 0.99 10 0.027 0.023 0.053 
Streptococcus pneumoniae serogroup 12A/B/F 94 0.99 10 0.018 0.068 0.009 
Streptococcus pneumoniae serotype 13 94 0.99 10 0.003 -0.023 0.003 
Streptococcus pneumoniae serotype 14 91 0.99 100 0.078 -0.041 0.056 
Streptococcus pneumoniae serogroup 15A/B/C/F 98 0.99 10 0.056 -0.059 0.038 
Streptococcus pneumoniae serogroup 16F 92 0.99 10 0.03 -0.013 0.029 
Streptococcus pneumoniae serotype 17F 99 0.99 10 0.054 -0.026 0.018 
Streptococcus pneumoniae serogroup 18A/B/C 91 0.99 10 0.023 0.021 0.047 
Streptococcus pneumoniae serotype 19A 92 0.99 10 0.001 0.054 0.005 
Streptococcus pneumoniae serogroup 19B/F 93 0.99 10 0.006 0.001 0.003 
Streptococcus pneumoniae serotype 20 102 0.99 10 0.015 0.054 0.05 
Streptococcus pneumoniae serotype 21 101 0.99 10 0.098 0.075 0.11 
Streptococcus pneumoniae serogroup 23A/B/F 96 0.99 10 0.013 -0.056 0.021 
Streptococcus pneumoniae serotype 23F 90 0.99 100 0.002 -0.073 0.038 
Streptococcus pneumoniae serogroup 34/37/17A 92 0.99 10 0.002 0.09 0.013 
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Table 2.4: Analytical specificity of the quantitative real-time PCR assay 
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2.2.2.  Detection of pneumococcal carriage and serotype detection by culture and qPCR 
There was a modest concordance between qPCR and culture for the detection of 
pneumococcus from infant NP swabs (kappa = 0.58), with the LytA qPCR assay being more 
sensitive than culture (82% vs. 71%; p<0.001); Table 2.5. The qPCR demonstrated high 
sensitivity (84%) and specificity (88%) compared to culture used as a referent standard for 
detection of pneumococcus, with the overall density of pneumococcal carriage being higher in 
culture-positive (4.4, 95% CI: 4.34 - 5.05 CFU/ml) than culture-negative samples (3.77; 
95%CI: 3.59 - 3.95 CFU/ml); Figure 2.2.  
 
Table 2.5: Yield of culture and molecular qPCR for the detection Streptococcus pneumoniae 
in nasopharyngeal swabs (n = 374) 
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Culture (+) 8(2) 258(69) 266(71) 
<0.001 0.58 84 88 Culture (-) 59(16) 49(13) 108(29) 
Total 67(18) 307(82) 374(100) 
Numbers are value (%), p-values of <0.05 were considered significant.  
 
 
Figure 2.2: Density of pneumococcal carriage as determined by quantitative PCR (qPCR) 
grouped by culture positive and culture negative samples 
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Discordant results for identification of overall pneumococcus between qPCR and culture were 
strongly associated with density of pneumococcal carriage (Table 2.6). The majority (47/49; 
96%) of qPCR positive but culture-negative samples had estimated copy numbers of <10
4 
colony forming units (CFU) /ml per swab. Similarly, the majority (7/8; 87.5%) of qPCR 
negative but culture-positive samples were reported as “scant” (<5 colonies/plate) on culture. 
As pneumococcal density measured by qPCR increased, so did the detection by culture 
increase, with a perfect concordance (21/21; Kappa=1.0) between culture and qPCR at a 
carriage density of >10
6
 CFU/ml. 
 
Table 2.6: Detection of overall pneumococcal carriage by culture, stratified by colonisation 
density measured by quantitative PCR (qPCR) 
Density (CFU/ml) 
Number culture positive/ number in density category by PCR 
(%) 
Undetected 8/67 (12) 
0- 10
2
 1/4 (25) 
> 10
2
-10
3
 22/37 (59) 
>10
3
-10
4
 64/81 (79) 
>10
4
-10
5
 85/97 (88) 
>10
5
-10
6
 65/67 (97) 
>10
6 
-10
7
 18/18 (100) 
>10
7
-10
8
 3/3 (100) 
Total 266/374 (71) 
CFU/ml, colony forming units per millimetre as measured by qPCR. Values are number culture positive/number 
in density category by qPCR (%). 
 
There was a high concordance (Kappa = 0.73) between serotypes/groups identified by culture 
and those identified by qPCR, including for those specific serotypes which were individually 
identifiable on qPCR (kappa = 0.68); data not shown. The qPCR method, however, identified 
an additional 150 (57.5%) serotypes/serogroups above those identified by the culture method, 
including higher detection prevalence by qPCR of serotypes/serogroups 5 (6.61% vs. 0%; 
p<0.001), 9A/L/N/V (10.7% vs. 4%; p<0.001), 11A/B/C/D/F (3.5% vs. 1.1%, p=0.002), 13 
(2.1% vs. 0.3%, p=0.008), 14 (7% vs. 4.8%, p=0.002), 18A/B/C (4.5% vs. 2.4%, p=0.011), 
19B/F (18.7% vs. 15.5%, p=0.033) and 34/37/17A (2.1% vs. 1.1%, p=0.05) (Figure 2.3). Of 
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these additional serotypes detected by qPCR, 98.8% had densities <10
4 
CFU/ml (Table 2.7). 
Further, 78% (117/150) of the additional serotypes detected by qPCR were co-carried with 
other pneumococcal serotypes, with only 12.8 % (15/117) of these, being the highest density 
colonising serotype (Table 2.8). 
Figure 2.3: Overall prevalence of nasopharyngeal (NP) pneumococcal colonisation as 
detected by traditional culture and quantitative PCR (qPCR) in a PCV-unvaccinated, HIV-
uninfected cohort. 
 
Concordance between traditional culture and quantitative PCR (qPCR) were calculated using McNemar’s test 
with serogroups detected by qPCR included as serotypes. p-values of <0.05 were considered significant. 
Serogroup 6A/B (54): 35.2% Serotype 6A and 64.8% Serotype 6B on culture method. Serogroup 6C/D (1): 
100% Serotype 6C on culture method. Serogroup 11/A/B/C/D/F (4): 100% were serotype 11A on culture 
method. Serogroup 15/A/B/C/F (14): 21%, 64.3%, and 14.2% were serotypes 15A, 15B and 15C on culture 
method respectively. Serogroup 18A/B/C (9): 100% were serotype 18C on culture method. Serogroup 19B/F 
(58): 8.6% were serotype 19B and 91.4% were serotype 19F on culture method. Serogroup 23A/B (5): 60% were 
serotype 23A and 40% were serotype 23B on culture method. Serogroups 34/37/17A (4): 100% were serotype 34 
on culture method.
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Table 2.7: Detection of pneumococcal serotype carriage by culture, stratified by colonisation density measured by quantitative PCR (qPCR) 
 
Pneumococcal 
density by 
qPCR (CFU/ml) 
Serotype/group 1
 
3
 
4
 
5
 
6
A
/B
 
6
C
//
D
 
7
C
 
9
A
/L
/N
/V
 
1
0
A
 
1
1
A
/B
/C
/F
 
1
2
A
/B
/F
 
1
3
 
Undetected 0/371 1/369(0.3) 0/371 0/351 3/319(0.9) 0/369 0/372 1/333(0.3) 0/370 0/361 0/374 0/366 
0- 10
2
 0 0 0/1 0 0 0 0/1 0/19 0 0/7 0 0 
> 10
2
-10
3
 0/2 0/1 0/1 0/23 7/7(100) 0/2 0 1/8(13) 0 0/2 0 0/5 
>10
3
-10
4
 0 1/1(100) 1/1(100) 0 12/16(100) 0/2 1/1(100) 7/7(100) 0/1 2/2(100) 0 0/1 
>10
4
-10
5
 0/1 1/2(50) 0 0 18/18(100) 0 0 5/6(83) 1/1(100) 2/2(100) 0 0/1 
>10
5
-10
6
 0 1/1(100) 0 0 9/9(100) 0 0 1/1(100) 0/2 0 0 0 
>10
6 
-10
7
 0 0 0 0 5/5(100) 1/1(100) 0 0 0 0 0 1/1(100) 
>10
7
-10
8
 0 0 0 0 0 0 0 0 0 0 0 0 
>10
8
 0 0 0 0 0 0 0 0 0 0 0 0 
Total 0/374 4/374(1.1) 1/374(0.3) 0/374 54/374(14.4) 1/374(0.3) 1/374(0.3) 15/374(0.3) 1/374(0.3) 4/374(1.1) 0/374 1/374(0.3) 
Serotype/group 1
4
 
1
5
A
/B
/C
/F
 
1
6
F
 
1
7
F
 
1
8
A
/B
/C
 
1
9
A
 
1
9
B
/F
 
2
0
 
2
1
 
2
3
A
/B
 
2
3
F
 
3
4
/3
7
/1
7
A
 
Undetected 1/348(0.9) 2/356(0.6) 0/366 1/371(0.3) 1/357(0.3) 1/360(0.3) 0/304 1/372(0.3) 1/370(0.3) 3/365(0.8) 5/324(1.5) 0/366 
0- 10
2
 0 0 0 0/1 0/1 0/2 10/12(83.3) 0 0 0 0 1/2(50) 
> 10
2
-10
3
 2/11(18) 1/3(33.3) 3/3(100) 0/1 1/7(14.3) 1/3(33.3) 8/12(66.7) 0 2/2(100) 2/8(25) 17/26(65.4) 1/4(25) 
>10
3
-10
4
 10/10(100) 5/9(55.6) 3/3(100) 1/1(100) 4/5(80) 8/9(88.9) 21/23(91.3) 0 0 0/1 15/16(93.8) 1/1(100) 
>10
4
-10
5
 4/4(100) 6/6(100) 0/1 0 3/4(75) 0 15/18(83.3) 2/2(100) 0 0 7/8(87.5) 1/1(100) 
>10
5
-10
6
 1/1(100) 0 0 0 0 0 3/4(75) 0 2/2(100) 0 0 0 
>10
6 
-10
7
 0 0 0 0 0 0 1/1(100) 0 0 0 0 0 
>10
7
-10
8
 0 0 1/1(100) 0 0 0 0 0 0 0 0 0 
>108 0 0 0 0 0 0 0 0 0 0 0 0 
Total 18/374(4.8) 14/374(3.7) 7/374(1.9) 2/374(0.5) 9/374(2.4) 10/374(2.7) 58/374(15,5) 3/374(0.8) 5/374(1.3) 5/374(1.3) 44/374(13.4) 4/374(1.1) 
   
 
 
 
Number of culture positive/number in density category by qPCR (%) 
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Table 2.8: Yield of additional serotypes detected only by quantitative PCR (qPCR) in relation 
to being co-carriage with other pneumococcal serotypes 
Serotype/group 
Number of serotypes co-
carried/additional serotypes detected 
by qPCR (%) 
Number of dominating colonizing 
serotype/number of serotypes co-carried 
(%)
* 
1 2/3(75) 1/2(50) 
3 2/2(100) 2/2(100) 
4 2/2(100) 0/2 
5 23/23(100) 1/23(4.3) 
6A/B 3/4(75) 2/3(66.7) 
6C/D 4/4(100) 0/4 
7C 0/1 0 
9A/L/N/V 19/26(73) 0/19 
10A 2/3(75) 1/2(50) 
11A/B/C/F 7/9(77.8) 2/7(28.6) 
12A/B/F 0 0 
13 6/7(85.7) 0/6 
14 7/9(77.8) 1/7(14.3) 
15A/B/C/F 5/6(83.3) 1/5(25) 
16F 0/1 0 
17F 1/2(50) 0/1 
18A/B/C 7/9(77.8) 1/7(14.3) 
19A 3/5(60) 0/3 
19BF 12/13(92.3) 2/12(16.7) 
20 0 0 
21 0 0 
23A/B 5/6(83.3) 1/5(20) 
23F 6/11(54.5) 0/8 
34/37/17A 1/4(25) 0/1 
Total  117/150 15/117(12.8) 
*Density of pneumococcal carriage was used to determine if the additional serotypes detected only by 
quantitative PCR (qPCR) were dominant colonising serotypes (Highest density coloniser). 
 
 
2.2.3.  Pneumococcal co-colonisation 
Molecular qPCR was more sensitive than culture in detecting pneumococcal serotypes that 
were co-carried with two and three or more serotypes detected in 19.2% vs. 4.5% (p<0.001) 
and 9.4% vs. 0% (p<0.001) of swabs respectively (Table 2.9). A further 14% (43/307) of 
LytA positive NP swabs were negative for all the serogroups/serotypes we tested for, 
implying they were either non-typable, belonged to one of the untested serotypes, or were 
LytA positive non-pneumococcal streptococcal species. Due to the strong concordance 
between serotypes identified by qPCR also being identified by culture; however, we could 
assume that at least 11/43 (25.6%) of NT serotypes identified by qPCR belonged to one of the 
serotypes we did not test for (results not shown). 
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Table 2.9: Pneumococcal co-colonisation as measured by traditional culture and quantitative 
molecular PCR (n = 374) 
 
Culture qPCR  p-value 
a
 
Not colonised  108(29) 67(18) 
<0.001 
Colonised  266(71) 307(82) 
1 serotype  239(99.8) 176(57.3) <0.001 
2 serotypes  12(4.5) 59(19.2) <0.001 
3 + serotypes 0 29(9.4) <0.001 
Values are number (%). For multiple pneumococcal carriages % values are calculated based on total 
number of samples positive for LytA. PCV7, 7-valent pneumococcal conjugate vaccine. 
a
 as defined by 
McNemer’s test. p-value <0.05 were considered significant.  
 
 
Serotypes/serogroups 6A/B, 19BF, 23F, 5, and 9A/L/N/V were the most common serotypes to 
be simultaneously co-carried as detected by molecular qPCR (Figure 2.4), with serogroups 
6A/B and 19B/F being the most common co-colonisers (prevalence 11/88, 12.5%), followed 
by serogroup 19B/F and serotype 5 (prevalence 8/88, 9.1%). Serotype/groups 6A/B 
(prevalence 52/264, 19.7%), 19B/F (prevalence 51/264, 19.3%) and 23F (prevalence 40/264, 
15.2%) were the highest density colonisers from samples that tested positive by qPCR 
(dominant first colonising serotype), with serotype 5 (prevalence 21/88, 23.9%) and 
serogroup 9A/L/N/V (prevalence 7/29, 24%) being the most common second and third 
colonisers respectively, as determined by density of carriage from samples that tested positive 
by qPCR. Further, serogroup 6A/B was most frequently found as a primary isolate 
(prevalence 42/44; 95.5% occasions) with other co-colonising serotypes, serotypes/group 1, 3, 
20, and 34/37/17A were identified as primary isolates only, and serotype 17F and 10A were 
respectively identified as second and third colonisers only. The serotype specific propensity of 
whether a given serotype/serogroup is more likely to be found as a primary or non-primary 
isolate is shown in Figure 2.5, with serotypes/serogroups 6A/B (p<0.001), 19B/F (p<0.001), 
23F (p<0.001), 15A/B/C/F (p<0.001) and 34/37/17A (p=0.008) being more likely to be 
identified as a primary than a non-primary isolate and serotype 5 being more likely to be 
identified as a non-primary isolate (p<0.001). 
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Figure 2.4: Serotype/group specific ranking of multiple pneumococcal carriage 
Each isolate of S. pneumoniae was ranked according to its carriage density as determined by 
quantitative PCR (qPCR) to other isolates present in the same sample. Single colonisers were included 
in the analysis as primary colonising serotypes. 
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Figure 2.5: Serotype specific propensity of whether a given serotype/serogroup is more likely 
to be found as a primary or non-primary isolate 
 
Pneumococcal serotypes identified from nasopharyngeal swabs of black South-African children were classified 
according to whether they occurred as a primary or non-primary isolate as determined by carriage density of 
qPCR positive samples. Single colonisers were included in the analysis as primary isolates. The box at the top of 
the graph is an inset of the blocked region at the bottom * Results were considered significant when the p-value 
was < 0.05. 
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2.3.  DISCUSSION 
The findings of our study showed that qPCR was more sensitive in detecting concurrent 
carriage with multiple pneumococcal serotypes, with at least 28.7% of all LytA positive 
nasopharyngeal samples having multiple serogroups/types identified, compared to 4.5% of 
culture positive cases. Further, we were able to quantify the relative proportion of these 
serotypes and found the majority of the additional serotypes detected by qPCR to have a 
lower bacterial load (<10
4
 CFU/ml) than the dominant colonising serotype, indicating why 
these less dominant serotypes are likely missed by traditional culture methods that may be 
suboptimal for detecting low density carriage.  
 
Serotypes/serogroups 6A/B, 19B/F, 23F, 5 and 9A/L/N/V were found as common co-
colonisers of the nasopharynx. While serotypes/serogroups 6A/B, 19B/F, 23F and 9A/L/N/V 
are included among PCV-7 targeted serotypes, serotype 5 is a non-PCV7 serotype, hence 
immunisation with PCV7 could provide an opportunity for this serotype to occupy the vacant 
niche and contribute to replacement disease in our setting, as it has also been shown to have 
high invasive disease potential in South Africa 
13,100 
. Further, several models have 
demonstrated a competition between pneumococcal serotypes for both acquisition and 
persistence of colonisation 
58,214,215
, with more prevalent and higher colonising density 
serotypes being less metabolically demanding and thus better able to grow in a nutrient 
deficient environment. Our findings were in line with those from Dhoubhadel et al, in that 
concurrent colonising serotypes had different bacterial loads, with one serotype dominating 
over the other(s), which may explain the competition among concurrent colonising serotypes 
for growth due to limited nutrients and space 
43
. Further, few studies have been powered to 
determine if certain pairs of serotypes occur more frequently together, with most finding no 
significant combinations above the 5% threshold error 
59,215,216
. Our study, however, found 
serogroups 6A/B and 19B/F to be the most common concurrent colonisers, occurring in 
12.5% of co-colonised children, followed by serogroup 19B/F and serotype 5, which were 
found in 9.1% of co-colonised children. 
 
A limited number of studies have investigated for concurrent colonisation with pneumococcal 
serotypes in children, with rates varying from 1.5% to 40% according to geographical 
distribution and method used 
33,37,62,139
. Findings from most of these studies, however, were 
limited in that the majority used non quantitative traditional culture based methods that were 
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insensitive in detecting multiple carriages, and therefore likely underestimated the true 
prevalence of this phenomenon 
139
. Concurrent carriage of multiple pneumococcal serotypes 
in the present study was found in 28.7% of all colonised children. This finding was 
comparable to a recent study by Wyllie and collaborators that also used qPCR, where 
concurrent colonisation of multiple pneumococcal serotypes was found in 22% of colonised 
Nepalese children 
65
. Other methods have also been used to investigate concurrent 
colonisation such as conventional PCR 
38,39
, colony blot 
40
, RFLP 
41
 and microarray 
42
, with 
the latter recently been shown to have the best performance overall for pneumococcal 
serotyping 
217
. In studies done by Valente et al and Kandasamy et al, microarray found 
concurrent colonisation in 20% and 22% of colonised Portuguese and Nepalese children 
respectively 
59,63. While these results are comparable to our findings, Kamng’ona and 
colleagues found concurrent colonisation in 40% of Malawian children by microarray, a 
higher rate compared to our findings 
62
. Our qPCR method, however, had the added benefit in 
that we were able to quantify the relative proportion of concurrent colonising serotypes, it did 
not rely on an initial culture step which might change the relative proportion of the various 
strains, and it is less labour intensive and less expensive.  
 
Our study was limited in that the qPCR method did not detect all pneumococcal serotypes and 
thus co-carriage in samples colonised with these pathogens could have been missed and the 
rate of concurrent colonisation could have been underestimated. Secondly, our method was 
not able to discriminate between all serotypes within their respective serogroups; however, 
due to high concordance between culture and qPCR for the detection of serotypes, the relative 
proportion of these serotypes could be estimated as similar to the proportion detected by 
culture. We were also not able to compare non-typables detected by culture and qPCR, as the 
qPCR method was not optimised to test for all pneumococcal serotypes and thus analysis 
could be misleading as a proportion of the NT detected by qPCR would rather indicate that 
we did not have the assay to test for all serotypes, rather than it being true pneumococcal NT. 
In addition, the loss of sensitivity by qPCR when comparing results to culture was most 
probably a result of degradation of DNA as a result of long-term storage and/or repeated 
freezing and thawing of samples. As this was a retrospective study, there was no residual 
sample after testing available and therefore additional culture of the frozen samples to confirm 
sample failure was not possible. Further, we were not able to compare the densities of 
serotypes detected by qPCR in culture negative vs. culture positive swabs as our study was 
not adequately powered. Lastly a recent study by the PneuCarriage project group found qPCR 
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to have a large number of false positive results when testing pneumococcal spiked samples 
217
. While this is concerning, the majority of false positives were for assays not included in 
our method. However, serotype 5 was the only serotype to be more commonly isolated as a 
non-primary than a primary isolate which raises a question of whether this serotype is unable 
to be cultured or if the qPCR method was giving off false positives for this assay, and thus 
further investigation is needed which was not possible in this study due to lack of residual 
sample remaining after molecular testing. However, a Cq cut off <35Cqs was implemented, 
and both positive and negative controls were used for all assays which should reduce this 
effect.  
 
In conclusion, molecular detection of pneumococcal serotypes was more sensitive than 
culture and allowed us to detect multiple serotypes. The ability of qPCR to detect 
pneumococcus at a low carriage density will allow us to gain a better understanding of 
serotype carriage and its impact in disease prevalence.  
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CHAPTER 3: PNEUMOCOCCAL CONJUGATE VACCINE AND 
NASOPHARYNGEAL PNEUMOCOCCAL COLONISATION IN 
AFRICAN CHILDREN 
 
The human nasopharynx is colonised with multiple commensal and some potentially 
pathogenic organisms, including Streptococcus pneumoniae 
200.
 Vaccination of infants 
with the pneumococcal conjugate vaccine (PCV) reduces their risk of acquisition of 
vaccine-serotype nasopharyngeal colonisation, whereas there is an increase in detection 
of non-vaccine serotype colonisation 
134
. The basis for the increase in non-vaccine 
serotype colonisation could involve either replacement colonisation of the nasopharynx 
because of the vacant ecological niche resulting from PCV-vaccination reducing the 
nasopharyngeal colonisation acquisition rate of vaccine-serotype, or unmasking of 
prevailing non-vaccine serotype colonisers which were not previously recognised by 
traditional culture method that are biased in detecting only the dominant colonising 
serotype 
136
. Molecular detection of pneumococci in the nasopharynx have several 
advantages over traditional culture based methods, including detection of multiple 
serotypes from a single sample with high sensitivity, as well as quantitative PCR 
methods being able to measure the density of colonisation and relative proportion of 
colonising serotypes as shown in chapter 2. 
 
The aim of this chapter was to evaluate the effect of infant vaccination with 7-valent 
PCV (PCV7) on the density of serotype-specific nasopharyngeal colonisation to 
delaminate the relative role of serotypes replacement versus unmasking as the cause for 
the increase in non-vaccine serotype colonisation in PCV7-vaccinated children. 
 
3.1 MATERIAL AND METHODS  
 
3.1.1.  Study population 
We retrospectively analysed archived nasopharyngeal swab samples collected from a PCV-
unvaccinated and PCV7-vaccinated cohort of HIV-uninfected infants in Soweto, South 
Africa. The parent study of the PCV7-vaccinated cohort initially enrolled 125 HIV-exposed-
uninfected (HEU) and 125 HIV-unexposed infants (6 – 12 weeks old when enrolled) between 
April 2005 and June 2006 as part of a larger study investigating the effect of HIV-exposure 
and timing of ART initiation in HIV-infected children on immune response to PCV7 
142,185
. 
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These infants were scheduled to receive three doses of PCV7 (i.e. Prevnar®; Wyeth Vaccines, 
NJ, USA) at 6, 10 and 14 weeks of age
 
, as well as other scheduled childhood vaccines 
included in the public immunisation program at the time of study. In addition, a parallel 
cohort of of 251 PCV7 naïve infants and their mothers were enrolled between January 2007 
through to October 2007, including 125 infants born to HIV-infected women but who were 
HIV-uninfected (HEU); and 126 infants born to HIV uninfected mothers (HIV-unexposed) 
which the population was fully described in chapter 2, section 2.1.1. 
142
. During the course of 
both studies, PCV immunisation of children in Soweto (birth cohort 28,000 per annum) was 
limited mainly to study-participants (approximately 600) of the PCV7-vaccinated cohort, as 
the vaccine was only introduced into the pubic immunisation program in May 2009 
218
. 
 
Nasopharyngeal (NP) swabs were taken at several time intervals, including at 9 and 15-16 
months of age in both cohorts. Swabs were stored in skim milk-tryptone-glucose-glycerol 
(STGG) transport media at the Respiratory and Meningeal Pathogen Research Unit (RMPRU) 
in South Africa, as recommended by WHO 
212
. The samples were previously cultured for S. 
pneumoniae using standard culture methods and pneumococcal serotyping undertaken using 
the Quellung method as described 
36. 
Serotypes 4, 6B, 9V, 14, 18C, 19F or 23F were 
categorised as PCV7 vaccine-serotypes and the rest as non-vaccine serotypes.  
 
3.1.2.  Multiplex qPCR methods 
The details for the multiplex qPCR have been described in chapter 2, section 2.1.2.  
 
3.1.3.  Statistical analysis 
Statistical analysis was performed with STATA Version 11.0 (Statacorp, Texas, USA). 
Pearson X
2
 test or student t-test was used to compare baseline characteristics between the 
cohorts. Comparisons and adjusted odd ratios of prevalence of bacterial colonisation between 
cohorts were analysed using logistic regression models adjusted for covariates, including race, 
passive smoke exposure, day care attendance, co-trimoxazole usage, and mean age in weeks 
at sample collection. For density of carriage, geometric mean densities (GMD) and 95% 
confidence intervals (95% CI) of pneumococcal mean concentrations were calculated 
following log10 transformation on the data, using analysis of covariance to adjust for possible 
covariates. Furthermore, the serotype specific propensity of whether a given 
serotype/serogroup was more likely to be found as a primary or non-primary isolate, was 
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analysed using a two-tail Binomial test, in which the observed proportion of primary to non-
primary isolates were compared. Seorotype/serogroups were determined as being a primary or 
a non-primary isolate according to their respective carriage density, in which the primary 
isolate had a higher carriage density than the non-primary isolate(s). Results were considered 
significant when the p-values were <0.05. 
 
3.1.4.  Ethical consent 
Ethical consent for the initial enrolment of the two cohorts was obtained from the Medical 
Human Research Ethics Committee (HREC) of the University of Witwatersrand [Vaccinated 
cohort: HREC: 040704, also registered under Clinical trials number NCT00099658, and the 
PCV-unvaccinated cohort: HREC: 050705]. Approval for further testing of samples was 
obtained from the HREC (M120972). Written, informed consent had been obtained from the 
parents/guardians of all the study participants at the time of initial enrolment.  
 
3.2.  RESULTS  
Molecular qPCR analysis involved 713 (83%) of the initial 857 nasopharyngeal swabs 
collected from children, at either 9 or 15-16 months of age (Figure 3.1). Within each cohort, 
there were no differences in the colonisation patterns done by standard methodology, between 
those in whom samples were and were not available (Appendices A & B). Among the 
children in whom samples were available, 92% were African, and 52% were male (Table 3.1). 
Day care attendance was higher in PCV-vaccinated children at 9 (52% vs. 22.1%; p<0.001) 
and 16 months of age (53.6% vs.37.3%; p=0.002), while the mean age (in weeks) at time of 
sample collection was 40.7 (Standard deviation, SD 2.3) and 69.5 (SD 6) in PCV-
unvaccinated children, and 39.3 (SD 3.1; p<0.001) and 66.7 (SD 1.8; p<0.001) in PCV-
vaccinated children at 9 and 16 months of age respectively. Although the differences in age 
are small and thus unlikely to be epidemiologically or clinically significant in terms of the 
likelihood of affecting the results, we subsequently adjusted for this as well as the above 
mentioned differences using multivariate analysis.  
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Figure 3.1: Schematic diagram of study population 
Diagram indicating the number of children initially enrolled in a PCV-unvaccinated and PCV7-vaccinated cohort 
of HIV-uninfected children, as well as the number of nasopharyngeal (NP) swabs available for subsequent 
molecular qPCR analysis. PCV7-vaccinated participants were excluded from analysis if they did not receive all 
three doses of the pneumococcal conjugate vaccine (PCV) within protocol-defined window periods. The number 
of NP swabs available for molecular testing was defined by whether there was an adequate volume of sample 
remaining. EQA, samples were used for external quality assessment.
501 Infants enrolled 
213 infants received all 3 doses of PCV7 
251 PCV7-unvaccinated  
PCV7-vaccination schedule  
1
st
 dose (administered ± 6 weeks of age): n = 220  
2
nd
 dose (administered ± 10 weeks of age): n = 245 
3
rd
 dose (administered ± 14 weeks of age): n = 246 
 
250 PCV7-vaccinated  
Nasopharyngeal (NP) swabs collected 
9 months = 207 NPs 
16 months = 200 NPs 
  
Nasopharyngeal (NP) swabs collected 
9 months = 229 NPs 
16 months = 221 NPs 
  
857 NP swabs collected in total 
Nasopharyngeal swabs available for 
subsequent molecular testing.  
9 months = 175 NP swabs 
16 months = 164 NP swabs 
  
Nasopharyngeal swabs available for 
subsequent molecular testing.  
9 months = 181 NP swabs 
16 months = 193 NP swabs 
  
713 NP swabs available for qPCR analysis  
No sample = 76 
Inadequate volume = 76  
No swab = 19  
Missed visit = 3 
Unable/unwilling to adhere = 11  
Withdrew consent = 2  
Lost to follow up = 3 
 
No swab = 52 
Missed visit = 52  
No sample = 68 
EQA = 13  
Inadequate volume = 55  
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Table 3.1: Demographic features at two study visits when analysed for nasopharyngeal (NP) bacterial colonisation in PCV7-vaccinated and 
PCV-unvaccinated, HIV-uninfected children 
 9 month old children 16 month old children 
 PCV-unvaccinated PCV7-vaccinated 
p -value  PCV-unvaccinated PCV7-vaccinated p -value  
Number of children enrolled  250 251 - 250 251 -  
Available NP swabs for molecular analysis  181 175 - 193 164 -  
HIV status: Exposed (%) 111 (61.3) 104 (59.4) 0.40 99 (51.3) 97 (59.1) 0.24 
                 : Unexposed (%) 70 (38.7) 71 (40.6)  94 (48.7) 67 (40.9)  
Mean birth weight (SD) grams  3061 (440) 3097 (482) 0.45 3079 (427) 3126 (476) 0.43 
Male sex (%) 87 (48.1) 96 (54.9) 0.12 99 (51.3) 89 (54.3) 0.25 
Race: Black African (%) 181 (100) 150 (85.7) <0.001 193 (100) 132 (80.5) <0.001 
        : Mixed ancestry (%) - 25 (14.3)  - 32 (19.5)  
Smoking household contact (%) 66 (36.5) 81 (42.3) 0.003 65 (33.68) 64(39) 0.004 
Co-trimoxazole prophylaxis (%) 95 (52.5) 81 (46.3) 0.2 71(36.8) 68(41.5) 0.15 
Mean numbers of children (SD) < 5 years  1.6 (0.8) 1.6 (0.7)  0.6 1.6 (0.82) 1.5 (0.84) 0.21 
Mean number of household contacts (SD)  5.3 (2.2) 5.2 (2.3)  0.81 5.2 (2.07) 5.1 (2.36) 0.17 
Day care attendance (%) 40 (22.1) 91 (52)  <0.001 72 (37.31) 81 (53.64) 0.002 
Breast feeding (%) 41 (22.7) 44 (25.1) 0.33 37 (19.2) 38 (23.3) 0.43 
Mean age (SD) in weeks at visit 40.7 (2.3) 39.3 (3.1) <0.001 69.5 (6.01) 66.7(1.6) <0.001  
 
Pearson X
2
 test or student t-test was used to compare baseline characteristics between the cohorts and demographic features with a p-value <0.2 were included as possible 
cofounders in multivariate analysis. PCV7, Seven-valent pneumococcal conjugate vaccine. NP, nasopharyngeal. SD, standard deviation. 
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3.2.1.  Pneumococcal co-carriage with respect to PCV7-vaccination status 
Molecular qPCR detected one, two and three or more serotypes in 42.8%, 16.5% and 5.3% 
NP swabs respectively. The remaining 13.2% NP swabs were LytA positive, but negative for 
all the serotypes that were tested, implying they were either non-typable, belonged to untested 
serotypes, or were LytA positive non-pneumococcal streptococcal species. Failure to detect 
qPCR-typable pneumococci at 9 months of age was more common in PCV7-vaccinated 
(28.9%) than PCV-unvaccinated children (17.1%; p=0.01; Table 3.2); however, by 16 months 
of age, this difference was only of borderline significance (25% vs. 18.7 %; p=0.06). Further, 
PCV-unvaccinated children were more likely to have only a single serotype identified 
compared to PCV7-vaccinated children at both 9 (64.6% vs. 59.2%; p=0.025) and 16 months 
(50.3% vs. 44.7%; p=0.019) of age respectively.  
 
Amongst co-carriers, concurrent colonisation by PCV7-serotypes and non-vaccine serotypes 
was lower among PCV7-vaccinated than PCV-unvaccinated children at both 9 (62.1% vs. 
66.7%, p=0.006) and 16 (55.3% vs. 63.2%, p=0.004) months of age. Concurrent carriage of 
multiple PCV7-serotypes only was also lower in PCV7-vaccinated compared to PCV-
unvaccinated children at 9 (13.8% vs. 30.7%; p=0.002) and 16 (2.6% vs. 22.4%; p=0.005) 
months of age. In contrast, concurrent carriage of multiple non-vaccine serotypes was higher 
in PCV7-vaccinated compared to PCV-unvaccinated children at 9 (24.1% vs. 2.6%, p=0.015) 
and 16 (42% vs. 14.3%, p=0.002) months of age.  
 
Table 3.2: Co-colonisation by vaccine-types and non-vaccine type pneumococcus in HIV-
uninfected children as measured by quantitative molecular PCR 
 
9 month old children  16 month old children  
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Not colonised  31(17.1) 50(28.9) 
0.01 
36(18.7) 41(25) 
0.06 
Colonised  150(82.9) 125(71.4) 157(81.3) 123(75) 
Not typable
a 
14(9.3) 22(17.6) 0.09 29(18.5) 29(23.4) 0.88 
Single carriers 97(64.6) 74(59.2) 0.025 79(50.3) 55(44.7) 0.019 
Multiple carriers  39(26) 29(23.2) 0.87 49(31.2) 39(31.7) 0.63 
+ 1 VT 12(30.7) 4(13.8) 0.002 11(22.4) 1(2.6) 0.005 
VT and NVT  26(66.7) 18(62.1) 0.006 31(63.2) 21(55.3) 0.004 
+1 NVT 1(2.6) 7(24.1) 0.015 7(14.3) 16(42) 0.002 
 
p -values were determined by multivariate logistic regression, controlling for race, smoking household contact, 
co-trimoxazole use, day care attendance and mean age at time of sample collection. Values are number (%). 
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PCV7, 7-valent pneumococcal conjugate vaccine. 
a
 Non-typables (NT), LytA positive, serotype negative 
samples. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 23F). NVT, non-vaccine 
serotypes/serogroups (1, 3, 5, 6C/D, 7C, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 
23A/B, and 34/37/17A). p-value <0.05 considered significant. 
 
 
Among PCV-unvaccinated children, PCV7-serogroups 6A/B (prevalence: 52/264, 19.7%), 
19B/F (prevalence: 51/264, 19.3%), and PCV7-serotype 23F (prevalence: 40/265, 15.2%) 
were the highest density colonising serotypes. Further, non-vaccine serotype 5was the most 
prevalent second colonising serotype ranked by having a lower density than the primary 
colonising serotype, but a higher density than the tertiary colonising serotype. Similarly, 
PCV7-serogroup 9A/L/N/V was the most prevalent tertiary colonising serotype/serogroup 
ranked by having a lower density than both the primary and secondary colonising serotypes 
(Figure 3.2). 
 
 
Figure 3.2: Serotype/group specific ranking of multiple pneumococcal carriage in PCV-
unvaccinated children  
Each isolate of S. pneumoniae was ranked according to its carriage density as determined by quantitative PCR 
(qPCR) to other isolates present in the same sample. Single colonisers were included in the analysis as primary 
colonising serotypes.  
 
 
Among PCV7-vaccinated children, PCV7-serogroups 19B/F (prevalence: 43/197, 14.7%), 
6A/B (prevalence: 29/197, 14.7%) and non-vaccine serotype 19A (prevalence: 29/197, 
14.7%) were the highest density colonising serotypes and non-vaccine serotype 5 being the 
most common 2
nd
 (prevalence: 11/68, 16.2%) and 3
rd 
(prevalence: 4/9, 44.4%) colonising 
serotype based on its density of carriage (Figure 3.3).  
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Figure 3.3: Serotype/group specific ranking of multiple pneumococcal carriage in PCV7-
vaccinated children 
Each isolate of S. pneumoniae was ranked according to its carriage density as determined by quantitative PCR 
(qPCR) to other isolates present in the same sample. Single colonisers were included in the analysis as primary 
colonising serotypes. 
 
Further, the serotype specific propensity of whether a given serotype/serogroup is more likely 
to be found as a primary or non-primary isolate is shown in Figure 3.4, with vaccine 
serotypes/serogroups 6A/B (p<0.001 and p<0.001), 19B/F (p<0.001 and p<0.001) and 23F 
(p<0.001 and p<0.001) and non-vaccine serotypes/groups 15A/B/C/F (p=0.035 and p<0.001) 
and 34/37/17A (p=0.035 and p=0.008) being more likely to be identified as a primary than 
non-primary isolate in both PCV-vaccinated and PCV-unvaccinated groups. Non-vaccine 
serotype 19A was, however, more likely to be identified as a primary (78.4%) than non-
primary isolate in PCV-vaccinated children alone (21.6%; p<0.001). Further, non-vaccine 
serotype 5 was more likely to be identified as a non-primary isolate and in both PCV-
vaccinated (p<0.008) and PCV–unvaccinated groups (p<0.001). These results did not differ 
between time points. 
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Figure 3.4:Serotype specific propensity of whether a given serotype/serogroup is more likely to be found as a primary or non-primary isolate in PCV7-
vaccinated (red) and PCV-unvaccinated (blue) children 
Pneumococcal serotypes identified from nasopharyngeal swabs were classified according to whether they occurred as a primary or non-primary isolate as determined by carriage 
density. Single colonisers were included in the analysis as primary isolates. The box at the top box at top of the graph is an inset of the blocked region at the bottom. Green dots 
represent two or more serotypes with the same colonising profile. * Results were considered significant when the p-value was <0.05. 
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The average densities of the 1
st
 colonising serotype (3.59 vs. 3.99 CFU/ml, p=0.01), 2
nd
 
colonising serotype (3.9 vs. 4.38 CFU/ml, p=0.05) and 3
rd
 colonising serotype (1.7 vs. 2.35 
CFU/ml, p=0.005) were higher in PCV7-vaccinated compared to PCV-unvaccinated children 
at 9 months of age; however, no difference in densities were found by 16 months  of age 
(Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Density of concurrent colonising pneumococcal serotypes between PCV7-
vaccinated and PCV-unvaccinated children, grouped by 1
st
, 2
nd
, 3
rd
 and 4
th
 colonising serotype 
as determined by density of carriage 
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3.2.2.  Prevalence of NP bacteria as determined by qPCR with respect to PCV 
vaccination status 
Overall prevalence of pneumococcal colonisation was lower in PCV7-vaccinated (71.4%) 
than PCV-unvaccinated children (82.9%; p=0.01; Table 3.3) at 9 months of age. The 
reduction in carriage was due to a lower prevalence of PCV7-serotype colonisation in PCV7-
vaccinated (36%) than PCV-unvaccinated children (61.9% p=0.002), with PCV7-serogroup 
9A/L/N/V (72.1% reduction, p=0.008) and 23F (67.1% reduction; p=0.006) showing the 
greatest decrease compared to prevalence in PCV-unvaccinated children; Figure 3.6a. A 
corresponding increase in prevalence of non-vaccine serotype colonisation in PCV7-
vaccinated (40%) compared to PCV-unvaccinated children (33.7%; p=0.02) was evident at 9 
months of age; which was driven largely by an increase in prevalence of a limited number of 
serotypes including serogroup 12A/B/F (100% increase; p=0.013) and 19A (53.4% increase; 
p=0.021). 
 
By 16 months of age, there was no difference in overall pneumococcal colonisation between 
PCV7-vaccinated (75%) and PCV-unvaccinated children (81%; p= 0.06). The lower 
prevalence of PCV7-serotype colonisation in PCV7-vaccinated (32.9%) than PCV-
unvaccinated children (51.8%; p=0.007), was largely offset by the increase in non-vaccine 
serotype colonisation among the PCV7-vaccinated children (62.2% vs. 37.8%; p=0.013); 
Figure 3.6b). PCV7-serogroup 9A/L/N/V (87.8% reduction, p<0.001) and vaccine-serotypes 
14 (67.1% reduction, p=0.05) and 23F (57% reduction, p=0.02) showed the greatest decrease, 
while NVT serotypes 19A (70.7% increase p<0.001) and 21 (83.3% increase, p=0.04) 
showing the greatest increase.
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Table 3.3: Prevalence of pneumococcal nasopharyngeal (NP) colonisation in PCV7-vaccinated and PCV-unvaccinated, HIV-uninfected children 
as measured by molecular qPCR 
 
9 month old children 16 month old children 
 
P
C
V
7
-
u
n
v
ac
ci
n
at
ed
  
 
(n
 =
 1
8
1
) 
P
C
V
7
-
v
ac
ci
n
at
ed
  
  
  
(n
 =
 1
7
5
) 
O
R
 (
9
5
%
 C
I)
, 
p
 -
v
al
u
e*
 
aO
R
 (
9
5
%
 C
I)
, 
 
p
 -
v
al
u
e*
 
P
C
V
7
-
u
n
v
ac
ci
n
at
ed
  
(n
 =
 1
9
3
) 
P
C
V
7
-
v
ac
ci
n
at
ed
  
  
  
(n
 =
 1
6
4
) 
O
R
 (
9
5
%
 C
I)
, 
 
p
 -
v
al
u
e*
 
aO
R
 (
9
5
%
 C
I)
, 
p
 -
v
al
u
e*
 
LytA 150 (82.9) 125 (71.4) 
0.52 (0.31-0.86),      
p = 0.01 
0.45 (0.23 - 0.87),    
p = 0.01 
157 (81) 123 (75) 
0.68 (0.41-1.14),   
p = 0.147 
0.55 (0.29-1.03),    
p =0.06 
VT serotypes 112 (61.9) 63 (36) 
0.35 (0.21- 0.58),     
p <0.001 
0.37 (0.19 - 0.7),      
p = 0.002 
100(51.8) 54(32.9) 
0.44 (0.27-7.01),   
p <0.001 
0.41(0.26-0.63),    
p = 0.007 
NVT serotypes 54(33.7) 70(40) 
1.74 (1.08 - 2.82),    
p = 0.002 
1.88 (1.02 - 3.48),    
p = 0.02 
73(37.8) 102 (62.2) 
1.81 (1.12-2.93),   
p <0.001 
2.2 (1.18-4.1),       
p = 0.01 
Adjusted odd ratios (aOR) for pneumococcal colonisation were determined by multivariate logistic regression, controlling for race, smoking household contact, co-
trimoxazole use, day care attendance and mean age at time of sample collection, by use of generalised estimating equations. PCV7, seven-valent pneumococcal conjugate 
vaccine. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 14, 18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7C, 10A, 
11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 23AB, 34/37/17A). *p-values of <0.05 were considered significant.
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Figure 3.6: Prevalence of nasopharyngeal (NP) pneumococcal colonisation in PCV7-
vaccinated and PCV-unvaccinated, HIV-uninfected children at a) 9 months and b) 16 months 
of age 
p-values were determined by multivariate logistic regression, controlling for race, smoking household contact, co-
trimoxazole use, day care attendance and mean age at time of sample collection, by use of generalised estimating equations. 
PCV7, seven-valent pneumococcal conjugate vaccine. p-values of <0.05 were considered significant.  
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3.2.3.  Association of PCV vaccination and density of pneumococcal nasopharyngeal 
carriage 
The density of pneumococcal carriage was higher in PCV7-vaccinated (4.68; 95% CI; 4.45-
4.9 CFU/ml) than PCV-unvaccinated infants (4.28; 95% CI; 4.09-4.47 CFU/ml) at 9 months, 
of age (p=0.007); Table 3.4. This was associated with an increase in the density of overall 
vaccine serotypes/serogroup (3.8 vs. 3.4 CFU/ml; p=0.048), despite lower prevalence thereof; 
and an increase in overall density of non-vaccine serotypes/serogroups (3.6 vs. 3.1 CFU/ml; 
p=0.018). No difference in density of individual PCV7-serotypes/serogroups was found 
between PCV-unvaccinated and PCV7-vaccinated groups; however, the density of non-
vaccine serotype 19A was higher in PCV7-vaccinated (3.76 vs. 2.83 CFU/ml; p=0.0463) 
compared to PCV-unvaccinated children, which was consistent with a higher carriage 
prevalence in PCV7-vaccinated children. Further, the density of non-vaccine serogroup 
23A/B was also found to be higher in PCV7-vaccinated (4.48 vs. 2.07 CFU/ml; p=0.002) 
compared to PCV-unvaccinated children, despite no change in carriage prevalence. By 16 
months of age, there was no overall difference in density of pneumococcal colonisation 
between the PCV7-vaccinated and PCV7-unvaccinated groups, although there was an 
increase in density of non-vaccine serotypes/groups in PCV7-vaccinated compared to PCV-
unvaccianted children, including serotype/groups 5 (2.79 vs. 2.01 CFU/ml; p=0.015), 19A 
(4.15 vs. 3.04 CFU/ml; p=0.013), and 23A/B (3.59 vs. 1.58 CFU/ml, p=0.013); in addition to 
the higher prevalence of 19A alone. 
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Table 3.4: Density of nasopharyngeal carriage in PCV7-vaccinated and PCV7-unvaccinated, 
HIV-uninfected children as measured by quantitative PCR (qPCR) 
 
 
9 month old children 16 month old children 
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GMD (95% CI) GMD (95% CI) 
Pneumococcus (LytA) 4.28 (4.09-4.47) 4.68 (4.45-4.90) 0.007 4.33 (4.16-4.5) 4.44 (4.23-4.66) 0.53 
       Vaccine 
serotypes/groups 3.4 (3.2-3.6) 3.8 (3.5-4.1) 0.048 3.59 (3.36-3.83) 3.73 (3.4-4.0) 0.48 
4 3.8
a
 2.18 (-2.1-6.47) 
 
4.53
a
 - 
 6A/B 4.41(4.0-4.82) 4.41 (3.9-4.92) 0.99 4.17 (3.66-4.68) 4.0 (3.44-4.58) 0.68 
9A/L/N/V 2.52(1.96-3.08) 2.84 (1.48-4.19) 0.52 2.36 (1.77-2.96) 3.99 (0.81-6.04) 0.09 
14 2.46(1.7-3.22) 3.66 (-0.68-6.65) 0.15 3.29 (2.68-3.91) 2.75 (1.29-4.20) 0.37 
18A/B/C 2.80(2.26-3.49) 1.96
a
 0.39 3.58 (2.51-4.65) 4.30 (3.36-5.25) 0.32 
19B/F 3.36(2.99-3.74) 3.79 (3.28-4.3) 0.16 3.52(3.12-3.96) 3.65 (3.12-4.17) 0.71 
23F 2.9 (2.59-3.4) 3.76 (2.24-5.28) 0.84 3.04 (2.67-3.4) 3.44 (2.45-4.44) 0.71 
       Non - vaccine 
serotypes/groups 3.1 (2.7-3.4) 3.6 (3.0-3.4) 0.018 3.33 (3.0-3.66) 3.74 (3.42-4.06) 0.08 
1 2.31
a
 2.29 (-1.03-5.61) 
 
3.47 (-11.4- 18.31) 1.99
a
 
 3 5.13
a
 3.55
a
 
 
- - 
 5 2.0 (1.63-2.36) 2.29 (1.85-2.7) 0.23 2.01 (1.83-2.19) 2.79 (1.53-4.04) 0.015 
6C/D 4.2 (-25.5-33.94) 2.76 (1.71-3.81) 0.60 2.99 (2.32-3.67) 3.99 (-12.12-20.1) 0.38 
7C 3.25
a
 3.13 (0.5-5.76) 
 
1.57
 a
 2.66 (1.51-3.79) 
 10B 4.15 (-10.47-18.78) 3.09
a
 
 
4.65 (4.0-5.3) 3.26 (2.15-4.36) 0.06 
11A/B/C/D/F 1.79 (-2.66-6.24) 2.67 (1.32-4.0) 0.34 2.88 (1.9-3.87) 4.06 (0.82-7.3) 0.23 
12A/B/F 2.44
a
 3.38(1.39-5.38) 
 
- - 
 13 2.99 (0.22-6.01) 4.7 (2.86-6.54) 0.21 2.84 (1.08-4.61) 3.21 (1.38-5.04) 0.65 
15A/B/C/F 3.66(3.11-4.2) 4.1 (3.4-4.79) 0.27 3.88 (3.23-4.53) 4.03 (3.27-4.79) 0.75 
16F 3.26 (2.24-4.28) 3.65 (2.4-4.89) 0.65 4.84 (2.67-7.01) 5.07 (2.77-7.37) 0.84 
17F - - 
 
3.10 (-1.31-7.5) 2.48 (-12.1-17.05) 0.72 
19A 2.83 (2.26-3.7) 3.76 (3.36-4.1) 0.046 3.04 (2.26-3.83) 4.15 (3.66-4.64) 0.013 
20 4.20(2.33-6.07) 2.01
a
 
 
- - 
 21 3.62 (-0.65-7.89) 3.32 (-13.7-20.36) 0.87 5.22
a
 2.82 (1.82-3.8) 
 23A/B 2.07(1.48-2.67) 4.48 (0.82-8.14) 0.002 1.58 (1.28-1.87) 3.59 (0.88-6.32) 0.013 
34/37/17A 2.83 (1.33-4.34) 3.76 (2.24-5.28) 0.84 4.34 (0.50-8.17) 4.67 (3.7-5.61) 0.71 
 
For density of carriage geometric mean densities (GMD) and 95% confidence intervals (95% CI) of 
pneumococcal and bacterial mean concentrations were calculated following log10 transformations on data and 
compared with multivariate analysis controlling for race, smoking household contact, co-trimoxazole use, day 
care attendance and mean age at time of sample collection. PCV7, seven-valent pneumococcal conjugate 
vaccine. CI, confidence intervals.-, too few observations to calculate p-value.* p-values of <0.05 were 
considered significant. 
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3.3.  DISCUSSION  
In this study quantitative molecular qPCR was used to compare pneumococcal serotype/group 
specific colonisation in cohorts of PCV7-vaccinated and PCV-unvaccinated African children. 
Analysis clearly showed the vaccine effect, typified by a decrease in the prevalence of PCV7-
serotypes and a corresponding increase in NVT serotypes 
149,219,220
. This study, however, was 
also the first to show serotype replacement and unmasking as the cause for this increase in 
non-vaccine serotype colonisation in PCV7-vaccinated children. 
 
Although serotype specific analysis was often limited by a small sample size for a given 
serotype, the carriage prevalence of the majority of NVT serotypes remained unchanged 
following PCV7-vaccination, with the exception of serotype 19A, for which prevalence of 
colonisation increased. Although this increase in serotype 19A has been previously 
documented in PCV7-vaccinated populations 
141,219,221,222
, the qPCR method also allowed 
quantification and showed an increase in density of this serotype, as well as this serotype 
being more commonly reported as a primary isolate in PCV7-vaccinated children, whilst 
being equally a primary (46.2%) or non-primary (53.8%) isolate in PCV-unvaccinated 
children. This would indicate that the increase in serotype 19A among PCV7-vaccinated 
children was due to a combination of replacement disease as well as unmasking of 
colonisation which would not have been identified using conventional culture methods. In 
addition, the increase in the carriage prevalence and density of PCV7-serotype 19A is of 
important clinical relevance as it could explain the emergence of serotype 19A as the major 
replacement serotype causing IPD following PCV7 introduction in several settings 
223-225
.  
 
An increase in the colonisation density of non-vaccine serotype 5 and serogroup 23A/B was 
identified in PCV7-vaccinated compared to PCV-unvaccinated children, in the absence of an 
increase in overall colonisation prevalence. As serotype 5 is rarely seen in conventional 
carriage studies, these results suggest an unmasking of serotype 5 by the qPCR method. 
Nonetheless, serotype 5 has a high invasive disease potential in our setting 
13,100 
and an 
increase in the carriage density as a result of PCV-immunisation could enhance its ability to 
cause mucosal and invasive disease and potentially offset some of the effectiveness of PCV7 
immunisation. 
 
  
78 
 
Further, a composition shift in co-colonised children from a mix of NVT’s and VT’s to almost 
pure NVTs as a result of PCV7 immunisation was observed, supporting an unmasking of 
serotype carriage; however, co-colonised children also had a lower density of colonisation 
with NVTs then singly colonised hosts, therefore further supporting that both an increase in 
detection probability (unmaking) and an increase in NVT acquisition (true replacement) 
played a role in the vaccine effect 
134
. 
 
Of note among PCV7-vaccinated children, despite a lower prevalence of PCV7-serotytpe 
colonisation at 9 months of age, the density of colonisation of both PCV7-serotype and NVT 
pneumococci was higher in them compared to PCV-unvaccinated children. Although we 
might expect PCV vaccination to reduce the density of VT carriage, the opposite was found. 
One possible explanation for this observation is that pneumococcal carriage density may be 
influenced by the prevalence of antibodies to common pneumococcal surface antigens 
(CPAs). Ditse et al, found lower titers to CPAs in PCV7-vaccinated infants at 10 months, 
most likely a result of reduced pneumococcal exposure, although by 18 months these 
differences were not significant, which was consistent with colonisation density in our study 
226
. Another explanation, however, could simply be that the vaccine is less effective in 
preventing colonisation with PCV7-serotypes among a subset of children who remained 
colonised, possibly due to a poorer immune response or other factors contributing to the 
colonisation by these PCV7-serotypes.  
 
Our findings were similar to Ercibengoa et al, in that we detected multiple co–carriages in 
21.9% of LytA positive swabs 
227
, much higher compared with other studies that relied mostly 
on culture based methods (1.3% - 12%) 
37,50,57,60
. Despite the increase in NVT carriage as a 
result of the vaccine effect, the prevalence of concurrent pneumococcal carriage remained 
unchanged; however, the composition of multiple pneumococcal serotypes shifted from 
serotypes/groups 6A/B, 19B/F and 23F to serotypes/groups 6A/B, 19A and 19B/F being the 
dominant colonising serotype as a result of PCV vaccination. Serotype 5 remained the most 
common second coloniser in both groups.  
 
Our study was limited in that a) the PCR method was not optimised to discriminate between 
all the VT serotypes within their respective serogroups. However, due to the high 
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concordance between serotypes identified by culture and qPCR, we can assume from 
colonisation data using traditional culture methods that 93.3%, 88.9% and 91.4% of all 
serogroups 9A/L/N/V, 18A/B/C and 19B/F identified by qPCR to be vaccine-serotypes 9V, 
18C and 19F respectively. b) We had limited serotype coverage in the assay and thus the 
effect of other serotypes on the vaccine efficacy for protection against colonisation might be 
underestimated. c) Further, we were not able to identify non-typable pneumococcus which 
may have limited our understanding of the vaccine effect, as recent genome sequencing 
projects have shown an increase in non-typable isolates following PCV immunisation 
228
. d) 
The study was not adequately powered to evaluate all serotype specific differences as the 
sample size of detected minor serotypes was too small. e) Our control group was enrolled 
after our vaccinated group. However, due to the limited coverage of PCV in the community it 
is thus unlikely that a broader indirect effect of the vaccine reducing transmission by young 
vaccinated children would have affected the nasopharyngeal colonisation patterns. f) Lastly, 
our study was not a randomised clinical trial and the cohorts were not matched and 
coincidental temporal fluctuations due to difference in year when the cohorts were enrolled 
and other unknown factors could have thus influenced the results, although this is unlikely. 
 
In conclusion, the ability of molecular qPCR to detect multiple concurrent colonising 
serotypes at a low carriage density allowed us to gain a better understanding of serotype 
carriage and indicates that the underlying mechanism for the increase in non-vaccine serotype 
colonisation in PCV vaccinated children is likely due to both serotype replacement as well as 
unmasking of underlying pre-existing colonising serotypes. 
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CHAPTER 4: EVALUATION OF THE ASSOCIATION OF 
PNEUMOCOCCAL CONJUGATE VACCINE IMMUNISATION AND 
DENSITY OF NASOPHARYNGEAL BACTERIAL COLONISATION 
USING A MULTIPLEX QUANTITATIVE POLYMERASE CHAIN 
REACTION ASSAY 
 
Invasive and mucosal disease due to bacterial pathogens such as Streptococcus pneumoniae, 
Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Streptococcus 
pyogenes and Neisseria meningitidis follow on colonisation of the pharynx by these bacteria. 
Further, bacterial and host factors may contribute to interaction in the nasopharyngeal 
colonisation patterns by these bacteria 
72,229
. Vaccination with pneumococcal conjugate 
vaccine (PCV) reduces the risk of nasopharyngeal colonisation acquisition by vaccine-
serotypes; however, it increases colonisation by non-vaccine serotypes 
134
. This increase in 
non-vaccine serotype colonisation could be due to increased risk of acquisition or 
“unmasking” of previous low-level nasopharyngeal colonisation by these serotypes 136. 
Although the majority of these “replacing” non-vaccine serotypes have low invasive potential, 
they could still cause mucosal disease such as acute otitis media (AOM) 
230
 The PCV induced 
effect on pneumococcal nasopharyngeal colonisation could also affect colonisation patterns of 
other bacteria, including S. aureus which has an inverse association with S. pneumoniae 
colonisation and possibly particularly seven-valent PCV (PCV7) serotypes 
27,80
; and H. 
influenzae which is positively associated with pneumococcal colonisation 
83,175,231
.  
 
Since bacterial nasopharyngeal colonisation is the precursor to disease of the upper and lower 
respiratory tract, analysis of nasopharyngeal colonisation in PCV-vaccinated and PCV-
unvaccinated children could provide a measure for predicting whether there might be changes 
in susceptibility to mucosal and systemic bacterial infections in these children as a result of 
PCV immunisation 
229
. The majority of studies on nasopharyngeal colonisation have focused 
on non-quantitative culture based methods as recommended by a WHO working group 
36
. 
This could underestimate the prevalence of pneumococcal colonisation and does not allow for 
quantitative evaluation of bacterial colonisation or the effect of PCV thereon, which may be 
associated with susceptibility for disease by these bacteria 
232,233
. 
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In this chapter, we evaluated the association of PCV7 immunisation of infants on the 
prevalence and density of nasopharyngeal colonisation at 9 and 16 months of age; by 
common, potentially pathogenic bacteria including PCV7 serotypes, non-vaccine serotypes, 
Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Streptococcus 
pyogenes and Neisseria meningitidis. 
 
4.1.  MATERIAL AND METHODS  
 
4.1.1  Study population 
As described in Chapter 3, Section 3.1.1. 
 
Nasopharyngeal samples had been previously cultured for S. pneumoniae, H. influenzae and 
S. aureus using standard culture methods and the dynamics of colonisation over the first two 
years of life have been described 
81,198
. In this chapter, we expand on the previous findings 
and explore the association of PCV7 immunisation on the density of colonisation by these 
bacteria, as well as colonisation by M. catarrhalis, S. pyogenes and N. meningitidis as 
measured by multiplex qPCR. 
 
4.1.2.  Multiplex qPCR methods 
Control strains for S. pneumoniae, H. influenzae, M. catarrhalis, S. aureus, N. meningitidis 
and S. pyogenes were obtained from the National Institute for Communicable Diseases 
(NICD). DNA from these strains were used to optimise PCR assays and as positive controls. 
In addition, Escherichia coli, Klebsiella pneumoniae, and Salmonella spp strains were used as 
controls to test for non-specific PCR. 
 
Stored nasopharyngeal swab samples were thawed and processed. Briefly, nasopharyngeal 
swabs were vortexed for 30 seconds to release bacterial DNA into the transport media and 
total nucleic acids were automatically extracted from STGG with the NucliSens ® easyMAG 
® extraction system (BioMérieux, Marcy l’Etoile, France) according to manufacturer’s 
instructions. Similarly, total nucleic acids were also extracted from pneumococcal reference 
strains grown in Todd-Hewitt broth supplemented with 5% yeast, S. aureus, M. catarrhalis, S. 
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pyogenes and N. meningitidis reference strains grown in Todd-Hewitt broth alone, and H. 
influenzae grown in Brain-Heart infusion (BHI) broth with the NucliSens ® easyMAG ® 
extraction system according to manufactures instructions. Samples and pneumococcal 
reference strains were stored at – 20 °C. 
 
The sequences for oligonucleotide primers and dye-labelled MGB probes were taken from 
previously published sequences, or designed with the ABI primer express software package, 
version 3.0 (Applied Biosystems, ABI, Foster City, USA). Primer and Probe sequences are 
described in Table 4.1.
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Table 4.1: Oligonucleotide primers and probe
a
 sequences for quantitative molecular Real-time PCR detection of respiratory pathogens 
Primers/Probe
a
 
name 
     Sequence (5′ - 3′) Target gene Gene Function Bacteria Source 
lytA-Fwd
 
lytA-Rev
 
lytA-Probe
 
TCTTACGCAATCTAGCAGATGAAGC 
GTTGTTTGGTTGGTTATTCGTGC 
(VIC)-TTTGCCGAAAACGCTTGATACAGGG-(MGB) 
 
lytA Autolysin Streptococcus pneumoniae McAvin et al., 2001 
IgA1-Fwd
 
IgA1-Rev
 
IgA1-Probe 
CAAAATTGCCAAGATTAAATGCTT 
TGCTCGCCATACTGCACAA 
(FAM)-CCTGCGGTTAAACC-(MGB) 
 
IgA1 Immunoglobin 
A1 protein 
Haemophilus influenzae Mc Gillivary et al., 2005 
Nuc-Fwd
 
Nuc-Rev
 
Nuc-probe 
GCTCAGCAAATGCATCACAAA 
CACTATATACTGTTGGATCTTCAGAACCA 
(FAM)-AGATAACGGCGTAAATA-(MGB) 
 
Nuc Thermonuclease Staphylococcus aureus This study 
copB-Fwd
 
copB-Rev
 
copB-probe 
CCGCTTTTACAACCACTGCTT 
TGTATCGCCTGCCAAGACAA 
(NED)-CAGCTGTTAGCCAGCC-(MGB) 
 
copB Outer-membrane 
protein 
Moraxella catarrhalis This study 
spy-Fwd
 
spy-Rev
 
spy-Probe 
GCACTCGCTACTATTTCTTACCTCAA 
GTCACAATGTCTTGGAAACCAGTAAT 
(VIC)-CCGCAACTCATCAAGGATTTCTGTTACCA-(MGB) 
 
Spy1258 Transcriptional 
regulator 
Streptococcus pyogenes CDC 2008 
  
84 
 
 
Probe
a
: Minor Grove Binding (MGB) dye labelled TaqMan probe. 
SodC-Fwd  
SodC-Rev 
SodC-Probe 
GCACACTTAGGTGATTTACCTGCAT  
CCACCCGTGTGGATCATAATAGA 
(FAM)-CATGATGGCACAGCAACAAATCCTGTTT-(MGB) 
SodC Cu-Zn 
superoxide 
dimutase 
Neisseria meningitidis  Thomas et al., 2011 
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4.1.3.  Primer optimisation, standard curves and quantification of the real-time PCR 
assays 
Optimisation of primers and probes for overall pneumococcus and its respective 
serotypes/serogroups has been explained in detail in chapter 2, section 2.1.3. In terms of the 
other bacterial targets, standard concentration curves and lower limits of detection (LLD) for 
each target bacteria were determined as described previously, with the exception of the 
bacterial control DNA being harvested at an OD600 = 1.0 (early exponential phase) instead of 
OD600 = 0.1. Similarly, correlation coefficients (r
2
), analytical sensitivity, intra-assay 
variation, accuracy and inter-assay variation were determined as described previously in 
chapter 2.  
 
All additional bacterial targets not described in chapter 2 showed good sensitivity and 
specificity with their respective primer and probe pairs with the limit of detection equivalent 
to 10 copies per PCR. Furthermore, the efficiency of these assays ranged from 91-96 %. 
Within the linear dynamic range, the correlation coefficients (r
2
) of all the assays were 0.99. 
All primer pairs and probes were tested with genomic DNA from all pneumococcal and 
bacterial controls, and no cross reactions occurred. In addition, both the inter-assay variation 
(repeatability) and inter-assay variation (reproducibility) for all respective assays was <0.1, 
while the accuracy for all respective assays was within ± 0.1.  
 
Bacterial targets were duplexed (Table 4.2) and paired reactions were tested to ensure that the 
Cq values did not shift by >1 Cq value, and that sensitivity and specificity remained the same 
as for single-plex reactions. 
 
Table 4.2: Primer/probe duplex combinations  
Primmer/probe combinations Duplex reaction 
S. pneumoniae & N. meningitidis A 
S. aureus & M. catarrhalis B 
H. influenzae & S. pyogenes C 
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4.1.4.  Real-time PCR multiplex assay 
The density of S. pneumoniae, H. influenzae¸ M. catarrhalis, S. aureus, S. pyogenes and N. 
meningitidis were measured in colony forming units (CFU)/ml. Amplification data was 
analysed with the Applied Biosystems 7500 software, version 2.3 (Foster City, USA) with a 
manually defined threshold. Negative samples were defined as those with Cq values <35.  
All samples positive for pneumococcus were further serotyped as described previously in 
chapter 2. Briefly; Serotypes/serogroups 4, 6A/B, 9A/L/N/V, 14, 18A/B/C, 19B/F or 23F 
were categorised as PCV7 vaccine-serotypes and serotypes/serogroups 1, 6C/D, 7C, 10A, 
11A/B/C/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 23A/B, and 34/37/17A as non-
vaccine serotypes. Samples negative for all tested bacteria were re-tested for human GAPDH 
to confirm the efficiency of the DNA extraction and the absence of PCR inhibitors, with all 
qPCR negative samples being positive for GAPDH 
 
4.1.5.  Statistical analysis 
Statistical analysis was performed with STATA Version 11.0 (Statacorp, Texas, USA). 
Pearson X
2
 test or student t-test was used to compare baseline characteristics between the 
cohorts. Comparisons and adjusted odd ratios of prevalence of bacterial colonisation between 
cohorts were analysed using logistic regression models adjusted for covariates, including race, 
passive smoke exposure, day care attendance, co-trimoxazole usage, and mean age in weeks 
at sample collection. For density of carriage, geometric mean densities (GMD) and 95% 
confidence intervals (95% CI) of bacterial mean concentrations were calculated following 
log10 transformation on the data, using analysis of covariance to adjust for possible covariates. 
To assess whether colonisation by one bacterial species was associated with colonisation by 
another, logistic regression models with generalised estimating equations (GEE) were used. 
Spearman correlations were used to compare the degree of correlation between densities of 
each pair of bacteria. Results were considered significant at a p-value of < 0.05.  
 
4.1.6.  Ethics approval  
As described in chapter 3, section 3.1.4. 
 
  
87 
 
4.2.  RESULTS  
Molecular qPCR analysis involved 713 (83%) of the initial 857 nasopharyngeal swabs 
collected from children, at either 9 or 15-16 months of age (Figure 4.1). Within each cohort, 
there were no differences in the colonisation patterns done by standard methods between 
those in whom samples were and were not available (Appendices A and B). Among the 
children in whom samples were available, 92% were black African, and 52% were male 
(Table 4.3). Day care attendance was higher in PCV-vaccinated children, while the mean age 
in weeks at the time of sample collection being 40.7 (Standard deviation, SD 2.3) and 69.5 
(SD 6) in PCV-unvaccinated children, and 39.3 (SD 3.1) and 66.7 (SD 1.8) in PCV-
vaccinated children at the 1
st
 and 2
nd
 visits, respectively. Although the differences in age are 
small and thus unlikely to be epidemiologically or clinically significant in terms of the 
likelihood of affecting the results, we subsequently adjusted for these differences as well as 
the above mentioned using multivariate analysis.  
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Figure 4.1: Schematic diagram of study population 
Diagram indicating the number of children initially enrolled in a PCV-unvaccinated and PCV7-vaccinated cohort 
of HIV-uninfected children, as well as the number of nasopharyngeal (NP) swabs available for subsequent 
molecular qPCR analysis. PCV7-vaccinated participants were excluded from analysis if they did not receive all 
three doses of the pneumococcal conjugate vaccine (PCV) within protocol-defined window periods. The number 
of NP swabs available for molecular testing was defined by whether there was an adequate volume of sample 
remaining. EQA, samples were used for external quality assessment. 
 
501 Infants enrolled 
213 infants received all 3 doses of PCV 
251 PCV7-unvaccinated  
PCV7-vaccination schedule  
1
st
 dose (administered ± 6 weeks of age): N = 220  
2
nd
 dose (administered ± 10 weeks of age): N = 245 
3
rd
 dose (administered ± 14 weeks of age): N = 246 
 
250 PCV7-vaccinated  
Nasopharyngeal (NP) swabs collected 
9 months = 207 NPs 
16 months = 200 NPs 
  
Nasopharyngeal (NP) swabs collected 
9 months = 229 NPs 
16 months = 221 NPs 
  
857 NP swabs collected in total 
Nasopharyngeal swabs available for 
subsequent molecular testing.  
9 months = 175 NP swabs 
16 months = 164 NP swabs 
  
Nasopharyngeal swabs available for 
subsequent molecular testing.  
9 months = 181 NP swabs 
16 months = 193 NP swabs 
  
713 NP swabs available for qPCR analysis  
No sample = 76 
Inadequate volume = 76  
No swab = 19  
Missed visit = 3 
Unable/unwilling to adhere = 11  
Withdrew consent = 2  
Lost to follow up = 3 
 
No swab = 52 
Missed visit = 52  
No sample = 68 
EQA = 13  
Inadequate volume = 55  
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Table4.3: Demographic features at two study visits when analysed for nasopharyngeal (NP) bacterial colonisation in PCV7-vaccinated and PCV-
unvaccinated, HIV-uninfected children 
 9 month old children 16 month old children 
 PCV-unvaccinated PCV7-vaccinated 
p-value PCV-unvaccinated PCV7-vaccinated p-value 
Number of children enrolled  250 251 - 250 251 -  
Available NP swabs for molecular analysis  181 175 - 193 164 -  
HIV status: Exposed (%) 111 (61.3) 104 (59.4) 0.40 99 (51.3) 97 (59.1) 0.24 
     : Unexposed (%) 70 (38.7) 71 (40.6)  94 (48.7) 67 (40.9)  
Mean birth weight (SD) grams  3061 (440) 3097 (482) 0.45 3079 (427) 3126 (476) 0.43 
Male sex (%) 87 (48.1) 96 (54.9) 0.12 99 (51.3) 89 (54.3) 0.25 
Race: Black African (%) 181 (100) 150 (85.7) <0.001 193 (100) 132 (80.5) <0.001 
  : Mixed ancestry (%) - 25 (14.3)  - 32 (19.5)  
Smoking household contact (%) 66 (36.5) 81 (42.3) 0.003 65 (33.68) 64(39) 0.004 
Co-trimoxazole administered (%) 95 (52.5) 81 (46.3) 0.2 71(36.8) 68(41.5) 0.15 
Mean numbers of children (SD) < 5 years  1.63 (0.8) 1.6 (0.7)  0.6 1.6 (0.82) 1.5 (0.84) 0.21 
Mean number of household contacts (SD)  5.3 (2.2) 5.2 (2.3)  0.81 5.2 (2.07) 5.1 (2.36) 0.17 
Day care attendance (%) 40 (22.1) 91 (52)  <0.001 72 (37.31) 81 (53.64) 0.002 
Breast feeding (%) 41 (22.7) 44 (25.1) 0.33 37 (19.2) 38 (23.3) 0.43 
Mean age (SD) in weeks at visit 40.7 (2.3) 39.3 (3.1) <0.001 69.5 (6.01) 66.7(1.6) <0.001  
 
Pearson X
2
 test or student t-test was used to compare baseline characteristics between the cohorts and demographic features with a p-value <0.2 were included as possible 
cofounders in multivariate analysis. PCV: Seven-valent pneumococcal conjugate vaccine. NP, nasopharyngeal. SD, standard deviation.
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4.2.1.  Detection of bacterial carriage by culture and qPCR 
There was modest concordance between qPCR and culture for the detection of pneumococcus 
from infant NP swabs at both 9 months (kappa = 0.59) and 16 months of age (kappa = 0.59). 
LytA qPCR assay was more sensitive than culture in detecting pneumococcus in both PCV-
unvaccinated (83% vs. 74%; p=<0.001) at 9 months; and 81% vs. 68% (p<0.001) at 16 
months age; Table 4.4); and among PCV7-vaccinated children (71% vs. 57%; p<0.001) at 9 
months of age; and 77% vs. 61% (p<0.001) at 16 months of age.  
 
Similarly, there was modest concordance between qPCR and culture for the detection of H. 
influenzae from infant NP swabs at 9 months (kappa = 0.50) and 16 months of age (kappa = 
0.61). The qPCR assay was more sensitive than culture in detecting H. influenzae in both 
PCV-unvaccinated children at 9 months (56% vs. 31%; p=<0.001) and 16 months of age 
(62% vs. 58%; p=0.04); and PCV7-vaccinated children (66% vs. 48% (p<0.001) at 9 months 
and 72% vs. 54% (p<0.001) at 16 months of age.  
 
There was also a moderate concordance between qPCR and culture for the detection of S. 
aureus from infant NP swabs at 9 months (kappa=0.068) and 16 months (kappa=0.065) of 
age. While there was no significant difference found between the methods in PCV-
unvaccinated children at 9 months of age (p=0.53), the qPCR method was more sensitive than 
culture for the detection of S. aureus in PCV-unvaccinated children at 16 months of age (19% 
vs. 13%; p=0.004). Amongst PCV7-vaccinated children, the qPCR method was more 
sensitive than culture in detecting S. aureus at both 9 (19% vs. 13%; p=0.004) and 16 (17% 
vs. 11%; p=0.03) months of age; Table 4.4.  
 
M. catarrhalis, S. pyogenes and N. meningitidis were not tested by culture and thus could not 
be compared to molecular qPCR. The overall detection prevalence, by qPCR at 9 months of 
age was 60.1% (214/356), 3.7% (13/356) and 2% (7/356) respectively; and 60.2% (215/357) 
5.3% (19/357) and 1.1% (4/357) at 16 months of age. 
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Table 4.4: Number (%) of bacterial culture and molecular qPCR for the detection of S. pneumoniae, H. influenzae and S. aureus in 
nasopharyngeal swabs 
9 month old children 16 month old children 
 
PCV-unvaccinated PCV7-vaccinated PCV-unvaccinated PCV7-vaccinated 
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S. pneumoniae                   
PCR (-) 27 (15) 4 (2) 31 (17) 45 (26) 5 (3) 50 (29) 32 (17) 4 (2) 36 (19) 39 (24) 2 (1) 41 (25) 
PCR (+)  20 (11) 130 (72) 150 (83) 31 (18) 94 (54) 125 (71) 29 (15) 128 (66) 157 (81) 25 (15) 98 (60) 123 (75) 
Total  47 (26) 134 (74) 181 (100) 76 (43) 99 (57) 175 (100) 61 (32) 132 (68) 193 (100) 64 (39) 100 (61) 164 (100) 
H. influenzae  
            
PCR (-) 78 (43.1) 2 (1) 80 (44) 59 (34) 4 (2) 63 (36) 68 (35) 5 (3) 73 (37) 42 (26) 4(2) 46 (28) 
PCR (+)  47 (26) 54 (30) 101 (56) 32 (18) 80(48) 112(66) 14 (7) 106 (55) 120 (62) 33 (20) 85 (52) 118 (72) 
Total  125 (69.1) 56 (31) 181 (100) 91 (52) 84 (48) 175 (100) 92(48) 111 (58) 193 (100) 75 (46) 89 (54) 164 (100) 
S. aureus  
            PCR (-) 157 (87) 4 (2) 161 (89) 141 (81) 1 (1) 142 (81) 156 (81) 1 (1) 157 (81) 131 (80) 5 (4) 137 (84) 
PCR (+)  6 (3) 15 (8) 20 (11) 11 (6) 22 (13) 33 (19) 11 (6) 25 (13) 36 (19) 15 (9) 13 (8) 28 (17) 
Total  163 (90) 18 (10) 181 (100) 152 (87) 23 (13) 175 (100) 167 (87) 26 (13) 193 (100) 146 (89) 18 (11) 164 (100) 
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The qPCR method demonstrated high sensitivity and specificity for all bacteria for which 
culture was undertaken and used as a referent standard, with 96.8%, 95.6% and 82.3% of 
culture-positive swabs being positive by qPCR and 90.5%, 94.3% and 97.5% of qPCR 
negative swabs being negative by culture for S. pneumoniae, H. influenzae and S. aureus, 
respectively (Table 4.5). Discordant results between culture and qPCR results were strongly 
associated with the density of carriage, with 88% (242/275) of culture negative, PCR positive 
samples having a bacterial load of <10
5
 CFU/ml. Similarly, 93% (42/45) of PCR negative, 
culture positive samples were scored as “scant” (<5 colonies/plate). This trend was observed 
across all bacterial pathogens, with the overall concordance between culture and PCR being 
98% (50/51), 94% (77/82) and 100% (5/5) for S. pneumoniae, H. influenzae and S. aureus 
respectively when estimated PCR loads were > 10
6
 CFU/ml.  
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Table 4.5: Detection of bacterial carriage by culture, stratified by colonisation density 
measured by quantitative PCR (qPCR) 
Pneumococcal 
density by qPCR 
(CFU/ml) 
Number culture positive/ number in density category by PCR (%) 
9 month old children 16 month old children 
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S. pneumoniae  
Undetected 4/31 (13) 5/50 (10) 4/36 (11) 2/41 (5) 15/159 (9) 
0-10
2
 1/2 (50) 0/1 0/2 0/3 1/8 (13) 
>10
2
-10
3
 14/20 (70) 5/16 (31) 8/17 (47) 6/14 (43) 33/67 (49) 
>10
3
-10
4
 31/38 (82) 11/21 (52) 33/43 (77) 17/21 (81) 92/123 (75) 
>10
4 
-10
5
 40/46 (87) 26/30 (87) 45/51 (88) 31/37 (84) 142/164 (87) 
>10
5
-10
6
 34/34 (100) 33/37 (89) 31/33 (94) 34/38 (89) 132/142 (93) 
>10
6 
-10
7
 9/9 (100) 16/17 (94) 9/9 (100) 6/6 (100) 40/41 (98) 
>10
7
-10
8
 1/1 (100) 3/3 (100) 2/2 (100) 4/4 (100) 10/10 (100) 
Total 134/181 (74) 99/175 (57) 132/193 (68) 100/164(61) 465/713 (65) 
      
H. influenzae 
 
Undetected 2/80 (3) 4/63 (6) 5/73 (7%) 4/46 (9) 15/262 (6) 
0-10
2
 0/10 0/5 - 0/1 0/16 
>10
2
-10
3
 5/22 (23) 5/14 (36) 5/9 (56) 2/6 (33) 17/51 (33) 
>10
3
-10
4
 12/22 (55) 13/23 (57) 12/16 (75) 9/17 (53) 46/78 (59) 
>10
4 
-10
5
 15/20 (75) 28/34 (82) 23/27 (85) 17/25 (68) 83/106 (78) 
>10
5
-10
6
 19/24 (79) 27/29 (93) 36/38 (95) 20/27 (74) 102/118 (86) 
>10
6 
-10
7
 3/3 (100) 7/7 (100) 25/25 (100) 28/33 (85) 63/68 (93) 
>10
7
-10
8
 - - 5/5 (100) 9/9 (100) 14/14 (100) 
Total 56/181 (31) 84/175 (48) 111/193 (58) 89/164 (54) 340/713 (48) 
      
S. aureus 
 
Undetected 4/161 (2) 4/145 (3) 1/157 (1) 6/137 (4) 15/598 (3) 
0-10
2
 - - - 0/1 0/3 
>10
2
-10
3
 5/9 (56) 6/13(50)  9/16 (56) 4/13 (31) 24/51 (54) 
>10
3
-10
4
 4/6 (67) 3/5 (60) 4/6 (67) 7/12 (58) 18/29 (71) 
>10
4 
-10
5
 2/2 (100) 3/4 (75) 4/5 (80) - 9/11 (82) 
>10
5
-10
6
 3/3 (100) 4/5 (80) 6/7 (86) 1/1 (100) 15/16 (94) 
>10
6 
-10
7
 - 2/2 (100) 2/2 (100) - 4/4 (100) 
>10
7
-10
8
 - 1/1 (100) - - - 
Total 18/181 (10) 23/175 (13) 26/193 (13) 18/164 (11) 85/713 (12) 
 
CFU/ml, colony forming units per millimetre as measured by qPCR. PCV7, seven-valent pneumococcal 
conjugate vaccine. Values are number culture positive/number in density category by qPCR (%). 
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4.2.2.  Prevalence of NP bacteria as determined by qPCR with respect to PCV 
vaccination status 
At least one bacteria was detected in 93.8 % (669/713) of all infant NP swabs, with 76.2% 
(543/713) of individuals being co-colonised with two or more species. At 9 months of age, 
overall pneumococcal colonisation was lower in PCV7-vaccinated (71.4%) than PCV-
unvaccinated children (82.9%) (Adjusted odd ratio [aOR] 0.45; 95% confidence intervals [CI] 
0.23-0.87; p= 0.018; Figure 4.2). The net reduction in carriage was due to a lower prevalence 
of vaccine-serotype colonisation in PCV7-vaccinated (36%) than PCV–unvaccinated children 
(62%, aOR 0.37; 95% CI 0.19-0.7; p=0.002). However, there was a corresponding increase in 
prevalence of non-vaccine serotype colonisation among the PCV7-vaccinated children (40% 
vs. 33.7%; aOR 1.88; 95% CI 1.02-3.48; p=0.023, Figure 4.2). By 16 months of age, there 
was no difference in overall pneumococcal colonisation between PCV7-vaccinated (75%) and 
PCV-unvaccinated children (81%; aOR 0.55; 95% CI 0.29-1.03; p= 0.062). This was due to 
the magnitude of lower prevalence of PCV7-serotype colonisation in PCV7-vaccinated 
(32.9%) than PCV-unvaccinated children (51.8%; aOR 0.41; 95% CI 0.26-0.63; p=0.007), 
being largely offset by the increase in non-vaccine serotype colonisation among the PCV7-
vaccinated children (62.2% vs. 37.8%; aOR 2.2; 95% CI 1.18-4.1; p=0.013); Figure 4.2).  
 
In contrast, the prevalence of colonisation by H. influenzae was higher in PCV7-vaccinated 
than PCV-unvaccinated children, including 66.3% vs. 55.8% (aOR 1.56, 95% CI 1.01-2.39; 
p=0.023), respectively, at 9 months of age; and 72% vs. 62% (aOR 1.88; 95% CI 1.07-3.3; 
p=0.017; Figure 4.2), respectively, at 16 months of age. Further, the prevalence of 
colonisation by S. aureus was higher in PCV7-vaccinated (18.9%) than PCV-unvaccinated 
children (11.1%, aOR 2.1; 95% CI 1.0-1.4; p=0.049) at 9 months of age; however, no 
difference between PCV7-unvaccinated (18.7%) and PCV-vaccinated (16.5%; aOR 0.81; 
95% CI 0.41-1.14; p=0.14) children was found at 16 months of age.  
 
No significant differences in the prevalence of colonisation at either 9 or 16 months of age 
was evident for, M. catarrhalis, S. pyogenes or N. meningitidis in respect to PCV7 
vaccination status.  
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 Figure 4.2: Prevalence of nasopharyngeal (NP) bacterial colonisation in PCV7-vaccinated and PCV-unvaccinated, HIV-uninfected children as 
measured by molecular qPCR 
 
p-values were determined by multivariate logistic regression, controlling for race, smoking household contact, co-trimoxazole use, day care attendance and mean age at time 
of sample collection, by use of generalised estimating equations. PCV7, seven-valent pneumococcal conjugate vaccine. VT, vaccine serotypes/serogroups (4, 6A/B, 
9A/L/N/V, 14, 18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7C, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 
23A/B, 34/37/17A). * p-Values of <0.05 were considered statistically significant. 
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PCV-unvaccinated 9 months (n=181)
PCV-Vaccinated 9 months  (n = 175)
PCV-unvaccinated 16 months  (n = 193)
PCV-Vaccinated  16 months (n = 164)
p=0.049 
p=0.002 
p=0.023 
p=0.007 
p=0.013 
p=0.023 
p=0.017 
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Logistic regression models demonstrated S. pneumoniae and H. influenzae to be positively 
associated with each other in PCV7-vaccinated children (p<0.001 and p=0.015) and PCV-
unvaccinated children (p=0.016 and p=0.023) at 9 and 16 months of age respectively (Table 
4.6), with associations being independent of PCV7-serotype group. Similarly, S. pneumoniae 
and M. catarrhalis colonisation were found to be positively associated with each other in both 
PCV7-vaccinated children (p=0.002 and p=0.021) and PCV-unvaccinated children (p=0.008 
and p=0.008) at 9 and 16 months of age respectively. These associations were independent of 
PCV7-serotype group. H. influenzae and M. catarrhalis were found to be positively 
associated with each other in PCV7-vaccinated (p=0.023 and p=0.019) and PCV-
unvaccinated children (p<0.001 and p=0.003) at 9 and 16 months of age respectively. The 
low prevalence of S. pyogenes and N. meningitidis colonisation limited comparisons from 
being made in relation to association of colonisation by other bacteria.  
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Table 4.6: Association of nasopharyngeal bacterial colonisation as determined by quantitative molecular PCR among PCV7-vaccinated and 
PCV-unvaccinated children 
 
Bacterial association 
9 month old children 16 month old children 
PCV7-vaccinated 
(n = 175) 
PCV-unvaccinated 
(n = 181) 
PCV7-vaccinated 
(n = 164) 
PCV-unvaccinated 
(n = 193) 
aO
R
 
(9
5
%
 C
I)
 
p
-v
al
u
e 
*
 
aO
R
 
(9
5
%
 C
I)
 
p
-v
al
u
e 
*
 
aO
R
 
(9
5
%
 C
I)
 
p
-v
al
u
e 
*
 
aO
R
 
(9
5
%
 C
I)
 
p
-v
al
u
e 
*
 
S. pneumoniae & H. influenzae 4.8 (2.22-10.4) <0.001 4.38 (2.6-5.17) 0.016 2.56 (1.2-5.47) 0.015 1.89(0.91-3.93) 0.023 
VT & H. influenzae 1.19(0.52-2.71) 0.68 1.24(0.47-2.89) 0.87 1.82(0.81-4.06) 0.14 1.25(0.69-2.25) 0.46 
NVT & H. influenzae 2.64(1.05-6.61) 0.058 0.94(0.49-1.81) 0.86 2.7(1.13-6.52 0.09 1.81(0.96-3.4) 0.07 
S. pneumoniae & M. catarrhalis 2.96 (1.51-5.83) 0.002 2.33 (1.05-5.18) 0.011 2.11 (1.08-5.3) 0.021 2.72 (1.26-5.85) 0.008 
VT & M. catarrhalis 0.48(0.23-1.02) 0.06 0.77(0.37-1.59) 0.47 2.75(1.22-6.18) 0.06 1.75(0.96-3.21) 0.07 
NVT & M. catarrhalis 1.48(0.7-3.14) 0.30 0.85(0.43-1.67) 0.63 1.43 (0.76-2.67) 0.26 1.82(0.96-3.45) 0.07 
S. pneumoniae & S. aureus 0.76 (0.34-1.71) 0.50 0.58 (0.19-1.73) 0.33 2.13 (0.69-6.56) 0.19 0.52 (0.22-1.2) 0.12 
VT & S. aureus 0.81(0.32-2.06) 0.66 0.68(0.23-2.03) 0.49 1.2(0.51-2.83) 0.67 0.74(0.36-1.54) 0.43 
NVT & S. aureus 1.49(0.58-3.87) 0.41 2.32(0.78-6.9) 0.13 1.34(0.59-3.07) 0.48 0.52(0.23-1.19) 0.12 
S. pneumoniae & S. pyogenes 0.59 9(0.1-3.6) 0.57 ND 
 
ND 
 
ND 
 
VT & S. pyogenes 0.6(0.05-6.79) 0.68 0.26(0.6-1.14) 0.07 ND 
 
ND 
 
NVT & S. pyogenes 1.61(0.14-18.25) 0.7 4.61(0.9-23.6) 0.07 ND 
 
ND 
 
S. pneumoniae & N. meningitidis  ND 
 
ND 
 
ND 
 
ND 
 
H. influenzae & M. catarrhalis 2.64 (1.87-4.09) 0.023 5.38 (2.81-10.32) <0.001 4.84 (3.1-6.78) 0.019 2.59 (1.35-4.63) 0.003 
H. influenzae & S. aureus 1.02 (0.46-2.28) 0.96 0.96 (0.38-2.45) 0.94 0.87 (0.33-2.26) 0.77 0.67 (0.31-1.44) 0.31 
H. influenzae & S. pyogenes 
2.07 (0.23-
18.96) 
0.52 1.34 (0.31-5.77) 0.70 ND 
 
ND 
 
H. influenzae & N. meningitidis 0.5(0.03-8.07) 0.62 2.41(0.25-23.7) 0.45 ND 
 
ND 
 
M. catarrhalis & S. aureus 0.69(0.32-1.48) 0.34 0.47 (0.19-1.21) 0.12 1.75 (0.7-4.37) 0.23 0.62 (0.29-1.32) 0.214 
M. catarrhalis & S. pyogenes 1.05 (0.17-6.45) 0.96 0.36 (0.8-1.46) 0.17 ND 
 
ND 
 
M. catarrhalis & N. meningitidis  ND 
 
0.62 (0.08-4.53) 0.64 ND 
 
ND 
 
S. aureus & S. pyogenes 
2.99 (0.48-
18.65) 
0.24 1.15 (0.14-9.93) 0.89 2.4 (0.44-13.14) 0.22 1.63 (0.42-6.39) 0.481 
S. aureus and N. meningitidis  ND   ND   ND   ND   
 
Adjusted odds ratios (aORs) for bacterial associations were determined by multivariate logistic regression, controlling for race, smoking house hold contact, co-trimoxazole 
use, day care attendance and mean age at time of sample collection, by use of generalised estimating equations. * p-values of  <0.05 were considered statistically significant. 
ND, not done as too few observations available for analysis. CI, confidence intervals. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 14, 18A/B/C, 19B/F and 23F). 
NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7C, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 23A/B, 34/37/17A). 
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4.2.3.  Association of PCV vaccination and density of bacterial nasopharyngeal carriage 
The overall density of pneumococcal carriage was higher in PCV7-vaccinated than PCV-
unvaccinated children at 9 months of age, with titers of 4.68 (95%CI: 4.45-4.90) CFU/ml 
compared to 4.28 (95%CI: 4.1-4.44) CFU/ml respectively (p=0.007). This was driven by an 
increase in carriage density, albeit lower prevalence of colonisation, of VT serotypes, with 
titers of 3.8(3.5-4.1) CFU/ml compared to 3.4(3.2-3.6) CFU/ml respectively (p=0.048) and by 
an increase in NVT serotypes, with titers of 3.6 (95%CI: 3.3-4) CFU/ml compared to 3.1 
(95%CI: 2.7-3.4) CFU/ml, respectively (p=0.018). There was, however, no difference in 
density of colonisation between the PCV7-vaccinated and -unvaccinated groups at 16 months 
of age (figure 4.3).  
 
A similar trend was noted for the density of the other bacteria at 9 months of age, where the 
density of colonisation was higher in PCV7-vaccinated than PCV-unvaccinated children for 
H. influenzae (4.34 vs. 3.86 CFU/ml; p=0.008), M. catarrhalis (3.52 vs. 2.98 CFU/ml; 
p<0.001) and S. aureus (4.02 vs. 3.06 CFU/ml; p=0.02). There was however, no difference in 
density of colonisation between PCV7-vaccinated and PCV-unvaccinated groups at 16 
months of age. No significant differences in density of colonisation were observed for S. 
pyogenes and N. meningitidis between PCV7-vaccinated and PCV-unvaccinated children. 
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Figure 4.3: Density of nasopharyngeal bacterial carriage in PCV7-vaccinated and PCV-
unvaccinated, HIV-unifected children as measured by quantitative molecular qPCR 
For density of carriage geometric mean densities (GMD) and 95% CI intervals (95% CI) of pneumococcal and 
bacterial mean concentrations were calculated following log10 transformations on data and compared with 
multivariate analysis controlling for race, smoking house hold contact, co-trimoxazole use, day care attendance 
and mean age at time of sample collection. PCV7, seven-valent pneumococcal conjugate vaccine. VT, vaccine 
serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups 
(1, 3, 5, 6C/D, 7C, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 23A/B, 34/37/17A). p-
values of <0.05 were considered significant. 
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Spearman correlation coefficients showed the overall densities of S. pneumoniae and H. 
influenzae to be weakly correlated in PCV7-vaccinated (rho=0.338; p<0.001 and rho=0.309, 
p=0.0025) and PCV-unvaccinated children (rho=0.4 and 0.464; p<0.001) at 9 and 16 months 
of age respectively. These correlations were independent of PCV7–serotype group.  
 
A weak positive correlation was also found between densities of S. pneumoniae and M. 
catarrhalis in PCV7-vaccinated (rho=0.333, p=0.002) children at 9 months of age, while a 
moderate correlation was found between the densities of S. pneumoniae and M. catarrhalis in 
PCV-unvaccinated (rho=0.45, p=0.005) children at 9 months of age. These correlations were 
evident for vaccine serotypes (rho=0.423, p=0.016 and rho=0.3186, p=0.006) in both cohorts 
respectively. A similar trend was noted at 16 months of age, with a weak positive correlation 
being found between the densities at both PCV7-vaccinated (rho=0.25, p=0.0035) and PCV-
unvaccinated (rho=0.343, p=0.0013). These correlations were, however, independent of 
PCV7-serotype group. A weak correlation was also identified between densities of H. 
influenzae and M. catarrhalis in PCV-vaccinated children (rho=0.36, p=0.048 and 
rho=0.2523, p=0.04) and PCV-unvaccinated (rho=0.19, p=0.03 and rho=0.343, p=0.0013) at 
9 and 16 months of age respectively. These associations were independent of PCV7–serotype 
group. No significant correlations with density of colonisation were found between other 
bacteria (Table 4.7).
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Table 4.7: Correlation of density of nasopharyngeal bacterial colonisers as determined by quantitative molecular PCR among PCV7-vaccinated 
and PCV-unvaccinated children 
 
Bacterial correlation  
9 month old children 16 month old children 
PCV7-vaccinated (n = 175) PCV-unvaccinated (n = 181) PCV7-vaccinated (n = 164) PCV-unvaccinated (n = 193) 
R
h
o
 
p
-v
al
u
e 
*
 
R
h
o
 
p
-v
al
u
e 
*
 
R
h
o
 
p
-v
al
u
e 
*
 
R
h
o
 
p
-v
al
u
e 
*
 
S. pneumoniae & H. influenzae 0.338 <0.001 0.4 <0.001 0.309 0.0025 0.46 <0.001 
VT & H. influenzae 0.085 0.59 0.287 0.78 0.1472 0.24 0.2321 0.16 
NVT & H. influenzae 0.152 0.27 0.09 0.61 -0.0858 0.58 0.3095 0.026 
S. pneumoniae & M. catarrhalis 0.333 0.002 0.4488 0.005 0.252 0.0035 0.343 0.0013 
VT & M. catarrhalis 0.423 0.016 0.3186 0.006 0.0857 0.48 0.2106 0.24 
NVT & M. catarrhalis 0.251 0.15 0.0791 0.61 0.1239 0.4 0.1619 0.34 
S. pneumoniae & S. aureus -0,489 0.84 0.28 0.31 0.192 0.38 -0.063 0.74 
VT & S. aureus 0.7364 0.07 -0.3143 0.54 0.432 0.21 0.151 0.54 
NVT & S. aureus 0.086 0.78 0.033 0.93 -0.373 0.19 0.611 0.34 
S. pneumoniae & S. pyogenes ND 
 
ND 
 
0.143 0.76 0.360 0.15 
VT & S. pyogenes ND 
 
ND 
 
0.867 0.33 0.1 0.83 
NVT & S. pyogenes ND 
 
ND 
 
ND 
 
0.31 0.46 
S. pneumoniae & N. meningitidis  ND 
 
ND 
 
ND 
 
ND 
 
H. influenzae & M. catarrhalis 0.360 0.048 0.19 0.03 0.2523 0.04 0.343 0.0013 
H. influenzae & S. aureus -0.139 0.56 -0.351 0.29 -0.159 0.54 -0.165 0.48 
H. influenzae & S. pyogenes -0.4 0.60 0.1 0.87 0.679 0.093 -0.077 0.81 
H. influenzae & N. meningitidis ND 
 
ND 
 
ND 
 
ND 
 
M. catarrhalis & S. aureus 0.286 0.30 0.519 0.15 0.412 0.11 0.24 0.32 
M. catarrhalis & S. pyogenes ND 
 
0.5 0.67 ND 
 
0.436 0.18 
M. catarrhalis & N. meningitidis  ND 
 
ND 
 
ND 
 
ND 
 
S. aureus & S. pyogenes ND 
 
ND 
 
ND 
 
ND 
 
S. aureus and N. meningitidis  ND 
 
ND 
 
ND 
 
ND 
 
 
Bacterial correlations were determined by spearman’s coefficients. ND, not done as too few observations available for analysis. PCV7, seven-valent pneumococcal conjugate 
vaccine. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7C, 10A, 11A/B/C/D/F, 
12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 23A/B, 34/37/17A). p-values of  <0.05 were considered significant. 
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4.3.  DISCUSSION   
This study successfully established a highly sensitive molecular qPCR method to examine the 
effect that PCV has on common bacterial nasopharyngeal colonisers in PCV7-vaccinated and 
PCV-unvaccinated children in South Africa. Our analysis was in agreement with culture 
based methods, and showed a decrease in the carriage prevalence of pneumococcus and a 
corresponding increase in the carriage prevalence of H. influenzae associated with PCV 
vaccination 
234
. Molecular qPCR allowed us to also investigate the density of carriage and 
showed that the overall density of H. influenzae was also higher in PCV7-vaccinated infants, 
which could possibly explain the moderate effects that PCV has on otitis media (OM), even 
with the vaccine having up to 80% efficacy in reducing vaccine-type pneumococcal 
colonisation
235-237
. This is further supported by studies done in USA which showed the 
incidence of H. influenzae acute otitis media to increase after PCV immunisation 
238
. 
 
There is contradicting data with respect to the effect that PCV has on S. aureus carriage, with 
most studies reporting a temporary increase in the prevalence of colonisation and others 
reporting no change. Our findings are in line with studies done in the Netherlands were a 
temporary increase in the colonisation prevalence of S. aureus was found after PCV7 
immunisation suggesting the effect there on to be around PCV7 vaccinations in infancy and 
subsequently diminishing after non-vaccine serotypes or other bacterial species colonise the 
vacant niche or by an age-dependent maturation of the immune system
170,177,239
. The qPCR 
method, however, also allowed quantification and showed a temporary increase in the density 
of S. aureus, raising concerns of the indirect effect PCV-vaccination may have on both S. 
aureus carriage and infection, and may possibly explain the rise in otitis media cases 
following immunisation with PCV 
240
. Two cross sectional studies, one in primary care 
visiting children from Massachusetts and the other in children from France with otitis media 
reported no change the prevalence of colonisation by S. aureus following PCV immunisation 
168,169
. These studies, however, were limited in that they included children of varying ages and 
therefore the temporary effect of PCV there on S. aureus carriage could easily have been 
missed. Further, the studies involved PCV-vaccinated populations with established heard 
effects and the effect of infant vaccination with PCV may have thus been less pronounced due 
to a pre-established low circulation and carriage of vaccine-type pneumococcal serotypes.  
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Nevertheless, the vaccine effect, typified as a decrease in vaccine-type serotypes and a 
corresponding increase in NVT serotypes as a result of PCV vaccination has been well 
documented 
149,219,220
; however, the findings from this study suggest that after the eradication 
of common PCV colonisers such as vaccine-type pneumococci, momentum is directed by 
both non-vaccine type serotypes and other bacterial species to colonise the vacant niche and 
thus direct bacteria-bacteria interactions may impact clinically important nasopharyngeal 
dynamics.  
 
Our findings are in line with other studies, in that positive associations with respect to 
prevalence were reported between pneumococcus, H. influenzae and M. catarrhalis 
83,175,231
. 
Whilst these observations may well be associated with non-bacterial factors such the presence 
of respiratory viruses which may cause an ubiquitous increase in bacterial outgrowth in 
mucosal secretions, these common observations could also be associated with the quality of 
nasopharyngeal swab that was collected, and as such, justifies further research into these 
interactions. 
 
The majority of studies of NP colonisation have focused on non-quantitative culture based 
methods, which have compared changes in the prevalence of bacterial carriage. Whilst this 
has been meaningful to some extent, the lack of quantitative data has hindered our 
understanding of these dynamics. Quantitative real-time PCR has become an increasingly 
important diagnostic tool in which multiple respiratory organisms can be detected from 
clinical specimens, with an increased sensitivity and specificity compared to standard culture 
methods. Furthermore, the ability to quantitatively detect multiple bacterial species within 
nasopharyngeal specimens provided a means for a better understanding of carriage and its 
relationship to disease. Improved methods of detection of respiratory pathogens will provide a 
means to improve the health care of patients as optimal therapy can be initiated sooner, 
effective treatment is improved and spread of disease can be reduced or prevented. 
Furthermore, a high bacterial load detected by real-time PCR in nasopharyngeal specimens 
can help predict the aetiological role for these bacterial species in invasive bacterial disease. 
However, the real-time qPCR has some disadvantages in that it requires expensive reagents 
and equipment, and a large sample volume is required to distribute across all reactions.  
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Our study was limited, as only a selection of NP organisms were analysed and thus analysis at 
a microbiome level may be advantageous. Furthermore, nasopharyngeal swabs do not favour 
the isolation of S. aureus and S .pyogenes in which anterior nares and throat swabs are better 
for detection, respectively 
241,242
. The prevalence of these bacteria could have thus been 
underestimated. Lastly, the qPCR method was not able to discriminate between all serotypes 
within their respective serogroup; however, due to the high concordance between serotypes 
identified by culture and qPCR, we can assume from colonisation data using traditional 
culture methods, that 71.4%, 80% and 92.6% of all serogroups 9A/L/N/V, 18A/B/C and 
19B/F identified by qPCR to be vaccine-serotypes 9V, 18C and 19F, respectively (Chapter 2). 
 
In conclusion, there is a natural balance between pneumococci and co-colonising bacterial 
species. Interfering with this may lead to disequilibrium within the host, which could affect 
susceptibility to disease from other serotypes and bacteria species. On-going surveillance, 
especially on the implication of such changes in the nasopharyngeal biome on particularly 
mucosal infections are warranted.  
 
 
  
 106 
 
CHAPTER 5: PERFORMANCE OF THE BIOMARK HD REAL-
TIME PCR SYSTEM (FLUIDIGM) FOR THE DETECTION OF 
COMMON NASOPHARYNGEAL BACTERIAL PATHOGENS AND 
SEROTYPING STREPTOCOCCUS PNEUMONIAE 
 
The human nasopharynx is a common ecological niche for several respiratory pathogens 
including S. pneumoniae, H. influenzae, M. catarrhalis, and S. aureus 
71
. Interactions between 
these bacteria and the establishment of carriage and disease is not well known 
73,74
, with 
findings being contradictory and relevant mechanisms to explain concurrent colonisation 
being unclear 
74-77
. The majority of studies of nasopharyngeal colonisation have focused on 
non-quantitative culture based methods and thus the lack of quantitative data has hindered our 
understanding of these dynamics 
199
. Recently molecular quantitative PCR-based methods 
have been developed and allowed for quantitative detection of multiple serotypes from a 
single nasopharyngeal specimen (Chapter 2). Serotyping pneumococci by qPCR, however, 
still has two main shortcomings, including that large sample volume is required to distribute 
across all the reactions, and that it is expensive (approximately R26 per sample per assay). 
Further, processing multiple qPCR reactions is labour intensive and time consuming. 
 
Fluidigm is a nanofluidic automated real-time PCR system that relies on microfluidic 
technology in which dynamic arrays of integrated fluidic circuits (IFCs) are used. These IFC’s 
contain thousands of controlled valves and interconnected channels in which molecules of 
biological samples and reagents can be automatically mixed in a variety of patterns. The 
instrument uses an array of non-fluidic chips called dynamic arrays for qPCR, in which a 
typical chip format allow for 9 216 PCR reactions (96.96 chip format; 96 samples x 96 
assays) in a single qPCR run (www.fluidigm.co.za)
 204
. Further, Fluidigm has several 
advantages over standard qPCR in that it allows for a larger number of reactions per plate, 
thus making it more cost effective (approximately R7 per sample per assay) and less time 
consuming. Further, IFCs not only reduces the reaction volume from 10µL – 20µL down to 
10nL scale, but the technology also allows for validations as well as increased parallelism and 
throughput of qPCR reactions 
204
.  
 
This chapter aimed to develop a novel Nanofludic real-time PCR assay that could 
simultaneously detect and quantify 11 bacterial pathogens, 53 pneumococcal serotypes (16 
individual serotypes and 37 serotypes in 13 groups) and 6 serotypes of H. influenzae 
 107 
 
(serotypes a-f) in 96 different samples (92 samples and 4 controls) in a single PCR run. In 
addition we compared results from traditional quantitative PCR and Fluidigm for the 
detection of bacterial colonisation and pneumococcal serotyping in a PCV-vaccinated cohort 
of black-African children. 
 
5.1. MATERIAL AND METHODS  
5.1.1.  Study population 
We retrospectively analysed archived nasopharyngeal swab samples collected from a PCV7-
vaccinated cohort of HIV-uninfected infants in Soweto, South Africa. Detailed information of 
the study cohort has been described in Chapter 3. Samples were previously screened for S. 
pneumoniae, H. influenzae, S. aureus, M. catarrhalis, S. pyogenes and N. meningitidis by 
conventional real-time polymerase chain reaction (qPCR) (Chapter 4), and pneumococcal 
serotyping was done on all samples that tested positive for S. pneumoniae (Chapter 3). In this 
Chapter, we compare previous findings by conventional real-time PCR to those of the 
Biomark HD system (Fluidigm) and in addition screened for an extra 9 serotypes/serogroups 
(7A/F, 8, 22A/F, 25A/25F/38 and 35B), and 5 bacteria (B. bronchiseptica, B. parapertusis, B. 
pertussis, B. holmesii and N. lactamica) as well as serotyped H. influenzae.  
 
5.1.2.  Bacterial and pneumococcal reference isolates  
Control strains for the pneumococcal serotypes (1, 2, 3, 4, 5, 6A, 6B, 6C, 6D, 7A, 7F, 7C, 8, 
9A, 9L, 9N, 9V, 10A, 10B, 11A, 11B, 11C, 11D, 11F, 12A, 12B, 12F, 13, 14, 15A, 15B, 15C, 
15F, 16A, 16F, 17A. 17F,18A, 18B, 18C, 19A, 19B, 19F, 20, 21, 22A, 22F,23A, 23B, 
23F,25A, 25F, 34, 35B and 37), H. influenzae serotypes (serotypes a-f), M. catarrhalis, S. 
aureus, N. meningitidis and S. pyogenes were obtained from the National Institute for 
Communicable Diseases (NICD). Additional isolates for B. bronchiseptica (ATCC ® 4617), 
B. parapertusis (ATCC ® 15311), B. pertussis (ATCC ® 2397) and N. lactamica (ATCC ® 
23970) were purchased from Davies Diagnostics (South Africa), while an isolate for B. 
holmesii (ATCC ® 51541) was purchased from LGC standards South Africa. DNA from 
these strains were used to optimise PCR assays and as positive controls.  
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5.1.3.  DNA extraction  
Stored nasopharyngeal swab samples were thawed and processed. Briefly, NP swabs were 
vortexed for 30 seconds to release bacteria into the transport media and total nucleic acids 
were automatically extracted from STGG with the NucliSens ® easyMAG ® extraction 
system (BioMérieux, Marcy l’Etoile, France) according to manufactures instructions. 
Similarly, total nucleic acids were also extracted from pneumococcal reference strains 
(positive control strains) grown in Todd-Hewitt broth supplemented with 5% yeast, S. aureus, 
M. catarrhalis, S. pyogenes, N. meningitidis and N. lactamica reference strains grown in 
Todd-Hewitt broth alone, H. influenzae serotypes a-f grown in Brain-Heart infusion (BHI) 
broth and Bordetella species grown in potato broth with the NucliSens ® easyMAG ® 
extraction system according to manufacturer’s instructions. Samples and reference strains 
were stored at - 20 °C. 
 
5.1.4.  Nanofluidic real-time PCR 
The sequences for oligonucleotide primers and FAM dye-labelled MGB probes were taken 
from previously published sequences, or designed with the ABI primer express software 
package, version 3.0 (Applied Biosystems, ABI, Foster City, USA). Primer and Probe 
sequences are described in Table 5.1. GAPDH was included to confirm the efficiency of the 
DNA extraction and BexA to confirm the presence of non-typable H. influenzae. Due to the 
high genotypic similarities between the capsule loci of certain pneumococcal serotypes, the 
qPCR method was unable to discriminate between some serotypes within a particular 
serogroup (i.e. 6A/B, 6C/D, 7A/F, 9A/L/N/V, 11A/B/C/D/F, 12A/B/F, 15A/B/C/F, 18A/B/C, 
19B/F, 22A/F, 23A/B, 25A/25F/38 and 34/37/17A), although able to identify serotypes 1, 3, 
4, 5, 7C, 8, 10A, 13, 14, 16F, 17F, 19A, 20, 21, 23F and 35B individually.
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Table 5.1: Oligonucleotide primers and probe
a
 sequences for quantitative molecular Nanofludic real-time PCR detection of respiratory pathogen 
Target Name  
Primer/Prob
e name  
Forward primer Reverse primer  Probe  
Reference  
Streptococcus pneumoniae  lytA  TCTTACGCAATCTAGCAGATGAAGC  GTTGTTTGGTTGGTTATTCGTGC TTTGCCGAAAACGCTTGATACAGGG  
McAvin et al, 
2001 
Haemophilus influenzae  IGA CAAAATTGCCAAGATTAAATGCTT TGCTCGCCATACTGCACA A  CCTGCGGTTAAACC 
McGillivary et al, 
2005 
Haemophilus influenzae type A HiA  GCAACCATCTTACAACTTAGCGAATAC GGTCTGCGGTGTCCTGTGTT AAGTGAAGCATGTCGCCATTCGTCCA 
Maaroufi et al, 
2007  
Haemophilus influenzae type B HiB TGTTCGCCATAACTTCATCTTAGC 
CTTACGCTTCTATCTCGGTGATTAATA
A 
CACAAAACTTCTCATTCTTCGAGCCTA 
Maaroufi et al, 
2007  
Haemophilus influenzae type C HiC TCTGTGTAGATGATGGTTCAGTAG TTAGGATATTTACGCTGCCATT TGCAGCTAAGATTATT 
Maaroufi et al, 
2007  
Haemophilus influenzae type D HiD TATTGATGACCGATACAACCTGTTTAAA CCAGAAATTATTTCTCCGTTATGTTGA AATGGTTGTAAAACTCTTCT 
Maaroufi et al, 
2007  
Haemophilus influenzae type E HiE GTTGAAAACAAACCGCACTTT ATCTTTAATTACCAGATCCCTTTCAT AACGAATGTAGTGGTAGTTAGA 
Maaroufi et al, 
2007  
Haemophilus influenzae type F HiF GGATAATCAAATACCACATTGGCTTA 
GTAGATTAGCCTCAATAACATGTGAA
TTAA 
TCATCGTGAGATCATTGATCACGAT 
Maaroufi et al, 
2007  
BexA  BexA  CTGAATTRGGYGATTATCTTTATGA ACAATCAAAYTCAACHGAAAGHGA AGGGATGAAAGCYCGRCTTGCAT 
Maaroufi et al, 
2007  
Staphylococcus aureus  SA GCTCAGCAAATGCATCACAAA 
CACTATATACTGTTGGATCTTCAGAAC
CA 
AGATAACGGCGTAAATA 
This Study 
Moraxella catarrhalis MCAT CCGCTTTTACAACCACTGCTT TGTATCGCCTGCCAAGACAA  CAGCTGTTAGCCAGCC This Study 
Streptococcus pyogenes  SPY GCACTCGCTACTATTTCTTACCTCAA GTCACAATGTCTTGGAAACCAGTAAT CCGCAACTCATCAAGGATTTCTGTTACCA CDC 2008 
Neisseria meningitidis  SodC GCACACTTAGGTGATTTACCTGCAT  CCACCCGTGTGGATCATAATAGA CATGATGGCACAGCAACAAATCCTGTTT 
Thomas et al., 
2011 
Neisseria lactamica LacZ TTGCCCGAGAACCATTGTATC GCGGTTCTTATCACGTTCTATATTTG TATTGGAGCGGACTAAA This Study 
Bordetella pertussis and Bordetella holmesii IS481 CAAGGCCGAACGCTTCAT GAGTTCTGGTAGGTGTGAGCGTAA CAGTCGGCCTTGCGTGAGTGGG Tatti et al, 2011 
Bordetella holmesii hIS1001 GGCGACAGCGAGACAGAATC GCCGCCTTGGCTCACTT CGTGCAGATAGGCTTTTAGCTTGAGCG C Tatti et al, 2011 
Bordetella parapertusis  pIS1001 TCGAACGCGTGGAATGG GGCCGTTGGCTTCAAATAGA AGACCCAGGGCGCACGCTGTC Tatti et al, 2011 
Bordetella pertussis, Bordetella parapertusis 
and Bordetella bronchiseptica  
PtxS CGCCAGCTCGTACTTC GATACGGCCGGCATT AATACGTCGACACTTATGGCGA 
Tatti et al, 2011 
Streptococcus pneumoniae serotype 1 1 CGTGCGGTAATTGAAGCTATGA TGTGGCCCCAGCAACTCT TGCTTGCCCTTGTATAGGGT Azzari et al, 2010 
Streptococcus pneumoniae serotype 3 3 GGTCAGCAGAAAGTATGCATTGG TCGTTTATCCAGGGTCTGATGA TATTGGATGTGGTTTATCGTGAAGA Azzari et al, 2010 
Streptococcus pneumoniae serotype 4 4 TGGGATGACATTTCTACGCACTA CCGTCGCTGATGCTTTATCA TCCTATTGGATGGTTAGTTGGTGA Azzari et al, 2010 
Streptococcus pneumoniae serotype 5 5 TTACGGGAGTATCTTATGTCTTTAATGG CAGCATTCCAGTAGCCTAAAACTAGA TTGTCTCAGCAACTCTATTTGGCTGTGGG Azzari et al, 2010 
Streptococcus pneumoniae serogroup 
6A/B/C/D 
6ABCD AAGTTTGCACTAGAGTATGGGAAGGT ACATTATGTCCRTGTCTTCGATACAAG TGTTCTGCCCTGAGCAACTGG Azzari et al, 2010 
Streptococcus pneumoniae serogroup 6C/D 6CD TTGGGATGATTGGTCGTATTAG CTCTTCAATTAGTTCTTCAGTTCG CCACGCAATTCGCCATC Azzari et al, 2010 
Streptococcus pneumoniae serogroup 7A/F 7A/F GATGGCATGTGGCAAACCA TTTGCCCTCCTTAATCATTTCAC TTGGCTATCGGCATGGTGGT Azzari et al, 2010 
Streptococcus pneumoniae serotype 7C 7C CGTCAGGAATAGGTGCAATCTCT TGAAATTCCAAGCGAAGCAA TTCATCTATTGGTTCTTATGGTGTT  This Study 
Streptococcus pneumoniae serotype 8 8 CCACTCATCAGTTTCCCATATGTTT TCAATAATTGAAGAAGCGAACGTT TGATGGCAGATGGGTTGGGACGAG Azzari et al, 2010 
Streptococcus pneumoniae serogroup 
9A/L/N/V 
9A/L/N/V TGGAATGGGCAAAGGGTAGTA TCGGTTCCCCAAGATTTTCTC TTAATCATGCTAACGGCTCATCGA Azzari et al, 2010 
Streptococcus pneumoniae serotype 10A 10A 
CCTCTCCTATCAACTATTACTCATTATAC
TACCT 
AATAACCATAAGTCCCTAGATCATTC
AAAG 
TCATTACAACTCCCTATGTGACACGGGTCTTT
T 
Azzari et al, 2010 
Streptococcus pneumoniae serogroup 
11A/B/C/D/F 
11ABCDF ACCGCATTTCTTATCGCACTATATT TCTCCTTACCATCAAACATGTTAATCA TGAATCAGTCTGACCGTTT 
This Study 
Streptococcus pneumoniae serogroup 12A/B/F 12ABF GATTATTCGCTTGCCTCTTCATG ATAGCCGAAATAAGCTTTCCAGAA ATTTGTAAGCGGACGTGCGATT Azzari et al, 2010 
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Streptococcus pneumoniae serotype 13 13 TCGCATTTAGTAGTAACCCCTTGA TTCTTGATTGAGGATGCATTTCC AGTAGTAAGAGATCATATTCAAG This Study 
Streptococcus pneumoniae serotype 14 14 CGACTGAAATGTCACTAGGAGAAGAT 
AATACAGTCCATCAATTACTGCAATA
CTC 
TGTCATTCGTTTGCCAATACTTGATGGTCTC Azzari et al, 2010 
Streptococcus pneumoniae serogroup 
15A/B/C/F 
15ABCF TTGAATCAGGTAGATTGATTTCTGCTA 
CTCTAGGAATCAAATACTGAGTCCTA
ATGA 
CTCCGGCTTTTGTCTTCTCTGT Azzari et al, 2010 
Streptococcus pneumoniae serogroup 16F 16F GCAACTGGTATTTTTGATATTGGAGAA CAAAGGAATGCCATGCCATA AAAATGCTAACTTCGTTGGAGG This Study 
Streptococcus pneumoniae serotype 17F 17F 
GTAAAGATTTCATGTCCTATAAGGGAGA
A 
AGGCGTCCCTGTTTATGAGAAG TTGTACATGGTCTGGATTT 
This Study 
Streptococcus pneumoniae serogroup 18A/B/C 18ABC CCTGTTGTTATTCACGCCTTACG TTGCACTTCTCGAATAGCCTTACTC AACCGTTGGCCCTTGTGGTGGA Azzari et al, 2010 
Streptococcus pneumoniae serotype 19A 19A TTCGACGACGTATCAGCTTCA TCATTGAGAGCCTTAACCTCTTCA ACCCAAAACGGTTGACGCATTATACT Azzari et al, 2010 
Streptococcus pneumoniae serogroup 19B/F 19BF GGTCATGCGAGATACGACAGAA TCCTCATCAGTCCCAACCAATT ACCTGAAGGAGTAGCTGCTGGAACGTTG Azzari et al, 2010 
Streptococcus pneumoniae serotype 20 20 AAAGATACTGGCTGAGGAGCTATCTATT 
AGTCAAAAGTACTCAACCATTCTGAT
ATATTC 
AGGATAAGGTCTACTTTGTGGGAGTTC Azzari et al, 2010 
Streptococcus pneumoniae serotype 21 21 CCATTTGAAGGACCAGTTGTTG AAAAAGCCACTATCAGGAATACCAA AATGGCATTGCTTCGTAAA This Study 
Streptococcus pneumoniae serotype 22A/F 22AF 
TCTATTAAATAACCCATTGGAATTGAAA
CG 
TCGCAATTGAAGACCACATAAACTG TCCGTAAT”T”CGCTTATGGGCACATTCTCCA Azzari et al, 2010 
Streptococcus pneumoniae serogroup 23A/B/F 23ABF GGTGGACTTTCCGATGCAA 
CACTGTCAACAAAAATGAGGTAATCT
C 
AAATGTCGGTATAGATAAAG 
This Study 
Streptococcus pneumoniae serotype 23F 23F TGCTATTTGCGATCCTGTTCAT AGAGCCTCCGTTGTTTCGTAAA TTTCTCCGGCATCAAACGTTAAG Azzari et al, 2010 
Streptococcus pneumoniae serogroup 
25A/25F/38 
25AF/38 GTCTTACGTAGAACCTCTCTGGATGA  TGGTCCTACAAGCGACATGTG  TTGCCACAGATTTGGAATATT TTGGTCGG  
This Study 
Streptococcus pneumoniae serogroup 
34/37/17A 
34/37/17A GGATACTATGTACGAACAGATGGACTTG CTCACTAACTCGCCCGAATAAAC CCGACTATACTCCATTTGA 
This Study 
Streptococcus pneumoniae serotype 35B 35B GCATGGAGGTGGAGCATACA 
TGTAAAGACTGCACAACTCGATATAA
AA 
CAATTTAAACAATATTAGTAAAGCGCAGGTC
AAGCAAA 
Azzari et al, 2010 
 
Probe
a
: Minor Grove Binding (MGB) FAM labelled TaqMan probe. 
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5.1.4.1.  Pre-amplification of DNA 
Specific target amplification (STA) was done per manufactures recommendations as the initial step 
(pre-amplification of DNA) for the Biomark HD system (Fluidigm). Briefly two separate pools of 
primers were prepared by mixing 24X TaqMan assays in each, to a final concentration of 0.2X per 
assay (Table 5.2). PCR reactions were carried out in 5µL volumes each containing 2.5µL TaqMan 
PreAmp Master Mix (Fluidigm, CA, USA), 1.25µL of pooled assay and 1.25µL of DNA. Reactions 
were amplified with the T100 Thermal Cycler (Bio-Rad Laboratories, CA, USA) and cycling 
conditions included an initial activation at 95ºC for 10 minutes followed by 14 two-step cycles 
(denaturation at 95ºC for 15 seconds and annealing/extension at 60ºC for 4 minutes). STA products 
from the two assays were combined and diluted 1:5 with dH2O and stored at -80 ºC.  
 
Table 5.2: Primer pools for Specific Target Amplification (STA) to be used in an initial step (pre-
amplification of DNA) for the Biomark HD system (Fluidigm) 
Pool A Pool B 
Streptococcus pneumoniae (lytA) GAPDH 
Haemophilus influenzae  Haemophilus influenzae type D 
Haemophilus influenzae type A Haemophilus influenzae type F 
Haemophilus influenzae type B BexA  
Haemophilus influenzae type C Staphylococcus aureus  
Haemophilus influenzae type E Moraxella catarrhalis 
Neisseria meningitidis  Streptococcus pyogenes  
Bordetella holmesii Neisseria lactamica 
Streptococcus pneumoniae serotype 1 Bordetella pertussis and Bordetella holmesii 
Streptococcus pneumoniae serotype 4 Bordetella parapertusis  
Streptococcus pneumoniae serotype 5 
Bordetella pertussis, Bordetella parapertusis and Bordetella 
bronchiseptica  
Streptococcus pneumoniae serogroup 6A/B/C/D Streptococcus pneumoniae serotype 3 
Streptococcus pneumoniae serotype 7C Streptococcus pneumoniae serogroup 6C/D 
Streptococcus pneumoniae serotype 8 Streptococcus pneumoniae serogroup 7A/F 
Streptococcus pneumoniae serogroup 9A/L/N/V Streptococcus pneumoniae serogroup 11A/B/C/D/F 
Streptococcus pneumoniae serotype 10A Streptococcus pneumoniae serogroup 12A/B/F 
Streptococcus pneumoniae serotype 14 Streptococcus pneumoniae serotype 13 
Streptococcus pneumoniae serotype 19A Streptococcus pneumoniae serogroup 15A/B/C/F 
Streptococcus pneumoniae serogroup 19B/F Streptococcus pneumoniae serogroup 16F 
Streptococcus pneumoniae serotype 21 Streptococcus pneumoniae serotype 17F 
Streptococcus pneumoniae serogroup 23A/B/F Streptococcus pneumoniae serogroup 18A/B/C 
Streptococcus pneumoniae serotype 23F Streptococcus pneumoniae serotype 20 
Streptococcus pneumoniae serogroup 25A/25F/38 Streptococcus pneumoniae serotype 22A/F 
Streptococcus pneumoniae serogroup 34/37/17A Streptococcus pneumoniae serotype 35B 
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5.1.4.2.     Real-time qPCR using the Biomark HD System (Fluidigm) 
The qPCR assays were carried out with 96.96 dynamic arrays (Fluidigm Corporation, CA, USA) 
according to manufactures instructions. Briefly 10X assay mixture and sample pre-mix were 
prepared, with each assay being prepared in duplicate. An IFC controller (Fluidigm) was used to 
prime the 96.96 dynamic arrays IFC Chip (Fluidigm) with control line fluid. 5µL of assay and 
sample mix was then transferred into the appropriate inlets of the primed chip and loaded with the 
IFC controller. After loading, the chip was placed in the Biomark instrument for quantitative PCR at 
95ºC for 10 minutes followed by 40 cycles at 95ºC for 15 seconds and 60 ºC for 1 minute. The data 
was analysed with real-time PCR Analysis Software in the BIOMARK instrument (Fluidigm 
Corporation, CA, USA). 
 
5.1.4.3.     Primer optimisation, Standard curves and quantification in the nanofludic real-time 
PCR system.  
Standard concentration curves and lower limits of detection (LLD) for each target bacteria were 
determined by amplifying four independent 10X serial dilutions of purified genomic DNA extracted 
from reference strains with the linear dynamic range being 10
1
 – 107 copies per standard curve. 
Target control DNA was harvested from early exponential phase cultures (OD600 = 0.1 for 
pneumococcus and OD600 = 1.0 for other bacteria), and the number of CFU/swab was estimated from 
Cq values relative to the standard curve, which is based on the quantitative culture of the control 
DNA.  
 
Correlation coefficients (r
2
) of each standard curve were determined and the amplification efficiency 
(e) of a given primer pair was calculated by e = 10
–1/m
 -1, where m is the slope of the standard curve. 
Lower limits of detection (LLD) or analytical sensitivity was determined by the minimum number of 
copies of DNA that could be measured repeatedly by the primers in the 10-fold serial dilutions. All 
primer pairs were tested with genomic DNA from all bacterial controls in a single Fluidigm run to 
determine the analytical specificity. Further, intra-assay variation (repeatability) was determined by 
running the same samples four times in the same assay run and presented as standard deviation (SD) 
for the copy number of the samples. A ratio of the difference between the observed copy number and 
the expected copy number was calculated to determine the accuracy of the assays, while the inter-
assay variation (reproducibility) was determined by the SD of the copy number of the same sample 
tested in different runs. A summary of the criteria for performance acceptance by the Fluidigm 
assays are summarised in Table 5.3.  
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Table 5.3: Minimum acceptance criterion for the qPCR assays as defined by the MIQE* guidelines
243
. 
 Definitions/acceptance criterion according to 
MIQE guidelines. 
Correlation coefficients 
Correlation coefficients indicate the width of the 
spreading of individual data around the linear 
regression line. The higher the r
2 
value the more 
robust the assay is.  
Acceptable range: r
2
 ≥ 0.98. 
Efficiency  
The PCR efficiency is dependent on the assay.  
Acceptable range: 90% -110% 
Lower limit of detection 
The limit of detection is the lowest amount of 
DNA in a sample that can be detected with 
reasonable certainty (95% probability) by the 
assay.  
The most sensitive LOD theoretically possible is 
3 copies per PCR. 
Specificity 
Analytical specificity refers to the qPCR assay 
detecting the appropriate target sequence rather 
than other nonspecific targets also present in the 
sample.  
Acceptable assay: An assay that will only 
generate amplification signals for its intended 
target sequences and should not produce an 
amplification signal when the target specific 
assays are applied to individual PCRs of pure 
genomic DNA from other bacterial species.  
Accuracy 
The difference between experimentally measured 
and actual concentrations, presented as fold 
changes or copy number estimates.  
Acceptable range: The accuracy for all respective 
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assays should be within  ±0.1fold change 
Repeatability 
The precision and robustness of the assay with 
the same sample repeatedly analysed in the same 
assay and is expressed as a standard deviation for 
the Ct variance 
Acceptable range: SD<0.167 
Reproducibility 
The variations in the results of the same sample 
run in different runs/assays. 
 Acceptable range: SD<0.167 
*MIQE, Minimum Information for Publication of Quantitative Real-Time PCR experiments.  
 
5.1.5.  Statistical analysis 
Statistical analysis was performed with STATA Version 11.0 (Statacorp, Texas, USA). The 
sensitivities of the standard qPCR assay and the nanofluidic qPCR were determined for all bacterial 
targets and pneumococcal serotypes that were tested by both methods with McNemar’s test using 
qPCR as a reference. For density of carriage, geometric mean densities (GMD) and 95% confidence 
intervals (95% CI) of bacterial mean concentrations were calculated following log10 transformation 
on the data and the densities for bacterial targets and pneumococcal serotypes detected by qPCR and 
Fluidigm were compared with a paired student t-test. Results were considered significant when the p-
value was < 0.05. 
 
5.1.6.  Ethics approval  
Ethical consent for the initial enrolment of the cohort was obtained from the Medical Human 
Research Ethics Committee (HREC) of the University of Witwatersrand [Vaccinated cohort: HREC: 
040704, also registered under Clinical trials number NCT00099658]. Approval for further testing of 
samples was obtained from the HREC (M140907). Written, informed consent had been obtained 
from the parents/guardians of all the study participants at the time of initial enrolment.  
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5.2.  RESULTS  
Nanofluidic qPCR analysis involved 335 (82.3%) of the initial 407 nasopharyngeal swabs collected 
at either 9 or 15-16 months of age (Figure 5.1). 83.4% children in whom samples were available, 
were black-African, and 49.1% were male. Due to similarities in findings at both 9 and 15-16 months 
of age, data was combined for main analysis. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1: Schematic diagram of study population 
Diagram indicating the number of children initially enrolled in the PCV7-vaccinated cohort of HIV-uninfected 
children, as well as the number of nasopharyngeal (NP) swabs available for subsequent traditional molecular 
qPCR analysis and Biomark HD system (Fluidigm). PCV7-vaccinated participants were excluded from analysis 
250 Infants enrolled 
PCV7-vaccination schedule  
1
st
 dose (Administered ± 6 weeks of age): n = 220  
2
nd
 dose (Administered ± 10 weeks of age): n = 245 
3
rd
 dose (Administered ± 14 weeks of age): n = 246 
 
213 infants received all 3 doses of PCV 
Nasopharyngeal (NP) swabs collected (n=407) 
9 months = 207 NPs 
16 months = 200 NPs 
  
No swab = 19  
Missed visit = 3 
Unable/unwilling to adhere = 11  
Withdrew consent = 2  
Lost to follow up = 3 
 
Nasopharyngeal swabs available for traditional molecular qPCR testing (n =339).  
9 months = 175 NP swabs 
16 months = 164 NP swabs 
  
No sample = 68 
EQA = 13  
Inadequate volume = 55  
No sample = 4 
Inadequate volume = 4  
Nasopharyngeal swabs available for Nanofludic qPCR testing (n=335).  
9 months = 171 NP swabs 
16 months = 164 NP swabs 
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if they did not receive all three doses of the pneumococcal conjugate vaccine (PCV) within protocol-defined 
window periods. The number of NP swabs available for molecular testing was defined by weather there was an 
adequate volume of sample remaining. EQA, samples were used for external quality assessment. 
 
 
5.2.1.  Performance of the nanofluidic real-time PCR system 
All assays were effective in amplifying their respective targets with a high sensitivity, 
specificity and linearity in the Biomark HD system, with the efficiency of the assays ranging 
from 89% to 105% (Table 5.3). Within the linear dynamic range, the correlation coefficients 
(r
2
) of the assays were 0.99, except for assays detecting H. influenzae E, IS481 (B. pertussis 
and B. holmesii) and S. pneumoniae serotype 19A, where r
2
 was 0.98. All assays showed high 
analytical sensitivities with their respective primer and probe pairs with the limit of detection 
equivalent 10 copies per PCR for all respective assays, with exception to primers/probes that 
detected H. influenzae serotype E, IS481 (B. pertussis and B. holmesii) and pneumococcal 
serotypes/serogroups 5, 6A/B/C/D, 6C/D, 13 and 21 in which the lower limit of detection was 
10 fold less (100 copies per PCR).  
 
All primer pairs and probes were tested with genomic DNA from all bacterial controls in a 
single PCR run, and no cross reactions occurred (Table 5.4). Both the inter-assay variation 
(repeatability) and inter-assay variation (reproducibility) for all respective assays was <0.1, 
while the accuracy for all respective assays was within ±0.1 (Table 5.4). 
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Table 5.4: Performance of the nanofluidic real-time PCR system 
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Streptococcus pneumoniae  104 0.99 10 0.011 0.028 0.045 
Haemophilus influenzae  96 0.99 10 0.05 -0.062 0.09 
Haemophilus influenzae type A 97 0.99 10 0.031 -0.025 0.038 
Haemophilus influenzae type B 91 0.99 10 0.008 -0.078 0.041 
Haemophilus influenzae type C 104 0.99 10 0.013 0.065 0.032 
Haemophilus influenzae type D 101 0.99 10 0.002 0.083 0.03 
Haemophilus influenzae type E 105 0.98 100 0.014 0.039 0.009 
Haemophilus influenzae type F 93 0.99 10 0.03 0.05 0.068 
Moraxella catarrhalis 97 0.99 10 0.02 -0.057 0.015 
Staphylococcus aureus 96 0.99 10 0.007 0.004 0.049 
Neisseria lactamica 100 0.99 10 0.063 0.023 0.026 
Neisseria meningitidis 91 0.99 10 0.029 -0.049 0.13 
ptxs1 99 0.99 10 0.025 -0.081 0.018 
HIS1001 104 0.99 10 0.045 -0.071 0.131 
PIS1001 91 0.99 10 0.009 0.068 0.021 
IS481 99 0.98 100 0.042 0.013 0.12 
Streptococcus pyogenes 105 0.99 10 0.018 -0.069 0.09 
Streptococcus pneumoniae serotype 1 93 0.99 10 0.011 0.034 0.013 
Streptococcus pneumoniae serotype 3 93 0.99 10 0.002 -0.049 0.05 
Streptococcus pneumoniae serotype 4 96 0.99 10 0.002 0.06 0.023 
Streptococcus pneumoniae serotype 5 105 0.99 100 0.012 0.055 0.041 
Streptococcus pneumoniae serogroup 6A/B/C/D 94 0.99 100 0.011 -0.059 0.029 
Streptococcus pneumoniae serogroup 6C/D 91 0.99 100 0.013 -0.026 0.047 
Streptococcus pneumoniae serogroup 7A/F 98 0.99 10 0.008 -0.054 0.034 
Streptococcus pneumoniae serotype 7C 90 0.99 10 0.027 -0.068 0.015 
Streptococcus pneumoniae serotype 8 101 0.99 10 0.002 0.104 0.019 
Streptococcus pneumoniae serogroup 9A/L/N/V 96 0.99 10 0.006 -0.059 0.016 
Streptococcus pneumoniae serotype 10A 90 0.99 10 0.083 -0.001 0.005 
Streptococcus pneumoniae serogroup 11A/B/C/D/F 93 0.99 10 0.027 0.011 0.021 
Streptococcus pneumoniae serogroup 12A/B/F 89 0.99 10 0.003 0.045 0.029 
Streptococcus pneumoniae serotype 13 96 0.99 100 0.011 -0.067 0.039 
Streptococcus pneumoniae serotype 14 91 0.99 10 0.009 -0.027 0.027 
Streptococcus pneumoniae serogroup 15A/B/C/F 102 0.99 10 0.078 -0.052 0.083 
Streptococcus pneumoniae serogroup 16F 105 0.99 10 0.011 -0.033 0.025 
Streptococcus pneumoniae serotype 17F 92 0.99 10 0.01 -0.041 0.01 
Streptococcus pneumoniae serogroup 18A/B/C 99 0.99 10 0.014 -0.016 0.09 
Streptococcus pneumoniae serotype 19A 90 0.98 10 0.018 0.077 0.025 
Streptococcus pneumoniae serogroup 19B/F 98 0.99 10 0.004 0.009 0.021 
Streptococcus pneumoniae serotype 20 103 0.99 10 0.014 0.069 0.003 
Streptococcus pneumoniae serotype 21 96 0.99 100 0.111 0.083 0.122 
Streptococcus pneumoniae serotype 22AF 99 0.99 10 0.019 -0.067 0.046 
Streptococcus pneumoniae serogroup 23A/B/F 103 0.99 10 0.074 -0.081 0.022 
Streptococcus pneumoniae serotype 23F 97 0.99 10 0.006 0.02 0.038 
Streptococcus pneumoniae serogroup 25A/25F/38 101 0.99 10 0.015 0.012 0.087 
Streptococcus pneumoniae serogroup 34/37/17A 101 0.99 10 0.001 -0.079 0.008 
Streptococcus pneumoniae serotype 35B 100 0.99 10 0.013 0.005 0.029 
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Table 5.5: Analytical specificity of the nanofluidic real-time PCR system 
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5.2.2.  Detection of bacterial nasopharyngeal carriage by conventional real-time PCR 
and nanofluidic real-time PCR (Fluidigm) 
There was excellent concordance between conventional qPCR and Fluidigm for the detection 
of S. pneumoniae (Kappa = 0.98), H. influenzae (kappa = 0.97), M. catarrhalis (Kappa = 
0.98), S. aureus (kappa = 0.98) and S. pyogenes (kappa = 0.96) and a high concordance 
between conventional qPCR and Fluidigm for the detection of N. meningitidis (Kappa=0.75; 
Figure 5.2, Table 5.5). Discordant results between the methods were strongly associated with 
density of carriage, with all additional bacteria detected either by qPCR or Fluidigm having an 
estimated copy numbers of <10
2 
colony forming units (CFU)/ml per swab (Figure 5.3). The 
sensitivity and specificity of the Fluidigm method compared to conventional qPCR were high 
with all assays having a sensitivity >92% and a specificity of >99% (Table 5.5).  
 
Figure 5.2: Prevalence of nasopharyngeal (NP) bacterial colonisation in PCV7-vaccinated, 
HIV-uninfected children as measured by traditional molecular real-time PCR (qPCR) and the 
Biomark HD System (Fluidigm) 
p-values of <0.05 was considered significant as determined by McNemar’s test. 
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Table 5.6: Concordance between traditional real-time PCR (qPCR) and the Biomark HD 
System (Fluidigm) for the detection of common of nasopharyngeal pathogens in PCV7-
vaccinated, HIV-uninfected children 
B
a
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 (
%
) 
S. pneumoniae  244(72.8) 246(73.4) 0.16 0.98 98.8 100 
H. influenzae  230(68.7) 232(69.3) 0.32 0.97 98.7 99 
M. catarrhalis 189(56.4) 192(57.3) 0.08 0.98 98.4 100 
S. aureus  57(17) 55(16.4) 0.16 0.98 100 99.3 
S. pyogenes 11(3.3) 12(3.6) 0.32 0.96 91.7 100 
N. meningitidis  3(0.9) 5(1.5) 0.16 0.75 91.7 100 
* Values are number (%). 
 
Figure 5.3: Density of colonisation by common nasopharyngeal bacterial pathogens as 
determined by traditional real-time PCR (qPCR) and the Biomark HD System (Fluidigm)  
 
B. bronchiseptica, B. parapertusis, B. pertussis, B. holmesii and N. lactamica were not tested 
by conventional qPCR and thus could not be compared to Nanofluidic real-time PCR; 
however, the overall detection prevalence by Fluidigm was 0.3%, 0%, 0%, 0%, and 4.2 % 
respectively. Further, H. influenzae was not serotyped by conventional qPCR and thus could 
not be compared to Fluidigm; however, of the H. influenzae positive samples, 3.9% were 
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serotype A, 1.3% were serotype B, 2.6% were serotype C, 1.3% were serotype D, 1.7% were 
serotype E, 4.3% were serotype F and 83.6% were non-typable.  
 
5.2.3.  Detection of pneumococcal serotype carriage by conventional real-time PCR and 
nanofluidic real-time PCR (Fluidigm) 
There was excellent concordance between conventional qPCR and Fluidigm for all the assays 
detecting S. pneumoniae serotypes/serogroups (kappa >0.8), with exception of primers/probes 
detecting serotypes/serogroups 1, although concordance was still high (kappa =0.75); Figure 
5.4, Table 5.7. The Fludigm method, however, detected an additional 7 serotypes above those 
identified by qPCR while the qPCR method detected an additional 2 serotypes above those 
detected by Fluidigm.  
 
 
Figure 5.4: Prevalence of pneumococcal serotype colonisation in PCV7-vaccinated, HIV-
uninfected children as measured by traditional molecular real-time PCR (qPCR) and the 
Biomark HD System (Fluidigm) 
 p-values of <0.05 was considered significant. 
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Table 5.7: Concordance between traditional real-time PCR (qPCR) and the Biomark HD 
System (Fluidigm) for the detection of pneumococcal serotypes in PCV-vaccinated, HIV-
uninfected children 
S
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%
) 
LytA 244(72.8) 247(73.7) 0.08 0.98 98.8 100 
1 3(0.9) 5(1.5) 0.16 0.75 60 100 
3 1(0.3) 1(0.3) - 1 100 100 
4 3(0.9) 4(1.2) 0.32 0.86 75 100 
5 13(3.9) 13(3.9) - 1 100 100 
6A/B 31 (9.3) 31 (9.3) - 1 100 100 
6C/D 2(0.6) 2(0.6) - 1 100 100 
7C 8(2.4) 6(1.8) 0.16 0.85 100 99.3 
9A/L/N/V 8(2.4) 8(2.4) - 1 100 100 
10A 5(1.5) 6 (1.8) 0.32 0.91 83.3 100 
11A/B/C/D/F 9(2.7) 9(2.7) - 1 100 100 
12A/B/F 5(1.5) 5(1.5) - 1 100 100 
13 6(1.8) 6(1.8) - 1 100 100 
14 7(2.1) 7(2.1) - 1 100 100 
15A/B/C/F 14(4.2) 14(4.2) - 1 100 100 
16F 9(2.7) 9(2.7) - 1 100 100 
17F 6(1.8) 6(1.8) - 1 100 100 
18A/B/C 6(1.8) 7(2.1) 0.32 0.93 85.7 100 
19A 36(10.7) 36(10.7) - 1 100 100 
19B/F 48(14.3) 50(14.9) 0.08 0.96 94 100 
20 1(0.3) 1(0.3) - 1 100 100 
21 5(1.5) 5(1.5) - 1 100 100 
23A/B 8(2.4) 8(2.4) - 1 100 100 
23F 15(4.5) 15(4.5) - 1 100 100 
34/37/17F 13(3.9) 13(3.9) - 1 100 100 
* Numbers are value (%) 
 
Discordant results between the methods were strongly associated with density of carriage, 
with all additional serotypes/groups detected either by qPCR or Fluidigm having estimated 
copy numbers of <10
2 
colony forming units (CFU)/ml per swab (Figure 5.5). The sensitivity 
and specificity of the Fluidigm method compared to conventional qPCR were high with the 
majority of the assays having a sensitivity > 80%, with exception of serotypes 1 and 3 which 
had sensitivities of 60% and 75% respectively. All Fluidigm assays, however, had a high 
specificity (≥99.3%), Table 5.6.  
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Figure 5.5: Density of colonisation of pneumococcal serotypes as determined by traditional 
real-time PCR (qPCR) and the Biomark HD System (Fluidigm) 
 
Serotypes/serogroups 7A/F, 8, 22A/F, 25A/25F/38 and 35B were not tested by conventional 
qPCR and thus could not be compared to nanofluidic real-time PCR; however, the overall 
detection prevalence by Fluidigm was 0.3%, 0.9%, 0.6%, 2.7% and 0.3% respectively for 
these serotypes  
 
5.2.4.  Density of bacterial nasopharyngeal carriage as determined by conventional 
qPCR and Fluidigm 
There was excellent correlation between the two methods (Rho >0.95) for measuring the 
density of carriage with no significant differences found for all bacterial pathogens and 
pneumococcal serotypes measured by conventional qPCR and Fluidigm (Table 5.8).  
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Table 5.8: Density of bacterial nasopharyngeal carriage as determined by conventional 
molecular real-time Polymerase chain reaction and the Biomark HD System (Fluidigm) 
 
Numbers are geometric mean densities (95% Confidence intervals). ND, not done as too few observations to  
measure 95% confidence intervals. p-values of <0.05 were considered significant as determined by a paired 
student t-test.  
 
 
 
 
 
 
Bacteria  Density detected by qPCR 
Density detected by 
Fluidigm  p-value  
S. pneumoniae  4.54(4.37-4.70) 4.39(4.24-4.54) 0.49 
H. influenzae 4.38(4.21-4.55) 4.56(4.39-4.73) 0.18 
M. catarrhalis 3.38(3.23-3.52) 3.29(3.15-3.44) 0.37 
S. aureus  3.48(3.17-3.79) 3.41(3.08-3.75) 0.13 
S. pyogenes 3.09(2.14-4.03) 3.68(3.04-4.32) 0.11 
N. meningitidis  3.24(-0.13-6.61) 2.96(0.20-5.73) 0.18 
    Pneumococcal serotypes/serogroups 
1 2.90(-0.92-6.71) 3.76(0.46-7.07) 0.22 
3 ND ND - 
4 2.85(-0.27-5.97) 2.30(-1.20-7.20) 0.79 
5 2.52(2.01-3.02) 2.46(2.0-2.91) 0.09 
6AB 4.25(3.88-4.61) 4.07(3.77-4.36) 0.06 
6CD 4.05(-1131-19.42) 3.60(-5.11-12.30) 0.54 
7C 3.49(1.73-5.25) 3.27(1.89-4.67) 0.33 
9ALVN 3.31(2.52-4.10) 3.23(2.52-3.95) 0.16 
10A 3.23(2.47-3.98) 3.62(2.64-4.1) 0.17 
11ABCDF 3.29(2.03-4.56) 3.21(2.16-4.27) 0.51 
12ABF 3.38(1.39-5.38) 3.58(1.76-5.40) 0.19 
13 3.96(2.85-5.06) 4.03(3.13-4.94) 0.82 
14 3.40(2.06-4.74) 2.93(2.37-3.48) 0.29 
15ACF 3.81(2.93-4.68) 3.54(3.01-4.07) 0.08 
16F 4.50(3.43-5.56) 4.23(3.01-5.44) 0.14 
17F 2.54(1.55-3.53) 2.55(1.67-3.44) 0.88 
18ABC 3.84(2.39-5.28) 3.84(2.96-4.73) 0.98 
19A 3.82(3.48-4.17) 3.75(3.4-4.10) 0.26 
19BF 3.87(3.49-4.24) 4.14(3.78-4.51) 0.66 
20 ND ND - 
21 3.38(2.23-4.53) 3.13(2.58-3.68) 0.55 
23AB 2.92(-0.76-4.92) 2.58(0.31-4.86) 0.16 
23F 3.64(3.12-4.16) 3.98(3.44-4.51) 0.18 
34/37/17A 3.90(3.08-4.72) 3.41(2.88-3.94) 0.06 
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5.3.  DISCUSSION 
 
A reliable nanofluidic real-time PCR system that was able to simultaneously detect 11 
bacterial pathogens, 53 pneumococcal serotypes (16 individual serotypes and 37 serotypes in 
13 groups) and 6 serotypes of H. influenzae (serotypes a-f) in 96 different samples (92 
samples and 4 controls) in a single PCR run was successfully established according to MIQE 
guidelines
243
. Further, findings from traditional quantitative PCR and Fluidigm in a PCV7-
vaccinated cohort of black-African children were compared and excellent concordance 
between the methods was found for both the carriage prevalence and density for bacterial 
species and pneumococcal serotypes.  
 
There was however some discordance between the methods with the qPCR method detecting 
an additional 3 bacterial species and 2 pneumococcal serotypes above those detected by 
Fluidigm, and the Fluidigm method detecting an additional 11 bacterial species and 7 
pneumococcal serotypes above those detected by qPCR. Nevertheless, these small differences 
(<5%) in the detection by the methods are expected as according to Poisson’s distribution the 
assays had a 95% probability of detecting their respective targets with reasonable certainty 
243
, 
which was further supported by the discordance between the methods being associated with a 
lower carriage density (<10
2
CFU/ml). Further, the Fluidigm method involved a pre-
amplification step which pre-selected for its’ respective targets and may explain why the 
method was able to detect additional bacteria and pneumococcal serotypes/serogroups of a 
lower carriage density above those detected by the qPCR method.  
 
While culture remains the gold standard for bacterial carriage and pneumococcal serotype 
characterisation, these assays lack quantitative data which limits our understanding of 
nasopharyngeal carriage and its relation to disease severity 
18,23-26
. Recently several molecular 
methods have been developed to overcome the shortcomings of these traditional culture 
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assays; however, they are still limited in that a large sample volume is required to distribute 
across all reactions, it is expensive and processing multiple qPCR reactions is labour intensive 
and time consuming (Chapter 2). Further, there are a limited number of quantitative studies 
that have described colonisation of a diverse number of bacterial pathogens and 
pneumococcal serotypes together. The Fluidigm assay was, however, able to overcome some 
of the shortcomings of traditional qPCR assays as it allows for a larger number of reactions 
per plate, thus making it more cost effective and less time consuming.  
 
The Biomark HD system is a new instrument that has only been used to serotype 
pneumococcus by one other group; however, their assay differed in that they used Evagreen (a 
dsDNA-binding dye) chemistry instead of TaqMan probes to quantify bacterial carriage, it 
was only able to detect 50 pneumococcal serotypes (17 individual serotypes and 33 serotypes 
in 12 groups) and did not include any additional bacterial pathogens 
43,205
. However, in terms 
of performance the assays were comparable. 
 
The study was limited in that the PCR method was not able to discriminate between all the 
serotypes within their respective serogroups. Further, as an initial step for gene expression on 
the Biomark HD Fluidigm system, manufacturers recommend STA for each sample to be 
done by combining all primers in a pool. However, due to the high similarity between some 
pneumococcal primers, non-specific binding of some primers to each other resulted which 
was prevented by separating primers into two separate pools and then combining the STA 
products from the two assays. Careful monitoring and optimisation is thus needed in future 
studies especially if more pneumococcal targets are to be added. Lastly when the sensitivity of 
some of the assays was lower in generally involved serotypes/groups with a lower prevalence 
of colonisation and thus our study was limited in power to have certainty. As this was a 
retrospective study, there was no residual sample after testing available to retest the samples 
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and to confirm the discordant results between the methods which would have been beneficial 
in providing clarity.  
 
In conclusion we developed a highly sensitive and specific assay that could simultaneously 
detect common pneumococcal serotypes, H. influenzae serotypes and other common 
nasopharyngeal bacterial pathogens and provide quantitative data in a single PCR run. 
Improved methods of detection of respiratory pathogens can provide a means to improve the 
health care of patients as optimal therapy can be initiated sooner, effectiveness of the 
treatment is improved and spread of disease can be reduced or even prevented 
206
. Further, a 
high bacterial load detected by real-time PCR in nasopharyngeal specimens might help 
predict the aetiological role for S. pneumoniae and other bacterial pathogens in bacterial 
disease 
207
.  
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CHAPTER 6: EVALUATION OF THE ASSOCIATION OF HIV-1 
INFECTION AND DENSITY OF COMMON NASOPHARYNGEAL 
BACTERIAL COLONISERS USING THE BIOMARK HD 
NANOFLUDIC SYSTEM IN PCV7-IMMUNISED CHILDREN 
LIVING IN SOUTH AFRICA 
Approximately 5% of children <5 years of age in South Africa are HIV-infected, with S. 
pneumoniae being the most important cause of invasive bacterial disease and the burden of 
disease being 40-fold greater in HIV-infected compared to HIV-uninfected children, even in 
the era of PCV 
244
. A limited number of comparative studies have investigated the association 
between HIV-infection and pneumococcal colonisation, with conflicting results on whether 
HIV-infection is associated with differences in prevalence of pneumococcal nasopharyngeal 
colonisation compared to HIV-uninfected children 
186
. While some studies have reported no 
difference in the carriage prevalence between HIV-infected and HIV-uninfected children, 
others from South Africa and The Gambia reported a higher prevalence of pneumococcal 
colonisation in HIV-infected children 
77,187
. Further, the effect that HIV-infection has on the 
prevalence of nasopharyngeal colonisation by other bacteria such as H. influenzae and S. 
aureus is also unclear. Whereas Madhi et al reported no difference in the carriage prevalence 
of S. aureus between HIV-infected and HIV-uninfected children in South Africa 
77
, others 
have reported higher prevalence of colonisation from South Africa and Tanzania in HIV-
infected children 
191,193,196
. Also, some studies have reported HIV-infected children to have a 
higher prevalence of H. influenzae colonisation 
77
, while others have reported a lower carriage 
prevalence of H. influenzae 
196,198
 or no difference between HIV-infected and -uninfected 
children 
191
.  
 
These studies were, however, limited in having only used routine culture as recommended by 
WHO, 
36
 which might be less sensitive than molecular detection methods and also does not 
provide insight into the density of colonisation. Also, the majority of these studies involved a 
population that were not immunised for PCV; and thus further investigation with more 
sensitive molecular methods on the association between HIV-infection and pneumococcal 
carriage prevalence and density in a PCV immunised cohort is needed. 
 
In this chapter, we applied a Nanofludic real-time PCR assay to evaluate the effect of HIV-
infection and HIV-exposure on prevalence and density of nasopharyngeal colonisation at 9 
and 16 months of age by common, potentially pathogenic bacteria including PCV7 
pneumococcal serotypes, non-PCV7 serotypes, Haemophilus influenzae, non-typable 
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Haemophilus influenzae, Staphylococcus aureus, Moraxella catarrhalis, Streptococcus 
pyogenes, Neisseria meningitidis, Neisseria lactamica, Bordetella pertussis, Bordetella 
parapertusis, Bordetella bronchiseptica and Bordetella holmesii.  
 
 
6.1. MATERIAL AND METHODS 
6.1.1.  Study population 
Archived nasopharyngeal swabs collected from a PCV7-vaccinated cohort of HIV-infected 
and HIV-uninfected infants in South Africa were retrospectively analysed. Detailed 
information of the cohort has been described 
142,185
. Briefly, participants included HIV-
infected infants with a CD4
+
 T-lymphocytes cells ≥25% randomised to initiate ART 
immediately (ART-Immed); or when clinically and or immunologically indicated as per then 
WHO recommendations for ART initiation in children (ART-Def), HIV-exposed-uninfected 
(HEU) and HIV-unexposed-uninfected (HUU) infants who were 6 – 12 weeks old when 
enrolled between April 2005 and June 2006. Infants were scheduled to receive three doses of 
PCV7 (i.e. Prevnar®; Wyeth Vaccines, NJ, USA) at 6, 10 and 14 weeks of age, as well as 
other recommended childhood vaccines in South Africa, including H. influenzae type-b 
conjugate vaccine (HibCV)
185,245
. During the course of the study, PCV immunisation of 
children in Soweto (birth cohort 28,000 per annum) was limited mainly to study-participants 
(approximately 600), as the vaccine was only introduced into the pubic immunisation 
program in May 2009 
218
.  
 
Nasopharyngeal (NP) swabs were taken at several time intervals, including at 9 and 15-16 
months of age. Swabs were stored in skim milk-tryptone-glucose-glycerol (STGG) transport 
media at the Respiratory and Meningeal Pathogen Research Unit (RMPRU) in South Africa, 
as recommended by WHO 
212
.  
 
6.1.2.  Real-time qPCR using the Biomark HD System (Fluidigm) 
Stored nasopharyngeal swab samples were thawed and processed. Briefly, NP swabs were 
vortexed for 30 seconds to release bacteria into the transport media and total nucleic acids 
were automatically extracted from STGG with the NucliSens ® easyMAG ® extraction 
system (BioMérieux, Marcy l’Etoile, France) according to manufacturer’s instructions. 
Samples were stored at – 20 °C. DNA extracts were quantified for 11 bacterial pathogens, 53 
pneumococcal serotypes (16 individual serotypes and 37 serotypes in 13 groups) and 6 
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serotypes of H. influenzae (serotypes a-f) with the Nanofludic real-time qPCR system as 
described in Chapter 5. Briefly, Specific target amplification (STA) was done per 
manufactures recommendations as the initial step (pre-amplification of DNA) for the Biomark 
HD system (Fluidigm). The qPCR assays were then carried out on the STA products with 
96.96 dynamic arrays (Fluidigm Corporation, CA, USA) according to manufactures 
instructions and bacterial loads were quantified using standard curves. Data was analysed with 
Real-Time PCR Analysis Software in the BIOMARK instrument (Fluidigm Corporation, 
USA). 
 
6.1.3.  Statistical analysis 
Statistical analysis was performed with STATA Version 11.0 (Statacorp, Texas, USA). 
Pearson X
2
 test or student t-test was used to compare baseline characteristics between the 
cohorts. Comparisons and adjusted odd ratios of prevalence of pneumococcal and bacterial 
colonisation between cohorts were analysed using logistic regression models adjusted for 
covariates, including race, gender, study centre, birth weight, co-trimoxazole prophylaxis 
administered and breastfeeding. Since we did not identify any difference in the prevalence 
and density of colonisation for all bacteria between the ART-immed and ART-Def groups, as 
well as between the HIV-exposed uninfected and HIV-unexposed uninfected groups in our 
analysis, we subsequently analysed these children as a composite group of HIV-infected and 
HIV-uninfected children respectively (Appendices D & E). The associations of 
nasopharyngeal bacterial colonisation between groups were determined by multivariate 
logistic regression models controlling for the above mentioned cofounders. For density of 
carriage, geometric mean densities (GMD) and 95% CI intervals (95%) of pneumococcal and 
bacterial mean concentrations were calculated following log10 transformation on the data, 
using analysis of covariance to adjust for possible covariates. Spearman correlations were 
used to compare the degree of correlation between densities of each pair of bacteria. Results 
were considered significant when the p-value was <0.05.  
 
6.1.4.  Ethics approval  
As described in chapter 5, section 5.16.  
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6.2.  RESULTS  
Nanofluidic qPCR analysis was undertaken on 763 (85.1%) of the initial 897 nasopharyngeal 
swabs collected at either 9 or 15-16 months of age (Figure 6.1). Within each cohort, there 
were no differences in the colonisation patterns done by standard methodology, between those 
in whom samples were available and not available (Appendices B and C). Ninety percent of 
the children for whom samples were available, were black-African, and 45.8% were male 
(Table 6.1). The mean age in weeks at time of sample collection did not differ between 
groups, being 39.6 (standard deviation; SD 1.5) and 39.3 (SD 3.2) weeks at 9 months of age 
(p=0.13) and 67.9 (SD 1.9) and 67.7 (1.6) weeks at 15-16 months of age (p=0.15) in HIV-
infected and HIV-uninfected children, respectively. The mean birth weight was lower in HIV-
infected (2967grams) than their HIV-uninfected counterparts (3092 grams; p=0.02) at 9 
months and at 15-16 months of age (2958 vs. 3126 grams; p=0.001). Co-trimoxazole 
prophylaxis was more frequently administered in HIV-infected children at both 9 months 
(99% vs. 46.2%; p<0.001) and 15-16 months (98.6% vs. 41.4%; p<0.001) of age. 
Furthermore, breastfeeding was higher in HIV-uninfected children than HIV-infected children 
at 9 months (25.4% vs. 1.4%; p<0.001) and 15-16 months of age (23.2% vs. 1.4%%; 
p<0.001).  
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Figure 6.1: Schematic diagram of study population 
Diagram indicating the number of children initially enrolled in a PCV7-vaccinated cohort of HIV-uninfected and 
HIV-infected children, as well as the number of nasopharyngeal (NP) swabs available for subsequent nanofluidic 
real-time PCR analysis. Participants were excluded from analysis if they did not receive all three doses of the 
pneumococcal conjugate vaccine (PCV) within protocol-defined window periods. The number of NP swabs 
available for molecular testing was defined by whether there was an adequate volume of sample remaining. 
HUU, HIV-unexposed uninfected. HEU, HIV-exposed uninfected. EQA, samples were used for external quality 
assessment.
565 Infants enrolled 
490 infants received all 3 doses of PCV7 
HIV uninfected = 213 infants 
HIV infected= 277 children  
 
315 HIV-infected  
PCV7-vaccination schedule  
1
st
 dose (Administered ± 6 weeks of age): n = 220  
2
nd
 dose (Administered ± 10 weeks of age): n = 245 
3
rd
 dose (Administered ± 14 weeks of age): n = 246 
 
250 HIV-uninfected 
Nasopharyngeal (NP) swabs collected 
9 months = 207 NPs 
16 months = 200 NPs 
  
Nasopharyngeal (NP) swabs collected 
9 months = 255NPs 
16 months =235 NPs 
  
897 NP swabs collected  
Nasopharyngeal swabs available for 
subsequent molecular testing.  
9 months = 173 NP swabs 
16 months = 164 NP swabs 
  
Nasopharyngeal swabs available for 
subsequent molecular testing.  
9 months = 208 NP swabs 
16 months = 218 NP swabs 
  
763 NP swabs available for qPCR analysis  
No sample = 64 
Inadequate volume = 64  
No swab = 19  
Missed visit = 3 
Unable/unwilling to adhere = 11  
Withdrew consent = 2  
Lost to follow up = 3 
 
No sample = 70 
EQA = 13  
Inadequate volume = 57  
PCV7-vaccination schedule  
1
st
 dose (Administered ± 6 weeks of age): n = 308 
2
nd
 dose (Administered ± 10 weeks of age): n = 301 
3
rd
 dose (Administered ± 14 weeks of age): n = 290 
 
No swab = 64  
Missed visit =16 
Unable/unwilling to adhere = 4  
Withdrew consent = 2  
Death = 42 
 
125 HEU 125 HUU 210 ART-immed 105 ART-delayed 
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Table 6.1: Demographic features at two study visits when analysed for nasopharyngeal (NP) 
bacterial colonisation in HIV-infected and HIV-uninfected, PCV7-vaccinated children 
  9 month old children  16 month old children  
  
H
IV
-i
n
fe
ct
ed
 
H
IV
-u
n
in
fe
ct
ed
 
p
-v
al
u
e 
H
IV
-i
n
fe
ct
ed
 
H
IV
-u
n
in
fe
ct
ed
 
p
-v
al
u
e 
Available samples for molecular analysis  208 173 
 
218 164 
 Mean birth weight (SD) grams  2967(489) 3092(448) 0.02 2958(451) 3126(476) 0.001 
Male sex (%) 80(45.5) 96 (55.5) 0.001 85(39) 89(54.3) 0.003 
Race: Black African (%) 199 (95.7) 148(85.5) 
0.001 
211(96.8) 132(80.5) 
<0.001 
         : Mixed ancestry (%) 9(4.3) 25(14.5) 7(3.2) 32(19.5) 
Smoking household contact (%) 90(43.3) 79(45.7) 0.49 92(44.4) 64(39) 0.57 
Co-trimoxazole prophylaxis (%) 206(99) 80(46.2) <0.001 215(98.6) 68(41.4) <0.001 
Mean number of household contacts (SD)  5.1(2.4) 5.3(2.3) 0.53 5.0(1.9) 5.1(2.4) 0.67 
Breast feeding (%) 3(1.4) 44(25.4) <0.001 3(1.4) 38(23.2) <0.001 
Mean age (SD) in weeks at visit 39.6(1.5) 39.3(3.2) 0.23 67.9(1.9) 67.7(1.6) 0.25 
Pearson X
2
 test or student t-test was used to compare baseline characteristics between the cohorts and 
demographic features with a p-value <0.2 were included as possible cofounders in multivariate analysis.  
 
 
 
6.2.1.  Prevalence of bacterial colonisation with respect to HIV-status 
 
6.2.1.1. Streptococcus pneumoniae colonisation 
In the multivariate adjusted analysis, prevalence of overall pneumococcal colonisation was 
lower in the composite groups of HIV-infected (58.6%) than HIV-uninfected children (69.9%, 
p=0.02; Table 6.2) at 9 months of age, largely due to the lower prevalence of non-vaccine-
serotype colonisation (27.8% vs. 40%, respectively; p=0.047), whilst there was no difference 
in prevalence of vaccine-serotype colonisation (37.5% vs. 36%; p=0.48). The serotype-
specific analysis was limited by the low number of serotypes identified in each group; 
however, the prevalence of non-vaccine serogroup 15A/B/C/F was 3.3 (8.2% vs. 3.5%; 
p=0.029) fold higher in HIV-infected than HIV-uninfected children at 9 months of age 
(Figure 6.2). By 16 months of age, there was no difference in the overall pneumococcal 
colonisation between the composite groups of HIV-infected and HIV-uninfected children 
(p=0.26), although the prevalence of non-vaccine serotype colonisation remained 1.7 fold 
higher in HIV-uninfected (60.4%) than HIV-infected children (50.9%, p=0.049; Table 6.2). 
Other differences included that the prevalence of vaccine serogroup 6A/B was 3.7 fold higher 
in HIV-uninfected (7.9%) than HIV–infected children (2.3%; p=0.03; Figure 6.3).  
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6.2.1.2.  H. influenzae  
Prevalence of overall H. influenzae colonisation was lower in the composite groups of HIV-
infected (42.3%) than HIV-uninfected children at 9 months of age (64.2%, p=0.003; Table 
6.2), which was largely due to the lower prevalence of non-typable H. influenzae colonisation 
(37.5% vs. 54.8%, p=0.006). Similarly, the prevalence of overall H. influenzae colonisation 
was also lower in the composite groups of HIV-infected (56%) than HIV-uninfected children 
at 16 months of age (73.4%, p=0.018), which was also largely due to lower prevalence of 
non-typable H. influenzae colonisation (50% vs. 59.2%, p=0.04). 
 
6.2.1.3.  Other bacterial nasopharyngeal colonisers  
No difference in the carriage prevalence of S. aureus, S. pyogenes, N. meningitidis, N. 
lactamica, B. pertussis, B. parapertusis, B. holmesii and B. bronchiseptica were found 
between HIV-infected and HIV-uninfected groups at 9 and 16 months of age respectively 
(Table 6.2); however, the carriage prevalence of M. catarrhalis was lower in the in HIV-
infected (43.3% than -uninfected children (57.8%, p=0.03) at 9 months of age only.  
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Table 6.2: Prevalence of nasopharyngeal (NP) colonisers in HIV-infected and HIV-uninfected, PCV7- vaccinated children 
  9 month old children  16 month old children  
 
HIV-
infected 
HIV-
uninfected OR (95% CI); p-value aOR (95% CI); p-value 
HIV-
infected 
HIV-
uninfected OR (95% CI); p-value aOR (95% CI); p-value 
n = 208 n = 173 n = 218 n= 164 
S. pneumoniae  122(58.6) 121(69.9) 0.61(0.40-0.93); p=0.02 0.58(0.35-0.96); p=0.04 149(68.4) 125(76.2) 0.67(0.43-1.07); p=0.09 0.74(0.45-1.24); p=0.26 
VT 78(37.5) 63(36) 1.20(0.75-1.91): p=0.47 1.24(0.71-2.18); p=0.48 74(33.9) 55(33.5) 1.27(0.80-2.03); p=0.31 0.85(0.50-1.44); p=0.55 
NVT  58(27.8) 70(40) 0.57(0.36-0.89); p=0.01 0.59(0.35-1.01);p=0.047 111(50.9) 105(64) 0.59(0.38-.90); p=0.015 0.65(0.41-1.04); p=0.049 
H. influenzae  88(42.3) 111(64.2) 0.44(0.29-0.67); p<0.001 0.48(0.29-0.79); p=0.003 122(56) 121(73.4) 0.45(0.29-0.70); p<0.001 0.50(0.31-0.81); p=0.005 
Hinf A 0 1(0.6) - - 4(1.8) 8(4.9) 0.36(0.11-1.23); p=0.1 0.45(0.12-1.73); p=0.25 
Hinf B 3(3.4) 2(1.2) 1.25(0.21-7.57):p=0.81 1.56(0.15-15.8); p=0.7 1(0.5) 1(0.6) 0.75(0.05-12.1); p=0.84 0.49(0.23-8.98); p=0.63 
Hinf C 1(1) 0 - - 0 6(3.7) - - 
Hinf D 2(2.3) 1(0.9) 1.67(0.15-18.57):p=0.68 2.57(0.22-30.67); p=0.46 2(0.9) 2(1.2) 0.75(0.10-5.38); p=0.78 0.49(0.06-3.98); p=0.51 
Hinf E 1(1.1) 2(1.2) 0.41(0.04-4.59):p=0.47 0.33(0.02-5.97); p=0.45 1(0.5) 2(1.2) 0.37(0.03-4.15); p-0.42 0.26(0.02-2.99); p=0.28 
Hinf F 4(4.8) 4(2.3) 0.82(0.20-3.36):p=0.79 3.41(0.43-26.78); p=0.24 5(2.3) 6(3.7) 0.62(0.19-2.06); p=0.43 0.46(0.11-1.61); p=0.21 
NTHinf 78(37.5) 97(54.8) 0.47(0.31-0.71):P<0.001 0.54(0.32-0.93); p=0.03 109(50) 97(59.2) 0.69(0.46-1.04); p=0.07 0.56(0.53-1.37); p=0.04 
M. catarrhalis  90(43.3) 100(57.8) 0.55(0.37-0.84): p=0.005 0.55(0.32-0.94); p=0.03 125(57.3) 92(56.1) 1.05(0.70-1.58); p=0.81 1.04(0.66-1.64); p=0.86 
S. aureus  34(16.3)  30(17.2) 0.99(0.53-1.88); p=0.99 0.77(0.36-1.67); p=0.51 31(14.2) 25(15.2) 1.07(0.59-1.93); p=0.82 0.99(0.52-1.94); p=0.99 
S. pyogenes 1(0.5) 5(2.9) 0.16(0.02-1.40); p=0.1 0.31(0.02-4.71); p=0.4 2(0.9) 7(4.3) 0.21(0.04-1.01); p=0.05 0.20(0.03-1.20); p=0.08 
N. meningitidis 3(1.44) 2(1.2) 1.25(0.27-7.58); p=0.81 1.54(0.15-15.7); p=0.72 1(0.5) 3(1.8) 0.24(0.03-2.34); p=0.23 0.23(0.02-2.52); p=0.23 
N. lactamica 7(3.4) 5(2.9) 1.17(0.36-3.75); p=0.79 1.35(0.30-6.02); p=0.7 11(5.1) 9(5.5) 0.92(0.37-2.26); p=0.85 0.54(0.20-1.46); p=0.23 
B. pertussis  0 0 - - 0 0 - - 
B. parapertusis  1(0.5) 0 - - 0 0 - - 
B. Holmesii 0 0 - - 0 0 - - 
B. bronchiseptica  0 1(0.6) - - 0 0 - - 
 
Adjusted odd ratios (aOR) for bacterial colonisation were determined by multivariate logistic regression, controlling for race, gender, study centre, birth weight, co-
trimoxazole prophylaxis administered and breastfeeding. 95% CI, 95% confidence levels. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 23F). 
NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7A/F, 7C, 8, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 22A/F, 23A/B, 25A/25F/38, 
34/37/17A and 35B). -, too few observations to calculate p-value. A p-value of <0.05 was considered significant. 
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Figure 6.2: Prevalence of nasopharyngeal (NP) pneumococcal colonisation among the HIV-
infected and HIV-uninfected children at 9 months 
 
 
 
 
Figure 6.3: Prevalence of nasopharyngeal (NP) pneumococcal colonisation among the HIV-
infected and HIV-uninfected children at 16 months 
p-values were determined by multivariate logistic regression, controlling for race, gender, study centre, birth 
weight, co-trimoxazole prophylaxis administered and breastfeeding. * p-values of <0.05 were considered 
significant. 
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6.2.2.  Association of bacterial colonisation between common nasopharyngeal (NP) 
pathogens stratified by HIV-status 
Logistic regression models showed S. pneumoniae to be positively associated with H. 
influenzae in HIV-uninfected (p<0.001) and HIV-infected (p<0.001) children at 9 months of 
age, with associations being driven by PCV7-serotypes, non-vaccine serotypes and NThinf 
(Table 6.3). Similarly, a positive association between pneumococcus and H. influenzae was 
found at 16 months in both HIV-infected (p=0.04) and HIV-uninfected (p=0.036) children; 
however, a positive association between non-vaccine serotypes and NThinf were only found 
in HIV-infected children (p=0.004); although positive trends between vaccine-serotypes, non-
vaccine serotypes and NThinf were still observed in both groups. 
 
Positive associations between M. catarrhalis and pneumococcus were found in HIV-infected 
(p<0.001) and HIV-uninfected (p<0.001) children at 9 months of age, with associations being 
driven by both PCV7-serotypes and non-vaccine serotypes. By 16 months of age, however, 
this association was only found in HIV-infected children (p<0.001), with associations being 
driven by non-vaccine serotypes alone (p=0.001); although, positive trends between M. 
catarrhalis, overall pneumococcus, PCV7-serotypes and non-vaccines serotypes were still 
observed in both HIV-infected and HIV-uninfected children. Furthermore, M. catarrhalis and 
H. influenzae were found to be positively associated with each other in both HIV-uninfected 
(p=0.03) and HIV-infected (p=0.001) children at 9 months of age; however, by 16 months of 
age, this association was no longer significant. In Addition, a positive association was found 
between M. catarrhalis and NThinf in HIV-infected children at both 9 (p=0.005) and 16 
(p=0.03) months of age respectively.  
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Table 6.3: Association of nasopharyngeal bacterial colonisation as determined by quantitative molecular PCR among PCV7-vaccinated and 
PCV-unvaccinated children 
  9 month old children 16 month old children 
 HIV-infected HIV-uninfected HIV-infected HIV-uninfected 
  aOR (95% CI); p-value aOR (95% CI); p-value aOR (95% CI); p-value aOR (95% CI); p-value 
S. pneumoniae & M. catarrhalis 4.14(2.22-7.75);p<0.001 4.59(2.24-9.43);p<0.001 3.65(1.98-6.73);p<0.001 1.69(0.79-3.60);p=0.17 
VT & M. catarrhalis 2.06(1.08-3.90);p=0.028 3.20(1.41-7.23);p=0.005 1.77(0.93-3.37);p=0.08 1.94(0.91-4.11);p=0.082 
NVT & M. catarrhalis 2.40(1.21-4.74);p=0.012 2.03(1.04-3.95);p=0.037 2.98(1.53-5.80);p=0.001 1.34(0.70-2.59);p=0.37 
S. pneumoniae & S. aureus 0.65(0.39-1,13);p=0.056 0.48(0.37-1.23);p=0,18 0.55(0.25-1.22);p=0.14 0.94(0.05-5.30);p=0.08 
VT & S. aureus 0.45(0.22-1.95);P=0.73 0.16(0,03-0.52);P=0.07 0.38(0.13-1.16);p=0.09 1.10(0.39-3.08);p=0.86 
NVT & S. aureus 0.99(0.28-3.84);P=0.84 0.54(0.09-3.56);p=0.65 0.76(0.31-1.85);p=0.54 1.94(0.77-4.89);p=0.16 
S. pneumoniae & H. influenzae 4.41(2.33-8.33);p<0.001 4.36(2.10-9.07);p<0.001 1.83(1.01-3.30);p=0.04 2.37(1.06-5.28);p=0.036 
VT & H. influenzae 3.37(1.75-6.49);p<0.001 2.98(1.27-6.99);p=0.012 1.39(0.75-2.59);p=0.29 1.50(0.65-3.47);p=0.34 
NVT & H. influenzae 4.2(2.10-8.39);p<0.001 2.75(1.34-5.62);p=0.006 2.95(1.54-5.66);p=0.001 1.89(0.89-4.04);p=0.1 
S. pneumoniae & NThinf 2.99(1.62-5.52);p<0.001 3.11(1.52-6.35);p=0.002 1.56(0.86-2.81);p=0.14 1.09(0.50-2.38);p=0.82 
VT & NThinf 2.36(1.24-4.48);p=0.009 3.90(1.68-9.07);p=0.002 1.13(0.61-2.09);p=0.69 1.08(0.42-1.82);p=0.72 
NVT & NThinf 3.0(1.52-5.91);p=0.001 2.49(1.26-4.90);p=0.008 2.47(1.32-4.61);p=0.004 1.34(0.69-2.61);p=0.39 
VT and NVT 0.53(0.24-1.21);p=0.13 1.23(0.58-2.50);P=0.59 0.73(0.36-1.47);p=0.38 0.75(0.36-1.56=5);p=0.43 
M. catarrhalis & S. aureus 0.48(0.18-1.22);p=0.12 1.09(0.41-2.89);p=0.87 0.45(0.20-1.0);p=0.052 1.79(0.67-4.78);p=0.25 
M. catarrhalis & H. influenzae 2.82(1.57-5.08);p=0.001 2.01(1.06-3.81);p=0.03 1.74(1.0-3.03);p=0.051 0.97(0.47-2.0);p=0.94 
M. catarrhalis & NThinf 2.36(1.30-4.26);p=0.005 1.65(0.88-3.09);p=0.11 1.87(1.06-3.27);p=0.03 1.03(0.53-2.0);p=0.92 
S. aureus & H. influenzae 1.35(0.57-3.22);p=0.49 0.99(0.37-2.64);p=0.98 1.18(0.53-2.61);p=0.69 0.73(0.27-1.97);p=0.54 
S. aureus & NThinf 1.71(0.72-4.09);p=0.22 1.07(0.41-2.82);p=0.89 1.29(0.59-2.84);p=0.52 1.06(0.41-2.75);p=0.9 
 
Adjusted odd ratios (AOR) for bacterial colonisation were determined by multivariate logistic regression, controlling for race, gender, study centre, birth weight, co-
trimoxazole prophylaxis administered and breastfeeding. HUU, HIV-unexposed-uninfected. HEU, HIV-exposed-uninfected. VT, vaccine serotypes/serogroups (4, 6A/B, 
9A/L/N/V, 18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7A/F, 7C, 8, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 
21, 22A/F, 23A/B, 25A/25F/38, 34/37/17A and 35B). NT, non-typable H. influenzae. 95% CI, 95% confidence levels. A p-value of <0.05 was considered significant.
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6.2.3.  Association of HIV-status and density of bacterial nasopharyngeal carriage 
The density of overall pneumococcal colonisation was higher in HIV-infected than HIV-
uninfected infants at 9 months of age, with titers of 4.81 (95% CI; 4.59-5.03) CFU/ml 
compared to 4.44 (95% CI; 44.24-4.63) CFU/ml respectively (p=0.014; Table 6.4, despite 
HIV-infected children having a lower carriage prevalence than HIV-uninfected counterparts. 
Other differences include a higher density of VT in HIV-infected compared to HIV-
uninfected children (4.21 vs. 3.72p=0.04).  By 16 months of age, however, there was no 
difference in density (p=0.89) and prevalence of pneumococcal colonisation between the 
HIV-infected and HIV-uninfected children. No difference in the density of H. influenzae was 
found between HIV-infected and HIV-uninfected infants at 9 months of age (p=0.18; Table 
6.4); however, by 16 months of age HIV-uninfected children had a higher density of overall 
H. influenzae colonisation, with titers of 4.95 (95% CI; 4.73-5.17) CFU/ml compared to 4.32 
(4.07-4.57) CFU/ml respectively, which was largely due to the higher carriage density of 
NThinf in HIV-uninfected children (5.0 vs. 4.23; p<0.001). No difference in density of S. 
aureus, S. pyogenes, N. meningitidis, N. lactamica, B. pertussis, B. parapertusis, B. holmesii 
and B. bronchiseptica was found between the groups. 
 
Table 6.4: Density of nasopharyngeal bacterial carriage stratified by HIV status 
  9 month old children 16 month old children 
  
HIV-infected 
n = 208 
HIV-uninfected 
n = 173 
p-value 
HIV-infected 
n = 218 
HIV-uninfected 
n= 164 
p-value 
S. pneumoniae 4.81(4.59-5.03) 4.44(4.24-4.63) 0.04 4.49(4.26-4.72) 4.39(1.18-4.61) 0.89 
VT 4.21(3.12-5.11) 3.72(3.45-3.99) 0.04 3.60(3.30-3.89) 3.61(3.30-3.93) 0.93 
NVT 3.48(3.16-3.79) 3.29(3.03-3.54) 0.35 3.45(3.09-3.81) 3.34(3.09-3.59) 0.42 
M. catarrhalis 3.55(3.33-3.77) 3.27(3.06-3.48) 0.42 3.49(3.29-3.69) 3.24(3.04-3.44) 0.24 
H. influenzae 5.0(4.72-5.29) 4.73(4.49-4.97) 0.08 4.32(4.07-4.57) 4.95(4.73-5.17) <0.001 
NThinf 4.92(4.62-5.23) 4.71(4.45-4.97) 0.07 4.23(3.97-4.50) 5.0(4.75-5.24) <0.001 
S. aureus 3.93(3.44-4.42) 4.03(3.43-4.63) 0.39 2.21(1.44-3.0) 3.03(2.71-3.34) 0.82 
S. pyogenes 3.44 4.27(3.89-4.64) - - - - 
N. meningitidis 4.87(-1.67-11.40) 2.04(1.81-2.27) 0.2 8.83 2.93(0.07-5.79) - 
N. lactamica 2.68(1.64-3.72) 2.24(1.92-2.57) 0.15 2.57(2.14-3.0) 2.21(1.85-2.56) 0.3 
For density of carriage geometric mean densities (GMD) and 95% CI intervals (95% CI) of pneumococcal and 
bacterial mean concentrations were calculated following log10 transformations on data and compared with 
multivariate analysis controlling for race, gender, study centre, birth weight, co-trimoxazole prophylaxis 
administered and breastfeeding. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 
23F). NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7A/F, 7C, 8, 10A, 11A/B/C/D/F, 12A/B/F, 13, 
15A/B/C/F, 16F, 17F, 19A, 20, 21, 22A/F, 23A/B, 25A/25F/38, 34/37/17A and 35B).m NThinf, non-typable H. 
influenzae. -, too few observations to calculate a p-value. A p-value <0.05 was considered significant. 
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Spearman correlation coefficients showed the overall densities of S. pneumoniae, H. 
influenzae and M. catarrhalis to be positively associated with each other in both HIV-infected 
and HIV-uninfected children at both study visits, with associations by vaccine-serotype, non-
vaccine serotype and NThinf (Table 6.5). Furthermore, a negative association between 
densities of S. pneumoniae and S. aureus was found in HIV-infected children at 9 months of 
age only.  
 
Table 6.5: Correlation of density of nasopharyngeal bacterial colonisers as determined by 
Nanofludic real-time qPCR Stratified by HIV-status 
  9 month old children  16 month old children  
 
HIV-infected  
n = 208 
HIV-uninfected 
n = 173 
HIV-infected 
n = 218 
HIV-uninfected 
n= 164 
 Rho; p-value 
S. pneumoniae & M. catarrhalis 0.336; p=0.005 0.271;P=0.013 0.308;p=0.002 0.321;p=0.005 
VT & M.catarrhalis 0.255; p=0.05 0.30; p=0.03 0.372;p=0.018 0.389;p=0.03 
NVT & M. catarrhalis 0.462;p=0.01 0.255; p=0.11 0.239;p=0.05 0.391;p=0.012 
S. pneumoniae & S. aureus -0.659:p=0.01 0.0964; p=.0.73 0.007;p=0.97 0.139;p=0.36 
VT & S. aureus 0.143; p=0.76 0.2; p=0.75 0.371;p=0.46 NP 
NVT & S. aureus -0.714; p=0.11 0.143;p=0.76 0.201;pp=0.52 NP 
S. pneumoniae & H. influenzae 0.329;p=0.01 0.422; p<0.001 0.441;p<0.001 0.368; p<0.001 
VT & H. influenzae 0.22; p=0.02 0.262; p=0.01 0.419;p=0.01 0.552; p<0.001 
NVT & H. influenzae 0.328;p=0.03 0.272; p=0.03 0.287;p=0.05 0.381;p=0.005 
S. pneumoniae & NThinf 0.27;p=0.04 0.363;p=0.002 0.421;p= p<0.001 0.262;P=0.024 
VT & NThinf 0.112;p=0.56 0.221;p=0.24 0.408;p=0.025 0.429;p=0.03 
NVT & NThinf 0.244;p=0.21 0.313; p=0.052 0.259;p=0.1 0.359;p=0.21 
M. catarrhalis & S. aureus -0.428;p=0.34 -0.518;p=0.08 0.007;p=0.97 0.259;p=0.1 
M. catarrhalis & H. influenzae 0.266;p=0.04 0.344;p=0.004 0.237;p=0.04 0.502;p<0.001 
M. catarrhalis & NThinf 0.296;p=0.05 0.342;p=0.01 0.288;p=0.02 0.514;p=0.001 
S. aureus & H. influenzae -0.084;p=0.8 0.147;p=0.65 NP 0.036;p=0.9 
S. aureus & NThinf -0.084;p=0.79 0.054;p=0.87 NP 0.016;p=0.96 
Bacterial correlations were determined by spearman’s coefficients. HUU, HIV-unexposed-uninfected. HEU, 
HIV-exposed-uninfected. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 23F). 
NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7A/F, 7C, 8, 10A, 11A/B/C/D/F, 12A/B/F, 13, 
15A/B/C/F, 16F, 17F, 19A, 20, 21, 22A/F, 23A/B, 25A/25F/38, 34/37/17A and 35B). NThinf, non-typable H. 
influenzae. NP, study not powered to calculate AOR and p-value due to too few observations. A p-value <0.05 
was considered significant.
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6.3.  DISCUSSION  
To our knowledge this is the first study to investigate the association of HIV-1 infection and the 
density of bacterial carriage of common nasopharyngeal colonisers such as S. pneumoniae, H. 
influenzae and S. aureus in a PCV7-immunised cohort. Our findings were in line with those from a 
previous study undertaken by us, which used WHO recommended culture to find a lower carriage 
prevalence of overall pneumococci, non-vaccine serotypes and H. influenzae in HIV-infected 
children 
198
. The current study, however, expanded on the previous analysis in that the Nanofludic 
real-time PCR method allowed for quantification and showed the density of overall pneumococcal 
carriage to be higher in HIV-infected children despite a lower carriage prevalence, which could 
possibly explain the higher disease burden in HIV-infected compared to HIV-uninfected children 
245
. 
 
While there were fundamental differences in the baseline characteristics of HIV-infected and HIV-
uninfected children including a higher administration rate of co-trimoxazole prophylaxis in HIV-
infected children and a higher rate of breastfeeding in HIV-uninfected children, the effect on 
pneumococcal carriage prevalence and density remained unchanged even after adjusting for these 
possible cofounders. Nevertheless, antibiotic usage including co-trimoxazole prophylaxis in general 
is higher in HIV-infected children and thus should be considered when interpretation the findings of 
our study especially since recent studies in Zambia showed co-trimoxazole to increase the risk of 
colonisation with co-trimoxazole resistant pneumococci within 6 weeks of starting prophylaxis and 
other studies reporting resistance as high as 50% – 80% in HIV-infected children which is 
predominantly found in vaccine-type pneumococci 
246-249
. Antimicrobial exposure in HIV-infected 
children can thus increase their risk to shed non-vaccine pneumococci due to their sensitivity to 
antimicrobials and further retain their vaccine serotypes which were consistent to our findings.  
  
 
Further, the HIV-infected children included in this study were initiated on antiretroviral treatment 
immediately upon diagnosis of their HIV-infection status or within the first year of life which might 
also explain the lower carriage prevalence of overall pneumococcus in the HIV-infected cohort as 
PCV have been shown to induce a more durable and functional antibody response in individuals on 
ART at the time of vaccination compared to ART-naïve individuals, independently of the baseline 
CD4+ cell count 
250
. The possible effects of ARTs on pneumococcal carriage density; however, are 
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unknown and the clinical relevance of this warrants further studies as the temporary increase in 
pneumococcal carriage density observed in this study might explain why invasive pneumococcal 
disease remains high in HIV-infected individuals despite ART usage 
251
. Further, it is possible that 
the PCV induced vaccine effect as shown in Chapter 3, were PCV7 immunisation resulted in a 
temporary increase in the density of pneumococcal carriage, was more pronounced in HIV-infected 
children who have underlying immunosuppressive mediators and might explain why an increase in 
the prevalence density of overall pneumococcus was observed in these children. In addition, the 
increase in the prevalence density of overall pneumococcus appeared to be driven by vaccine 
serotypes suggesting that failure of the immune response as a result of HIV-infection allowed for 
invasive vaccine serotypes to be carried at a higher carriage density, although further investigation 
is needed to provide clarity. 
 
 
In addition, we also identified that carriage prevalence and density of H. influenzae to be higher in 
HIV-uninfected children, which was consistent with our previous findings by culture 
198
 and to 
another study done in Tanzania 
196
, albeit differing from another South African study which 
reported that the prevalence of H. influenzae was higher in HIV-infected children
 77
. The increase in 
the carriage prevalence and density was driven by NThinf most likely due to the low detection rate 
of the serotypes a-f. Also while we found no change in the carriage prevalence or density of S. 
aureus, other studies from South Africa 
191,193
 and Tanzania 
196
 found the carriage prevalence of S. 
aureus to be higher in HIV-infected children. Differences in the findings from these studies could 
possibly be attributed to the different PCV-vaccination status of the children; however, additional 
studies in PCV7-vaccinated cohorts with more sensitive molecular methods are still needed to 
clarify these associations.  
 
 
Positive associations with respect to prevalence were found between pneumococcus, H. influenzae 
and M. catarrhalis in both HIV-infected and HIV-uninfected children, with associations being 
driven by vaccine serotypes, non-vaccine serotypes and NThinf. This finding is contradictory to 
other studies that found these associations in HIV-negative children alone 
72,77
. The HIV-infected 
children in our study, however, differed from previous studies on bacterial colonisation interactions 
in that children received antiretroviral treatment and were thus relatively immunocompetent. 
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Furthermore, no association between pneumococcus and S. aureus was found in all groups which 
are consistent with findings from another study in South Africa 
193
. 
 
Our study was limited in that the Fluidigm method was not optimised to discriminate between all 
serotypes within their respective serogroups. Furthermore, the study was not adequately powered to 
evaluate the difference in carriage density of serotypes/serogroups as the sample size of detected 
minor serotypes was too small. Only a selection of NP organisms were analysed and thus analysis at 
a microbiome level may be advantageous. Lastly, nasopharyngeal swabs do not favour the isolation 
of S. aureus and S. pyogenes in which anterior nares and throat swabs are better for detection, 
respectively 
241,242
. The prevalence of these bacteria could have thus been underestimated and the 
analysis on S. aureus prevalence needs to be interpreted with caution. 
 
Since NP colonisation is the precursor to disease of the upper and lower respiratory tract, analysis 
of the NP tract flora can provide a simple means to signal changes, which could inform future 
trends in the long term effectiveness of these vaccines, especially in children with HIV-1 infection 
whom have a higher disease burden. The ability of the Biomark HD system to simultaneously detect 
multiple pneumococcal serotypes and bacterial pathogens at a low carriage density allowed us to 
gain a better understanding of the association of HIV-infection and nasopharyngeal bacterial 
carriage. In our study we showed the carriage density of overall pneumococcus to be higher in HIV-
infected children, despite the lower carriage prevalence which might explain the higher invasive 
disease burden in HIV-infected compared to HIV-uninfected children as a high nasopharyngeal 
density of streptococcus pneumoniae has previously been shown to be associated with invasive 
pneumococcal pneumonia 
252
.   
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CHAPTER 7: INTEGRATED DISCUSSION AND CONCLUSIONS 
 
While culture remains the WHO recommended referent standard for evaluating pneumococcal 
nasopharyngeal colonisation and serotype characterisation, these assays lack quantitative data 
which has hindered our understanding of the association between PCV-immunisation on 
pneumococcal and bacterial nasopharyngeal carriage, including in HIV-infected children. The 
finding presented in this thesis, however, supports the use of molecular qPCR methods as 
alternatives to standard culture and future bacterial/pneumococcal colonisation studies should 
strongly considered using these methods, especially if investigating a population with a high HIV 
disease burden.  
 
 
While the qPCR methods were limited for pneumococcal serotyping in that they did not test for all 
known pneumococcal serotypes and that they were unable to differentiate between some serotypes 
that had high genetic similarities, the knowledge gained by being able to quantify the density of 
each colonising serotype outweighed these limitations. Future studies using these methods; 
however, could focus on expanding the number of assays so that all known pneumococcal serotypes 
are tested for and additional testing such as RFLP and sequencing could be done to further 
discriminate some serotypes with high genetic similarities. Nevertheless, by using sensitive 
molecular qPCR methods to compare the circulation of pneumococcal serotypes as well as other 
bacterial pathogens in a PCV7-vaccinated cohort of HIV-infected and HIV-uninfected children, as 
well as a PCV-unvaccinated cohort, we were able to make several important findings.  
 
 
When comparing the circulation of pneumococcal serotypes in a PCV7-vaccinated and PCV-
unvaccinated cohort of children, the PCV7 vaccine effect was clearly shown and for the first time 
the mechanism behind this effect was shown to be both serotype replacement colonisation of the 
nasopharynx because of the vacant ecological niche and unmasking of prevailing non-vaccine 
serotype colonisers which were not previously recognised by traditional culture method that are 
biased towards detecting the dominant colonising serotype. Although serotype specific analysis was 
often limited by a small sample size for a given serotype, findings from two non-PCV7 serotypes 
namely 19A and 5 were of importance. The increase in the prevalence and carriage density of 
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serotype 19A was shown to be a combination of both serotype replacement disease as well as 
unmasking, while the increase in the colonisation density of serotype 5 which is rarely seen in 
conventional culture studies was unmasked by the qPCR method. The findings are of important 
clinical relevance as serotype 5 has a high invasive disease potential in our setting 
(18, 19) 
and an 
increase in the carriage density as a result of PCV-immunisation could enhance its ability to cause 
mucosal and invasive disease and potentially offset some of the effectiveness of PCV7 
immunisation. Further, the increase in the carriage prevalence and density of PCV7-serotype 19A 
could explain the emergence of serotype 19A as the major replacement serotype causing IPD 
following PCV7 introduction in several settings which is probably a result of 19A being commonly 
characterized by clones that carry a high prevalence of antimicrobial resistance, thus facilitating its 
survival where other NVT’s perish (15-17) . 
 
 
Although there are now 10 and 13 valent PCV vaccines available that have been expanded to 
include serotypes 5 and 19A, PCV7 was only introduced into the public immunisation program in 
May 2009 in South Africa and has only recently being replaced by PCV10 and PCV13. Serotype 
19A and 5 are thus largely considered to be non-vaccine serotypes that have a high invasive disease 
potential in our settings and monitoring trends in the circulation of these serotypes post PCV7 
immunisation is of importance. Further, the increase in the detection of serotype 5 and 19A by 
molecular qPCR methods highlights the importance of continued surveillance of the circulating 
pneumococcal serotypes after the introduction of PCV10 and PCV13 with sensitive molecular 
methods that are able to detect serotypes at a low carriage density and thus accurately determine the 
effectiveness of these vaccines in reducing/eliminating carriage by these serotypes.  
 
 
While PCV7 immunisation has been effective in reducing the morbidity and mortality in children < 
5 years of age, there are concerns about the downstream effects of this vaccine as well as other to 
provide a vacant niche for bacteria that are resistant to antibiotics to colonise the host resulting in an 
increase in invasive disease caused by these bacteria in which treatment will be challenging. 
Findings from this thesis support the notion that after the eradication of common PCV7 colonisers 
such as vaccine-type pneumococci, momentum is directed by both non-vaccine type serotypes and 
other bacterial species to colonise the vacant niche and thus direct bacteria-bacteria interactions 
may impact clinically important nasopharyngeal dynamics. The prevalence and carriage density of 
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H. influenzae and S. aureus were shown to be higher in PCV-vaccinated children and could explain 
the moderate effects that PCV has on otitis media (OM), even with the vaccine having up to 80% 
efficacy in reducing vaccine-type pneumococcal colonisation
17-19 
although additional studies are 
still needed for clarity. Further, the temporary increase in the colonisation prevalence and density of 
S. aureus highlights the effect to be around PCV7 vaccinations in infancy and subsequently 
diminishing after non-vaccine serotypes or other bacterial species colonise the vacant niche or by an 
age-dependent maturation of the immune system
21-23
. These results highlighted the natural balance 
found between pneumococci and co-colonising bacterial species and interfering with this may lead 
to disequilibrium within the host, which could affect susceptibility to disease from other serotypes 
and bacteria species. On-going surveillance, especially on the implication of such changes in the 
nasopharyngeal biome on particularly mucosal infections are thus warranted.  
 
One of the most interesting findings of this study was the higher carriage density of overall 
pneumococci observed in HIV-infected PCV7 immunised children, despite them having lower 
carriage prevalence. While this might explain why invasive pneumococcal disease remains high in 
HIV-infected individuals despite ART usage, one cannot ignore other possible contributors such as 
the high rate of antibiotic usage in HIV-infected children as well as the HIV-infected children being 
initiated on antiretroviral treatment immediately upon diagnosis of their HIV-infection status or 
within the first year of life, especially since the possible effects of ARTs on pneumococcal carriage 
density is unknown. Nevertheless these findings are of important clinical relevance and warrants 
further study. It is, however, possible that the PCV induced vaccine effect was also more 
pronounced in HIV-infected children who have underlying immunosuppressive mediators and 
might explain why an increase in the prevalence density of overall pneumococcus was observed in 
these children. In addition, the increase in the prevalence density of overall pneumococcus appeared 
to be driven by vaccine serotypes suggesting that failure of the immune response as a result of HIV-
infection allowed for invasive vaccine serotypes to be carried at a higher carriage density, although 
further investigation is needed to provide clarity. Nonetheless these findings highlight the 
importance of continued surveillance of circulation of pneumococcal serotypes especially in a 
population with a high burden of HIV-1 infection.  
 
The findings from this thesis were limited in that the qPCR assays were unable to discriminate 
between all vaccine serotypes within their respective serogroups due to the high genotypic 
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similarities between the capsule loci of certain pneumococcal serotypes. Furthermore, not all 
pneumococcal serotypes and bacterial pathogens were tested for and thus carriage with samples 
colonised with these pathogens could have been missed and the rate of concurrent colonisation with 
multiple pneumococcal serotypes underestimated. The effect of other serotypes on the vaccine 
efficacy for protection against colonisation (VEcol) might have thus also been underestimated. In 
addition, the study was not adequately powered to evaluate all serotype specific differences as the 
sample size to detect minor serotypes was too small, particularity with respect to evaluating the 
difference in the carriage density of specific serotypes/serogroups. The loss of sensitivity when 
comparing the qPCR assays to each other, as well as when comparing traditional qPCR to culture 
was most probably a result of degradation of DNA as a result of long-term storage and/or freezing 
and thawing of samples. Further, nasopharyngeal swabs do not favour the isolation of S. aureus and 
S .pyogenes in which anterior nares and throat swabs are better for detection, respectively 
(238, 239)
. 
The prevalence of these bacteria could have thus been underestimated and may explain why no 
change in S. aureus prevalence due to PCV-vaccination was reported. In addition, the control group 
was enrolled after our vaccinated group. However, due to the limited coverage of PCV in the 
community it is thus unlikely that, a broader indirect effect of the vaccine reducing transmission by 
young vaccinated children, would have affected the nasopharyngeal colonisation patters. Lastly, our 
study was not a randomised clinical trial and the cohorts were not matched. Coincidental temporal 
fluctuations and other unknown factors could have thus influenced the results.  
 
 
While this study was meaningful in improving our understanding of the association of PCV7 
immunisation and HIV-1 infection on bacterial carriage prevalence and density, analysis was done 
in a PCV-7 immunised cohort and has now been replaced by PCV-13 in South Africa. The extent of 
serotype replacement may thus differ after the reductions of serotypes 19A and 5 colonisation 
which are included in PCV-13, and the ability of other bacterial species to colonise the vacant niche 
might be changed. Further investigation of pneumococcal and bacterial carriage in a PCV-13 
immunised cohort with sensitive molecular methods is thus still needed.  
 
 
In conclusion, improved molecular methods that were able to quantitatively detect multiple 
pneumococcal serotypes and other common nasopharyngeal bacterial pathogens at a low carriage 
density allowed us to gain a better understanding of the association of PCV immunisation and HIV-
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1 infection on the carriage density of vaccine-serotypes, non-vaccine serotypes and other common 
bacterial pathogens, in which other studies have been limited. There is a natural balance between 
pneumococci and co-colonising bacterial species, and interfering with this may lead to 
disequilibrium within the host, which could affect susceptibility to disease from other serotypes and 
bacteria species. Since NP colonisation is the precursor to diseases of the upper and lower 
respiratory tract, analysis of the NP tract flora can provide a simple means to signal changes, which 
could inform future trends in the long term effectiveness of these vaccines, especially in children 
with HIV-1 infection who have a higher disease burden. On-going surveillance, especially on the 
implication of such changes in the nasopharyngeal biome on particularly mucosal infections are 
warranted. Improved methods of detection of respiratory pathogens can provided a means to 
improve the health care of patients as optimal therapy can be initiated sooner, effectiveness of the 
treatment is improved and spread of disease can be reduced or even prevented. Further, a high 
bacterial load detected by real-time PCR in nasopharyngeal specimens might help predict the 
etiological role for S. pneumoniae and other bacterial pathogens in bacterial disease. 
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 APPENDICES 
Appendix A: Prevalence of pneumococcal serotypes in PCV-unvaccinated HIV-uninfected children between samples available and not-available 
for subsequent molecular qPCR testing 
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Appendix B: Prevalence of pneumococcal serotypes in PCV7-vaccinated HIV-uninfected children between samples available and not-available 
for subsequent molecular qPCR testing 
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Appendix C: Prevalence of pneumococcal serotypes in PCV7-vaccinated HIV-infected children between samples available and not-available for 
subsequent molecular qPCR testing. 
 
 
  
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
8.0
9.0
10.0
8 13 14 16 21 22 24 34 10a 10F 11A 12F 15B 15c 17F 18c 18F 19A 19f 23A 23f 33a 33f 34 35b 35F 6A 6B 7C 9n 9V
%
 c
h
ild
re
n
 c
o
lo
n
is
e
d
  
16 months SAMLE AVAILABLE (N = 426)
16 months Samples unavailable (N=64)
  
 
176 
 
Appendix D: Prevalence of nasopharyngeal (NP) colonisers between HIV-exposed uninfected children as well as between HIV-infected children 
who received immediate or delayed ART therapy 
  HEU  HUU  aOR (95% CI)  p-value ART-def.  ART-immed.  aOR (95% CI) p-value 
9 month old 
children  
n=102 n=71 
  
n=156 n=52 
  
S. pneumoniae  68(66.7) 53(74.6) 0.46(0.16-1.32) 0.059 94(60.3) 28(53.9) 1.3(0.69-2.44) 0.42 
VT 19(18.6) 21(29.6) 0.40(0.14-1.15) 0.09 41(26.3) 14(26.9) 0.96(0.48-1.97) 0.93 
NVT  31(30.4) 29(40.8) 0.41(0.16-1.03) 0.06 38(24.4) 10(19.2) 1.35(0.62-2.95) 0.45 
H. influenzae  67(65.7) 44(61.9) 1.17(0.46-3.01) 0.73 69(44.2) 19(36.5) 1.38(0.72-2.63) 0.33 
Hinf A - 1(1.4) - 
 
0 0 - - 
Hinf B 1(1) 1(1.4) 0.23(0.001-45.57) 0.58 2(1.3) 1(1.9) 0.66(0.06-7.46) 0.74 
Hinf C 1(1) 0 - 
 
0 0 - - 
Hinf D 1(1) 0 - 
 
2(1.3) 0 - - 
Hinf E 2(2) 0 - 
 
1(0.6) 0 - - 
Hinf F 1(1) 3(4.2) - 
 
4(2.56) 0 - 0.24 
NThinf 60(58.8) 37(52.1) 1.48(0.59-3.71) 0.4 60(38.5) 18(34.6) 1.18(0.61-2.78) 0.62 
M. catarrhalis  55(53.9) 45(63.4) 0.80(0.32-2.0) 0.63 73(46.8) 17(36.7) 1.81(0.94-3.5) 0.08 
S. aureus  18(17.6) 12(16.9) 1.0 (0.37-2.7) 0.99 16(10.3) 8(15.4) 0.63(0.25-1.57) 0.32 
S. pyogenes 1(1) 4(5.6) 0.13(0.01-1.71) 0.12 0 1(1.9) - - 
N. meningitidis 1(1) 1(1.4) - 
 
3(1.9) 0 - - 
N. lactamica 0 5(7) - 
 
7(4.5) 0 - - 
B. pertussis  0 0 - 
 
0 1(2.3) - - 
B. parapertusis  0 0 - 
 
0 0 - - 
B. Holmesii 0 0 - 
 
0 0 - - 
B. bronchiseptica  0 1(1.4) - 
 
0 0 - - 
     
  
  
16month old 
children  
n=97 n=67 
  
n=154 n=56 
  
S. pneumoniae  74(76.2) 51(76.1) 1.03(0.44-1.78) 0.23 109(70.8) 40(71.4) 0.80(0.42-1.54) 0.51 
VT 26(26.8) 20(30) 0.66(0.29-1.49) 0.32 43(27.9) 16(28.6) 0.86(0.43-1.73) 0.67 
NVT  42(43.3) 25(37.3) 1.62(1.06-2.50) 0.067 47(30.5) 16(28.6) 1.20(0.61-2.38) 0.6 
H. influenzae  67(69.1) 54(80.6) 0.57(0.25-1.33) 20 88(57.1) 34(60.7) 0.93(0.50-1.72) 0.82 
Hinf A 4(4.1) 4(6) 0.59(0.12-3.02) 0.53 4(2.6) 0 -  -  
Hinf B 0 1(1.5) - - 1(0.1) 0 -  -  
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Hinf C 4(4.1) 2(3) 0.94(0.13-7.0) 0.95 0 0 -  -  
Hinf D 1(1) 1(1.5) 0.36(0.02-6.56) 0.49 2(1.3) 0 -  -  
Hinf E 1(1) 1(1.5) - - 1(0.1) 0 -  -  
Hinf F 5(5.2) 1(1.5) 3.69(0.28-47.43) 0.33 3(2) 2(3.6) 0.54(0.09-3.30) 0.5 
NThinf 53(54.6) 44(56.7) 0.82(0.39-1.73) 0.6 79(51) 30(53.6) 0.93(0.50-1.72) 0.82 
M. catarrhalis  53(54.6) 37(55.2) 1.06(0.57-1.99) 0.85 86(55.8) 39(69.9) 0.53(0.28-1.03) 0.06 
S. aureus  15(15.5) 10(14.9) 1.0(0.40-2.49) 0.99 22(14.3) 9(16.1) 0.84(0.35-2.05) 0.71 
S. pyogenes 3(3.1) 4(6) 0.60(0.87-4.23) 0.61 2(1.3) 0 -  -  
N. meningitidis 1(1) 2(3) 0.19(0.01-2.12) 0.2 1(0.1) 0 -  -  
N. lactamica 4(4.1) 5(7.5) 0.27(0.06-1.18) 0.08 7(4.6) 4(7.1) 0.62(0.17-2.20) 0.56 
B. pertussis  0 0 - - 0 0 
  B. parapertusis  0 0 - - 0 0 
  B. Holmesii 0 0 - - 0 0 
  B. bronchiseptica  0 0 - - 0 0    
Adjusted odd ratios (aOR) for bacterial colonisation were determined by multivariate logistic regression, controlling for race, gender, study centre, birth weight, co-
trimoxazole prophylaxis administered and breastfeeding. 95% CI, 95% confidence levels. ART-immed, HIV-infected children with CD4+ cell count ≥25% started on ART at 
the time of first dose of PCV-7. ART-def., HIV-infected children with CD4+ cell count ≥25% at time of first PCV-7 dose that were started on antiretroviral treatment (ART) 
based on clinical or immunological indications. HUU, HIV-unexposed uninfected. HEU, HIV-exposed uninfected. VT, vaccine serotypes/serogroups (4, 6AB, 9ALNV, 
18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups (1, 3, 5, 6C/D, 7A/F, 7C, 8, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 22A/F, 
23A/B, 25A/25F/38, 34/37/17A and 35B). -, too few observations to calculate p-value. A p-values of <0.05 were considered significant. 
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Appendix E: Density of nasopharyngeal bacterial carriage stratified by HIV-exposure as well as weather HIV-infected children received 
immediate or delayed ART therapy 
 HUU HEU p-value ART-def. ART-immed p-value 
9 month old children 
  
   S. pneumoniae 4.48(4.20-4.75) 4.43(4.15-4.72) 0.34 4.83(4.56-5.09) 4.76(4.34-5.17) 0.8 
VT 4.49(4.11-4.87) 4.80(4.29-5.31) 0.42 5.29(4.89-5.69) 5.04(4.36-5.73) 0.53 
NVT 4.67(4.35-5.0) 4.64(4.24-5.05) 0.91 4.85(4.46-5.24) 4.67(4.11-5.24) 0.66 
M. catarrhalis 3.22(2.34-3.51) 3.35(3.04-3.66) 0.75 3.55(3.29-3.81) 3.56(3.16-3.96) 0.96 
H. influenzae 4.86(4.49-5.24) 4.68(4.35-5.0) 0.85 5.0(4.67-5.33) 4.99(4.37-5.61) 0.97 
NThinf 4.82(4.41-5.22) 4.64(4.30-4.99) 0.79 4.87(4.36-5.14) 4.91(4.26-5.34) 0.67 
S. aureus 3.512.83-4.19) 4.37(3.45-5.29) 0.82 3.98(3.31-4.66) 3.82(2.99-4.64) 0.74 
S. pyogenes 4.20(3.73-4.67) 4.56 - - - - 
N. meningitidis 2.06 2.02 - - - - 
N. lactamica - - - - - - 
16 moth old children 
  
   S. pneumoniae 4.39(4.08-4.70) 4.39(4.07-4.71) 0.85 4.46(4.19-4.73) 4.59(4.09-5.08) 0.65 
VT 4.54(3.87-5.20) 4.75(4.37-5.13) 0.98 4.61(4.23-4.99) 5.29(5.58-6.0) 0.08 
NVT 4.64(4.29-4.99) 4.69(4.22-5.17) 0.8 4.92(4.58-5.26) 4.62(4.04-5.19) 0.36 
M. catarrhalis 3.27(2.90-3.63) 3.23(2.99-3.47) 0.51 3.52(3.29-3.75) 3.43(3.01-3.84) 0.66 
H. influenzae 5.10(4.79-5.41) 4.83(4.51-5.14) 0.054 4.31(4.01-4.61) 4.45(3.98-4.93) 0.63 
NThinf 5.08(4.73-5.43) 4.93(5.58-5.28) 0.15 4.31(4.00-4.62) 4.45(3.97-4.87) 0.56 
S. aureus 3.17(259-3.76) 2.93(2.51-3.35) 0.29 2.16(1.98-3.05) 2.28(2.00-2.97) 0.78 
S. pyogenes 3.25(1.61-4.89) 3.33(0.47-6.19) - - - - 
N. meningitidis 3.19(-10.26-16.64) 2.41 - - - - 
N. lactamica 2.15(1.71-2.59) 2.28(1.27-3.29) 0.67 2.74(2.04-3.44) 2.28(1.96-2.61) 0.28 
For density of carriage. Geometric mean densities (GMD) and 95% CI intervals (95%) of pneumococcal and bacterial mean concentrations were calculated following log 10 
transformations on data and compared with multivariate analysis controlling for race, gender, study centre, birth weight, co-trimoxazole prophylaxis administered and 
breastfeeding. ART-immed, HIV-infected children with CD4+ cell count ≥25% started on ART at the time of first dose of PCV-7. ART-def., HIV-infected children with 
CD4+ cell count ≥25% at time of first PCV-7 dose that were started on antiretroviral treatment (ART) based on clinical or immunological indications. HUU, HIV-unexposed 
uninfected. HEU, HIV-exposed uninfected. VT, vaccine serotypes/serogroups (4, 6A/B, 9A/L/N/V, 18A/B/C, 19B/F and 23F). NVT, non-vaccine serotypes/serogroups (1, 3, 
5, 6C/D, 7A/F, 7C, 8, 10A, 11A/B/C/D/F, 12A/B/F, 13, 15A/B/C/F, 16F, 17F, 19A, 20, 21, 22AF, 23AB, 25A/25F/38, 34/37/17A and 35B).m NThinf, non-typable H. 
influenzae. -, too few observations to calculate p-value. A p-value of <0.05 was considered significant.
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